,p,p_src,p_type,i,i_src,i_type,o,o_src,o_type,ID
0,"['seasonal allergic rhinitis ( SAR ) .', 'Ontario , Quebec and Manitoba .', 'Two hundred and eighty-four out-patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) .', 'Two hundred and eighty-four out-patients', 'SAR', 'symptomatic during the ragweed season', '243', 'SAR .', 'SAR .', 'seasonal allergic rhinitis .', 'seasonal allergic rhinitis .']","[1, 4, 5, 5, 5, 5, 5, 13, 13, 0, 0]","['ss_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['budesonide Turbuhaler', 'budesonide aqua', 'budesonide Turbuhaler', 'budesonide aqua', 'budesonide .', 'budesonide .', 'Turbuhaler', 'Turbuhaler', 'Turbuhaler', 'aqua spray', 'Turbuhaler', 'aqua spray', 'budesonide aqua', 'budesonide Turbuhaler', 'budesonide aqua', 'budesonide Turbuhaler', 'budesonide powder', 'Turbuhaler', 'aqua', 'budesonide powder', 'Turbuhaler', 'aqua', 'budesonide Turbuhaler', 'budesonide aqua', 'budesonide Turbuhaler', 'budesonide aqua']","[1, 1, 1, 1, 8, 8, 10, 10, 11, 11, 11, 11, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","[""patients ' preferences for the two nasal devices"", 'quality of life .', ""patients ' preferences"", 'quality of life .', 'Mean daily nasal symptom scores', 'Mean daily nasal symptom scores', 'eye symptoms .', 'eye symptoms .', 'nasal and non-nasal adverse events', 'epistaxis', 'headache .', 'nasal and non-nasal adverse events', 'epistaxis', 'headache .', 'unpleasant taste', 'nasal irritation', 'nasal irritation', 'quality of life', 'quality of life', 'safe', 'efficacious', 'safe', 'efficacious']","[2, 2, 2, 2, 6, 6, 7, 7, 9, 9, 9, 9, 9, 9, 10, 10, 10, 12, 12, 13, 13, 13, 13]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",10070173
1,"['tonsillectomy with or without adenoidectomy in children .', 'tonsillectomy with or without adenoidectomy', 'children', '90 paediatric patients , ASA I , aged 4-10 years', '90 paediatric patients', 'ASA I', 'aged 4-10 years', 'children undergoing general anaesthesia for tonsillectomy .', 'children undergoing general anaesthesia for tonsillectomy', 'children .', 'children .']","[0, 0, 0, 1, 1, 1, 1, 6, 6, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine', 'granisetron', 'perphenazine']","[0, 0, 0, 0, 1, 1, 1, 1, 3, 3, 3, 3, 6, 6, 6, 6, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'efficacy', 'complete response , defined as no emesis with no need for another rescue antiemetic', 'complete response , defined as no emesis with no need for another rescue antiemetic', 'corresponding incidence', 'corresponding incidence', 'adverse events', 'adverse events', 'long-term prevention of post-operative vomiting', 'long-term prevention', 'post-operative vomiting', 'Anti-emetic efficacy', 'prevention', 'Anti-emetic efficacy', 'prevention']","[0, 0, 3, 3, 4, 4, 5, 5, 6, 6, 6, 0, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",10390665
2,"['8 healthy volunteers , and 6 women with untreated primary hypothyroidism', '8 healthy volunteers', '6 women', 'untreated primary hypothyroidism', 'healthy volunteers', 'healthy volunteers', 'healthy controls', 'The patients with hypothyroidism', 'patients with hypothyroidism', 'normal subjects and in patients with primary hypothyroidism', 'normal subjects and in patients with primary hypothyroidism', 'healthy volunteers and in patients with primary hypothyroidism .', 'healthy volunteers and in patients with primary hypothyroidism .']","[2, 2, 2, 2, 4, 4, 6, 7, 7, 10, 10, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Somatostatin', 'Somatostatin', 'somatostatin', 'somatostatin', 'saline', 'octreotide ( Sandostatin ;', 'saline', 'octreotide ( Sandostatin ;', 'octreotide', 'saline .', 'octreotide', 'saline .', 'octreotide', 'octreotide', 'saline ;', 'octreotide', 'octreotide', 'saline ;', 'octreotide', 'saline .', 'octreotide', 'saline .', 'octreotide', 'octreotide', 'saline ;', 'octreotide', 'somatostatin .', 'octreotide', 'octreotide', 'saline ;', 'octreotide', 'somatostatin .', 'somatostatin -- in', 'octreotide -- fails', 'somatostatin', 'somatostatin', 'octreotide', 'somatostatin', 'somatostatin ( octreotide )', 'somatostatin ( octreotide )']","[0, 0, 1, 1, 3, 3, 3, 3, 4, 4, 4, 4, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['regulation of melatonin secretion .', 'melatonin secretion .', 'regulatory influence on melatonin secretion', 'melatonin secretion', 'nocturnal melatonin secretion', 'nocturnal melatonin secretion', 'melatonin secretion', 'melatonin secretion', 'urinary excretion of melatonin', 'urinary excretion of melatonin', 'GH secretion', 'GH secretion', 'nocturnal melatonin secretion', 'nocturnal melatonin secretion', 'Urinary excretion of melatonin', 'Urinary excretion of melatonin', 'total nocturnal secretion of TSH', 'total nocturnal secretion of TSH', 'nocturnal secretion and urinary excretion of melatonin', 'regulator of melatonin secretion', 'nocturnal secretion and urinary excretion of melatonin', 'regulation of melatonin secretion', 'melatonin secretion']","[0, 0, 1, 1, 2, 2, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",10475150
3,"['36 premenopausal women , 20 of whom used OC .', '36 premenopausal women', '20', 'used OC', 'premenopausal OC or non-OC users .', 'premenopausal OC', 'non-OC users .', 'premenopausal women .', 'premenopausal women .']","[2, 2, 2, 2, 7, 7, 7, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['soy', 'soy', 'soy', 'soy', 'soy', 'soy', 'soy', 'normal diet', 'soy beverage', 'soy beverage', 'soy', 'soy', 'soy', 'soy', 'soy', 'soy']","[0, 0, 1, 1, 1, 2, 2, 3, 3, 3, 4, 4, 7, 7, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['hormonal effects', 'sex hormone metabolism', 'menstrual function or serum sex hormones', 'sex hormone metabolism', 'serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations', 'serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations', 'menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone', 'menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone', 'urinary estrogen metabolites', 'urinary estrogen metabolites', 'menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio', 'menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio', 'sex hormone metabolism', 'sex hormone metabolism']","[0, 1, 1, 1, 4, 4, 5, 5, 6, 6, 7, 7, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",10578479
4,"['during supportive periodontal therapy .', '40 subjects', '40 subjects', '20', '20', 'supportive periodontal therapy ( SPT ) .']","[3, 4, 4, 5, 6, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p']","['non-root substance removing curettes', 'plastic curettes', 'plastic curettes', 'conventional steel curettes', 'plastic curettes', 'conventional steel curettes', 'conventional steel curettes', 'conventional steel curettes', 'plastic curettes', 'plastic curettes', 'non-root substance removing curettes', 'non-root substance removing curettes', 'conventional steel', 'non-tooth substance removing plastic curettes']","[1, 2, 3, 3, 3, 3, 5, 5, 6, 6, 11, 11, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i']","['clinical effects', 'clinical effects', 'effects', 'bleeding on probing ( BOP ) and probing pocket depth ( PPD )', 'bleeding on probing ( BOP ) and probing pocket depth ( PPD )', 'BOP percentage', 'BOP percentage', 'BOP and PPD', 'BOP and PPD', 'BOP percentage', 'BOP', 'BOP', 'BOP percentage', 'BOP', 'BOP', 'Clinical effects', 'Clinical effects']","[2, 2, 3, 7, 7, 8, 8, 9, 9, 10, 10, 10, 10, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",10589810
5,"['61 inpatients with the diagnosis Rhinitis following nasal operation', '61 inpatients with the diagnosis Rhinitis following nasal operation', 'patients following nasal operations', 'patients following nasal operations', 'rhinitis following nasal operation', 'rhinitis following nasal operation', 'after nose surgery', 'after nose surgery']","[2, 2, 8, 8, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Xylometazoline', 'Dexpanthenol ( Nasic )', 'Xylometazoline alone .', 'Xylometazoline', 'Dexpanthenol ( Nasic )', 'Xylometazoline', 'verum', 'placebo', 'verum', 'placebo', 'Xylometazoline-Dexpanthenol', 'Xylometazoline', 'Xylometazoline-Dexpanthenol', 'Xylometazoline', 'Xylometazoline-Dexpanthenol', 'Xylometazoline', 'Xylometazoline-Dexpanthenol', 'Xylometazoline', 'xylometazoline', 'dexpanthenol ]', 'xylometazoline', 'dexpanthenol ]']","[0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 5, 5, 5, 5, 10, 10, 10, 10, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'tolerability', 'efficacy', 'tolerability', 'nasal-breathing-resistance according to scores was defined as target-parameter .', 'nasal-breathing-resistance according to scores', 'superiority', 'target-parameter', 'efficacy', 'tolerability', 'efficacy', 'tolerability', 'compliance', 'compliance', 'improvement', 'efficacy', 'improvement', 'efficacy', 'tolerability', 'tolerability', '[ Improving wound healing', 'wound healing']","[0, 0, 0, 0, 3, 3, 5, 5, 6, 6, 6, 6, 7, 7, 8, 8, 8, 8, 9, 9, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",10763172
6,"['patients who underwent hysterectomy .', 'underwent hysterectomy', 'Forty patients were divided into four groups of ten .', 'Forty patients were divided into four groups of ten .', 'abdominal surgery .', 'abdominal surgery .']","[0, 0, 1, 1, 12, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p']","['morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine', 'morphine']","[0, 0, 2, 2, 2, 2, 2, 2, 12, 12, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['natural killer ( NK ) cell activity', 'natural killer ( NK ) cell activity', 'blood NK cell activity', 'chromium release assay with K562 cells as targets , plasma catecholamines and cortisol levels .', 'postoperative pain score and side effects', 'postoperative pain score and side effects', 'NK cell activity', 'NK cell activity', 'NK cell activities', 'NK cell activities', 'plasma adrenaline', 'noradrenaline concentrations', 'plasma adrenaline', 'noradrenaline concentrations', 'plasma cortisol levels', 'plasma cortisol levels', 'pain score', 'pain score', 'NK cell activity', 'NK cell activity']","[0, 0, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 9, 9, 10, 10, 11, 11, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",10764172
7,"['hypertensive patients receiving drug treatment', 'hypertensive patients receiving drug treatment', 'hypertensives on chronic , stable antihypertensive therapy .', 'people with one or more cardiovascular risk factors .', 'people with one or more cardiovascular risk factors .', 'Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs :', 'hypertension', '142 hypertensive', '76 men', '66 women', 'mean age 59 +/- 5.9 years', 'treated with different antihypertensive drugs', 'hypertensives under treatment .', 'treated hypertensive patients .', 'treated hypertensive patients .']","[1, 1, 2, 3, 3, 4, 4, 4, 4, 4, 4, 4, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'vitamin E', 'aspirin', 'vitamin E', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin', 'aspirin']","[1, 1, 2, 2, 3, 3, 3, 3, 4, 4, 5, 5, 7, 7, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['blood pressure ( BP ) control', 'blood pressure ( BP ) control', 'clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP', 'clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP', 'clinic BP', '24-h ambulatory BP monitoring', 'clinic BP', '24-h ambulatory BP monitoring', 'clinic SBP and DBP', 'clinic SBP and DBP', 'Ambulatory SBP and DBP', 'Ambulatory SBP and DBP', 'BP', 'BP', 'clinic and ambulatory blood pressure', 'clinic and ambulatory blood pressure']","[1, 1, 2, 2, 5, 5, 5, 5, 6, 6, 7, 7, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",10912743
8,"['Young children with pervasive developmental disorder', 'Young children', 'pervasive developmental disorder', '( 7 with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS )', '7', 'autism', '8', 'pervasive developmental disorder not otherwise specified -- NOS', '( 7 with autism , 6 with pervasive developmental disorder NOS )', '7 with autism', '6 with pervasive developmental disorder NOS', 'Children with pervasive developmental disorder NOS', 'autism .', 'Children', 'pervasive developmental disorder', 'children with pervasive developmental disorder .', 'children', 'pervasive developmental disorder']","[0, 0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 4, 4, 4, 4, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['intensive treatment', 'parent training .', 'intensive treatment', 'parent training .', 'intensive treatment', 'intensive treatment', 'parent training', 'parent training .', 'parent training', 'parent training .', 'intensive treatment', 'parent training', 'intensive treatment', 'parent training', 'intensive early intervention', 'intensive early intervention']","[0, 0, 0, 0, 1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['intelligence , visual-spatial skills , language , and academics', 'adaptive functioning', 'behavior problems .', 'intelligence', 'visual-spatial skills', 'language', 'academics', 'adaptive functioning', 'behavior problems .']","[3, 3, 3, 3, 3, 3, 3, 3, 3]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",10934569
9,"['on dogs and cats', 'dogs and cats', 'dogs and cats showing signs of flea allergy dermatitis ( FAD ) .', 'dogs and cats showing signs of flea allergy dermatitis ( FAD ) .', 'Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD', '( 220 dogs , 189 cats )', 'Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD', '220 dogs , 189 cats', 'dogs and cats diagnosed clinically with FAD .', 'dogs and cats diagnosed clinically with FAD .', '397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA', '397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA', '673 dogs and 347 cats having an age range of 6 weeks to 19 years', '673 dogs and 347 cats', '19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .', '19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .', 'in dogs and cats', 'dogs and cats', 'dogs and cats .', 'dogs and cats .', 'dogs and cats presented as veterinary patients in North America .', 'dogs and cats presented as veterinary patients in North America .']","[0, 0, 1, 1, 3, 3, 3, 3, 9, 9, 10, 10, 12, 12, 13, 13, 15, 15, 16, 16, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['selamectin', 'selamectin', 'selamectin', 'selamectin', 'selamectin', 'selamectin', 'selamectin', 'fenthion', 'pyrethrins', 'selamectin', 'fenthion', 'pyrethrins', 'Selamectin', 'Selamectin', 'selamectin-treated', 'fenthion-treated', 'selamectin-treated', 'selamectin-treated', 'pyrethrin-treated', 'Selamectin', 'Selamectin', 'selamectin', 'ivermectin', 'selamectin', 'ivermectin', 'Selamectin', 'Selamectin', 'Selamectin', 'Selamectin', 'selamectin', 'selamectin', 'Selamectin', 'Selamectin', 'selamectin', 'selamectin']","[0, 0, 1, 1, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 7, 7, 7, 8, 8, 9, 9, 10, 10, 10, 10, 11, 11, 12, 12, 15, 15, 16, 16, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['efficacy', 'safety', 'efficacy', 'safety', 'flea comb counts and clinical evaluations of FAD', 'flea comb counts', 'clinical evaluations of FAD', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'mean flea counts', 'signs', 'heartworm prevention rate', 'microfilariae and adult heartworm antigen', 'heartworm prevention rate', 'adverse events .', 'adverse events .', 'effective', 'signs associated with FAD .', 'effective', 'signs associated with FAD .', 'effective', 'heartworms', 'safe', 'heartworms', 'safe', 'Efficacy', 'safety', 'Efficacy', 'safety']","[0, 0, 0, 0, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 9, 11, 11, 11, 14, 14, 15, 15, 15, 15, 16, 16, 16, 16, 16, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",10940525
10,"['Acute invasive diarrhea', 'in children .', 'children .', 'acute invasive diarrhea requiring an emergency visit in southern Israel .', 'invasive diarrhea .', 'acute invasive diarrhea in infants and children .', 'acute invasive diarrhea', 'infants and children', '201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room', '201', 'children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room', 'acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .', 'ambulatory pediatric patients requiring an emergency room visit .', 'acute invasive diarrhea in children .', 'acute invasive diarrhea', 'children']","[0, 0, 0, 1, 2, 3, 3, 3, 4, 4, 4, 15, 15, 0, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['ceftriaxone', 'ceftriaxone', 'ciprofloxacin', 'ciprofloxacin', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ciprofloxacin', '[ ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone', 'ciprofloxacin', 'ceftriaxone']","[1, 1, 3, 3, 4, 4, 4, 4, 10, 10, 10, 10, 11, 11, 13, 13, 13, 13, 15, 15, 15, 15, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'safety', 'efficacy', 'safety', 'Stool cultures for Shigella , Salmonella , Campylobacter spp .', 'Stool cultures for Shigella , Salmonella , Campylobacter spp .', 'and diarrheagenic Escherichia coli', 'and diarrheagenic Escherichia coli', 'Clinical response and safety', 'Clinical response and safety', 'Clinical cure or improvement', 'Clinical cure or improvement', 'adverse events', 'adverse events', 'Joint examination', 'Joint examination', 'safe and effective', 'safe', 'effective']","[3, 3, 3, 3, 5, 5, 6, 6, 7, 7, 10, 10, 13, 13, 14, 14, 15, 15, 15]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",11099086
11,"['children with malaria', 'children', 'malaria', 'malaria .', 'malaria .', 'children with malaria .', 'children', 'malaria']","[0, 0, 0, 1, 1, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['antipyretics', 'naproxen', 'metamizol', 'antipyretics', 'naproxen', 'metamizol', 'Antipyretic', 'Antipyretic', 'antipyretic drugs', 'antipyretic drugs']","[0, 0, 0, 0, 0, 0, 1, 1, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['reduction of fever peaks .', 'reduction of fever peaks .', 'fever clearance', 'fever clearance']","[0, 0, 1, 1]","['ss_o', 'hl_o', 'ss_o', 'hl_o']",11229858
12,"['10 healthy subjects .', '10 healthy subjects']","[0, 0]","['ss_p', 'hl_p']","['garlic and onion', 'garlic and onion', 'garlic or onion', 'essential oils', 'garlic or onion', 'essential oils', 'Garlic and onion', 'Garlic and onion', 'essential oil', 'garlic', 'onion .', 'garlic', 'onion .', 'garlic and onion', 'essential oil', 'garlic and onion', 'essential oils of garlic and onion', 'essential oils of garlic and onion']","[0, 0, 1, 1, 1, 1, 2, 2, 3, 3, 3, 3, 3, 4, 4, 4, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['serum cholesterol and plasma fibrinogen', 'coagulation time', 'fibrinolytic activity .', 'serum cholesterol and plasma fibrinogen', 'coagulation time', 'fibrinolytic activity .', 'effects', 'effects']","[2, 2, 2, 2, 2, 2, 3, 3]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",1131298
13,"['249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes .', '249 adults from Washington State aged 55 to 75', 'doctor-confirmed diagnosis of osteoarthritis', 'persons with osteoarthritis .', 'persons with osteoarthritis .']","[4, 4, 4, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['aquatic exercise classes', 'aquatic exercise classes', 'aquatic classes .', 'aquatic classes .', 'aquatic classes .', 'aquatic classes .', 'Aquatic exercisers', 'Aquatic exercisers', 'Aquatic exercise', 'Aquatic exercise', 'aquatic exercise .', 'aquatic exercise .', 'aquatic exercise', 'aquatic exercise']","[0, 0, 1, 1, 4, 4, 9, 9, 12, 12, 13, 13, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['cost and outcomes', 'cost', 'outcomes', 'Cost per quality-adjusted life year ( QALY ) gained', 'Cost per quality-adjusted life year ( QALY )', 'cost/QALY gained', 'cost/QALY', 'Quality of Well-Being Scale ( QWB )', 'Current Health Desirability Rating ( CHDR )', 'economic evaluation', 'arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )', 'Perceived Quality of Life Scale ( PQOL )', 'Quality of Well-Being Scale ( QWB )', 'Current Health Desirability Rating ( CHDR )', 'arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )', 'Perceived Quality of Life Scale ( PQOL )', 'life expectancy tables', 'QALYs .', 'QALYs .', 'Use of health care facilities', 'diaries/questionnaires', 'Medicare reimbursement rates', 'costs .', 'Use of health care facilities', 'Medicare reimbursement rates', 'Nonparametric bootstrap sampling of costs/QALY ratios', 'costs/QALY ratios', '( QWB )', '( CHDR , HAQ , PQOL )', '( QWB )', '( CHDR , HAQ , PQOL )', 'Costs/QALY', 'QWB', 'CHRD .', 'Costs/QALY', 'QWB', 'CHRD .', 'QALY gained', 'QALY', 'Economic evaluation', 'Economic evaluation']","[0, 0, 0, 2, 2, 3, 3, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 9, 11, 11, 11, 11, 11, 11, 12, 12, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",11317090
14,"['patients at high risk for cardiovascular events .', 'patients at high risk for cardiovascular events .']","[0, 0]","['ss_p', 'hl_p']","['ramipril', 'angiotensin-converting enzyme ( ACE ) inhibitor', 'ramipril', 'angiotensin-converting enzyme ( ACE ) inhibitor', 'ramipril', 'ramipril', 'vitamin E', 'vitamin E', 'ACE inhibitor', 'ACE inhibitor']","[0, 0, 0, 0, 1, 1, 2, 2, 3, 3]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure', 'risk of diabetes-related complications and of diabetes itself .', 'rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure', 'risk of diabetes-related complications and of diabetes itself .']","[1, 1, 1, 1]","['ss_o', 'ss_o', 'hl_o', 'hl_o']",11381289
15,"['in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .', 'patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .', '53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy', '53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy', 'patients insufficiently controlled on timolol .', 'patients insufficiently controlled on timolol .']","[0, 0, 2, 2, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['timolol', 'latanoprost', 'latanoprost', 'timolol', 'timolol', 'latanoprost', 'latanoprost', 'timolol', 'timolol', 'timolol', 'timolol', 'timolol', 'latanoprost', 'latanoprost', 'timolol .', 'timolol', 'timolol', 'latanoprost', 'latanoprost', 'timolol .', 'timolol', 'latanoprost', 'latanoprost', 'timolol', 'timolol', 'latanoprost', 'latanoprost', 'timolol', 'timolol', 'latanoprost', 'latanoprost']","[0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i']","['intraocular pressure ( IOP )', 'intraocular pressure ( IOP )', 'efficacy', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP', 'IOP-reducing', 'IOP-reducing']","[0, 0, 5, 5, 5, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",11401641
16,"[""patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy ."", ""patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy ."", 'Patients with measurable and assessable disease', 'Patients with measurable and assessable disease', 'A total of 474 patients were treated', '474', 'Recurrent epithelial ovarian carcinoma :']","[0, 0, 1, 1, 3, 3, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p']","['pegylated liposomal doxorubicin ( PLD )', 'topotecan', 'pegylated liposomal doxorubicin ( PLD )', 'topotecan', 'PLD', 'topotecan', 'PLD', 'topotecan', 'PLD', 'topotecan )', 'PLD', 'topotecan', 'PLD', 'topotecan', 'PLD', 'topotecan', 'PLD', 'topotecan .', 'PLD', 'topotecan', 'PLD', 'PLD', 'topotecan .', 'PLD', 'PLD', 'topotecan .', 'PLD', 'topotecan', 'PLD', 'topotecan', 'topotecan', 'topotecan', 'topotecan', 'topotecan', 'PLD', 'PLD', 'pegylated liposomal doxorubicin', 'topotecan .', 'pegylated liposomal doxorubicin', 'topotecan .']","[0, 0, 0, 0, 1, 1, 1, 1, 3, 3, 3, 3, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 11, 11, 12, 12, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'safety', 'efficacy', 'safety', 'overall progression-free survival rates', 'overall progression-free survival rates', 'overall response rates', 'overall response rates', 'Median overall survival times', 'Median overall survival times', 'overall survival', 'overall survival', 'survival', 'Severe hematologic toxicity', 'Severe hematologic toxicity', 'efficacy , favorable safety profile', 'convenient dosing', 'efficacy', 'safety']","[0, 0, 0, 0, 5, 5, 6, 6, 7, 7, 9, 9, 10, 11, 11, 12, 12, 12, 12]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",11454878
17,"['Sixty healthy women , half of whom had been using OCs for at least the previous 6 months', 'Sixty healthy women , half of whom had been using OCs for at least the previous 6 months', 'two thirds were smokers', 'two thirds were smokers', 'One third were nonsmokers .', 'One third were nonsmokers .', 'women .', 'nonsmoking women', 'nonsmokers .']","[3, 3, 4, 4, 5, 5, 9, 10, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p']","['oral contraceptives ( OCs )', 'oral contraceptives ( OCs )', 'OC', 'cigarette smoking', 'nicotine', 'OC', 'OCs', 'nicotine deprivation', 'nicotine', 'nicotine', 'nicotine', 'OC', 'nicotine', 'OC', 'nicotine', 'OC', 'OC', 'nicotine', 'nicotine', 'nicotine', 'nicotine', 'OC', 'OC', 'Oral contraceptive', 'Oral contraceptive']","[0, 0, 1, 2, 2, 2, 3, 4, 4, 4, 4, 7, 7, 7, 7, 8, 8, 9, 9, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['cardiovascular disease', 'Cardiovascular reactivity', 'cardiovascular and lipid reactivity .', 'cardiovascular and lipid reactivity .', 'Heart rate , blood pressure , and lipid measures', 'Heart rate , blood pressure , and lipid measures', 'heart rate and diastolic blood pressure reactivity', 'heart rate and diastolic blood pressure reactivity', 'cardiovascular or lipid stress reactivity', 'cardiovascular or lipid stress reactivity', 'cardiovascular reactivity', 'cardiovascular reactivity', 'cardiovascular reactivity', 'cardiovascular reactivity']","[0, 1, 2, 2, 6, 6, 8, 8, 9, 9, 10, 10, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",11495215
18,"['patients on thrombolytic therapy ( TLT ) .', 'patients on thrombolytic therapy ( TLT ) .', '106 males with Q-MI entered the study .', '106 males', 'Q-MI', 'MI patients receiving TLT', 'myocardial infarction']","[0, 0, 1, 1, 1, 7, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['neoton', 'thrombolytic therapy ( TLT )', 'neoton', 'thrombolytic therapy ( TLT )', 'TLT', 'neoton', 'TLT', 'streptokinase', 'streptokinase preparations', 'neoton .', 'TLT', 'neoton', 'TLT', 'streptokinase', 'streptokinase preparations', 'neoton .', 'TLT', 'neoton', 'neoton', 'neoton', 'neoton', 'Neoton', 'TLT', 'Neoton', '[ Neoton', 'thrombolytic therapy', 'Neoton', 'thrombolytic therapy']","[0, 0, 0, 0, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 4, 5, 5, 6, 6, 7, 7, 7, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['systolic function of the left ventricle , arrhythmia and clinical symptoms', 'systolic function of the left ventricle , arrhythmia and clinical symptoms', 'Left ventricular systolic function was measured by echocardiography', 'arrhythmia was analysed at Holter monitoring', 'Left ventricular systolic function', 'arrhythmia', 'systolic and diastolic volumes', 'systolic and diastolic volumes', 'left ventricular systolic dysfunction', 'left ventricular systolic dysfunction']","[0, 0, 3, 3, 3, 3, 5, 5, 7, 7]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",11642083
19,"['older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .', 'older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) )', '60-year-old subjects', '60-year-old subjects', 'the 60-year-old', 'the 60-year-old']","[0, 0, 9, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['antioxidant supplementation', 'antioxidant supplementation', 'dl-alpha-tocopheryl acetate', 'ascorbic acid', 'beta-carotene', 'placebo', 'dl-alpha-tocopheryl acetate', 'ascorbic acid', 'beta-carotene', 'placebo', 'Antipyrine', 'Antipyrine', 'Antipyrine', 'antioxidant supplementation', 'antioxidant supplementation', 'Antioxidant supplementation', 'antipyrine hydroxylates .', 'Antioxidant supplementation', 'antipyrine']","[0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 3, 3, 4, 9, 9, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['exercise-induced oxidative stress', 'Antipyrine', 'oxidative stress .', 'Antipyrine', 'para- and ortho-hydroxyantipyrine .', 'para- and ortho-hydroxyantipyrine to antipyrine .', 'para- and ortho-hydroxyantipyrine to antipyrine .', 'thiobarbituric acid reactive substances in plasma .', 'thiobarbituric acid reactive substances in plasma .', 'free radical products of antipyrine .', 'free radical products of antipyrine .', 'exercise-induced oxidative stress']","[0, 3, 3, 4, 4, 7, 7, 8, 8, 9, 9, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",11737955
20,"['patients with recently diagnosed rheumatoid arthritis ( RA )', 'patients with recently diagnosed rheumatoid arthritis ( RA )', 'Twenty-two patients with a history of recently diagnosed RA of less than 2 years', 'Twenty-two patients with a history of recently diagnosed RA of less than 2 years', '22 patients', '22 patients', 'recent onset RA .', 'recent onset rheumatoid arthritis :', 'recent onset rheumatoid arthritis :']","[0, 0, 1, 1, 2, 2, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['standard outpatient clinic treatment', 'standard outpatient clinic treatment']","[2, 2]","['ss_i', 'hl_i']","['predictors of depression .', 'depression .', 'clinical outcome and process measures', 'clinical outcome and process measures', 'predict depression', 'predict depression', 'initial level of depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .', 'depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .', 'role', 'disability , illness perceptions , pain and coping .', 'disability', 'illness perceptions', 'pain', 'coping']","[0, 0, 1, 1, 4, 4, 5, 5, 0, 0, 0, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",11750293
21,"['Eighteen patients who had undergone stoma surgery', 'Eighteen patients who had undergone stoma surgery', 'patients after stoma surgery .', 'patients after stoma surgery .', 'patients after stoma surgery .', 'patients after stoma surgery .']","[0, 0, 7, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['progressive muscle relaxation training ( PMRT )', 'progressive muscle relaxation training ( PMRT )', 'PMRT', 'PMRT', 'progressive muscle relaxation training', 'progressive muscle relaxation training']","[2, 2, 7, 7, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['anxiety level and self-reported quality of life ( QoL )', 'anxiety level and self-reported quality of life ( QoL )', 'Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .', 'Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .', 'C-STAI score', 'WHOQoL score', 'C-STAI score', 'WHOQoL score', 'WHOQoL', 'QoL', 'WHOQoL', 'QoL', 'QoL-Colostomy', 'QoL-Colostomy', 'quality of life', 'anxiety', 'quality of life', 'anxiety']","[0, 0, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 7, 7, 7, 7]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",11829043
22,"['44 patients with inclusion body myositis', '44 patients with inclusion body myositis', 'inclusion body myositis', 'inclusion body myositis']","[0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['methotrexate', 'methotrexate', 'methotrexate', 'placebo', 'methotrexate', 'placebo', 'methotrexate', 'methotrexate', 'methotrexate', 'methotrexate', 'methotrexate', 'placebo .', 'methotrexate', 'placebo .']","[0, 0, 2, 2, 2, 2, 4, 4, 5, 5, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['disease progression', 'disease progression', 'Mean change of quantitative muscle strength testing sum scores', 'Mean change of quantitative muscle strength testing sum scores', 'Quantitative muscle strength testing sum scores', 'Quantitative muscle strength testing sum scores', ""manual muscle testing sum scores , activity scale scores and patients ' own assessments"", ""manual muscle testing sum scores , activity scale scores and patients ' own assessments"", 'Serum creatine kinase activity', 'Serum creatine kinase activity', 'progression of muscle weakness', 'serum creatine kinase activity .', 'progression of muscle weakness', 'serum creatine kinase activity .', 'weakness progression', 'weakness progression']","[0, 0, 1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 5, 5, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",11891832
23,"['pterygium .', 'pterygium .', '208 patients ( 229 eyes ) with initial pterygium', '208 patients', 'initial pterygium', 'pterygium .', 'pterygium ]', 'pterygium']","[0, 0, 2, 2, 2, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['limbal epithelial autograft transplantation', 'pterygium excision', 'limbal epithelial autograft transplantation', 'pterygium excision', 'excision of pterygium', 'limbal epithelial autograft transplantation surgery', 'simple pterygium excision', 'excision of pterygium', 'limbal epithelial autograft transplantation surgery', 'simple pterygium excision', 'limbal epithelial autograft transplantation', 'limbal epithelial autograft transplantation', '[ Limbal epithelial autograft transplantation', '[ Limbal epithelial autograft transplantation']","[0, 0, 0, 0, 2, 2, 2, 2, 2, 2, 7, 7, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['therapeutic effects', 'corneal transparency with stable epithelial healing and no abnormal proliferation of pterygium-like tissue .', 'epithelial healing', 'abnormal proliferation of pterygium-like tissue .']","[0, 3, 3, 3]","['ss_o', 'ss_o', 'hl_o', 'hl_o']",12139812
24,"['Thirty-five university students were assessed', 'Thirty-five university students were assessed']","[2, 2]","['ss_p', 'hl_p']","['Reichert AT550 .', 'Reichert AT550 .', 'Reichert Xpert Plus , Goldmann applanation tonometer', 'Perkins tonometer .', 'Reichert Xpert Plus', 'Goldmann applanation tonometer', 'Perkins tonometer .', 'AT550 NCT', 'Goldmann tonometer', 'AT550 NCT', 'Goldmann tonometer', 'AT550 NCT', 'Goldmann tonometry', 'AT550 NCT', 'Goldmann tonometry', 'Reichert AT550 :', 'Reichert AT550 :']","[0, 0, 1, 1, 1, 1, 1, 5, 5, 5, 5, 6, 6, 6, 6, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['level of accuracy', 'measurements of intra-ocular pressure ( IOP )', 'level of accuracy', 'measurements', 'IOP', 'IOP', 'IOP', 'IOP', 'Clinical performance', 'Clinical performance']","[0, 0, 0, 0, 4, 6, 6, 6, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",12477021
25,"['A total of 57 consecutive patients with primary ureteropelvic junction obstruction', '57', 'patients with primary ureteropelvic junction obstruction', 'endopyelotomy', 'endopyelotomy']","[4, 4, 4, 14, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p']","['Internal stenting', 'Internal stenting', 'stent', 'stenting', 'stenting', '7/14Fr internal endopyelotomy stent placement', '7/14Fr internal endopyelotomy stent placement', 'Stent', 'stenting', 'endopyelotomy', 'stenting']","[0, 0, 2, 3, 3, 4, 4, 12, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['optimum duration of stenting', 'optimum duration of stenting', 'symptom based questionnaire', 'diuretic scanning', 'diuretic renography .', 'symptoms and ipsilateral glomerular filtration rate .', 'symptoms', 'ipsilateral glomerular filtration rate .', 'drainage pattern .', 'drainage pattern .', 'Stent related symptoms', 'urinary tract infections', 'Stent related symptoms', 'urinary tract infections', 'duration', 'stent related complications .', 'duration', 'stent related complications .', 'duration']","[3, 3, 5, 6, 6, 8, 8, 8, 10, 10, 12, 12, 12, 12, 14, 14, 14, 14, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",12576806
26,"['patients with advanced NPC .', 'patients with advanced NPC .', 'From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC', 'From December 1993 to April 1999', '284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC', 'patients with advanced NPC in endemic areas .', 'patients with advanced NPC', 'advanced nasopharyngeal carcinoma :', 'advanced nasopharyngeal carcinoma :']","[1, 1, 2, 2, 2, 13, 13, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['concurrent chemoradiotherapy ( CCRT )', 'radiotherapy ( RT )', 'concurrent chemoradiotherapy ( CCRT )', 'radiotherapy ( RT )', 'RT', 'chemotherapy', 'cisplatin', 'fluorouracil', 'RT .', 'chemotherapy', 'cisplatin', 'fluorouracil', 'CCRT', 'RT-alone', 'CCRT', 'RT-alone', 'CCRT', 'RT-only', 'CCRT', 'RT-only', 'CCRT', 'RT-only', 'CCRT', 'RT-only', 'CCRT', 'CCRT', 'concurrent chemotherapy', 'CCRT', 'RT', 'CCRT', 'RT', 'concurrent chemoradiotherapy', 'radiotherapy', 'concurrent chemoradiotherapy', 'radiotherapy']","[1, 1, 1, 1, 3, 4, 4, 4, 4, 4, 4, 4, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 11, 13, 13, 13, 13, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test .', 'Survival analysis', 'tumor relapse', 'tumor relapse', '5-year overall survival rates', '5-year overall survival rates', '5-year progression-free survival rates', '5-year progression-free survival rates', 'toxicity', 'leukopenia and emesis', 'toxicity', 'leukopenia', 'emesis', 'treatment-related deaths', 'treatment-related deaths', 'effect', 'overall and progression-free survival .', 'overall and progression-free survival .']","[5, 5, 7, 7, 8, 8, 9, 9, 10, 10, 10, 10, 10, 12, 12, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",12586799
27,"['people with diabetes', 'people with diabetes', '7674 participants with albuminuria data at baseline and at follow-up .', '7674 participants with albuminuria data at baseline and at follow-up', 'Inclusion criteria were known vascular disease or diabetes plus one other cardiovascular risk factor , exclusion criteria included heart failure or known impaired left ventricular function , dipstick-positive proteinuria ( > 1+ ) , and serum creatinine > 2.3 mg/dl ( 200 microM ) .', 'People without and with diabetes who are at high risk for cardiovascular disease', 'nondiabetic and in diabetic people .', 'nondiabetic and in diabetic people .', 'in people at high cardiovascular risk :', 'people at high cardiovascular risk']","[0, 0, 3, 3, 4, 8, 9, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","[""ramipril 's"", 'placebo', ""ramipril 's"", 'placebo', 'Ramipril', 'Ramipril', 'Ramipril', 'Ramipril']","[2, 2, 2, 2, 7, 7, 10, 10]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['progress from microalbuminuria', 'clinical proteinuria', 'renal insufficiency .', 'changes of proteinuria', 'clinical proteinuria', 'clinical proteinuria', 'progression of albuminuria', 'new microalbuminuria or new clinical proteinuria )', 'new microalbuminuria', 'clinical proteinuria .', 'progression of albuminuria', 'microalbuminuria', 'clinical proteinuria .', 'progression', 'progression', 'albuminuria .', 'albuminuria .', 'clinical proteinuria', 'progression of albuminuria .', 'progression of albuminuria .', 'Development of renal disease']","[0, 0, 0, 2, 5, 5, 6, 6, 6, 6, 6, 6, 6, 7, 7, 8, 8, 9, 10, 10, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",12595499
28,"['for colonoscopy', '100 adult patients', '100 adult patients', 'colonoscopy', 'outpatient colonoscopy .', 'outpatient colonoscopy .']","[0, 1, 1, 11, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['remifentanil', 'propofol', 'midazolam , fentanyl', 'propofol .', 'remifentanil', 'propofol', 'midazolam', 'fentanyl', 'propofol', 'remifentanil', 'propofol', 'remifentanil', 'propofol', 'fentanyl', 'midazolam', 'propofol', 'fentanyl', 'midazolam', 'propofol', 'remifentanil', 'propofol', 'remifentanil', 'propofol', 'remifentanil', 'propofol', 'fentanyl , midazolam', 'propofol', 'remifentanil', 'propofol', 'fentanyl', 'midazolam', 'propofol']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 11, 11, 11, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i']","['effective', 'Cardiorespiratory parameters and bispectral index were monitored and recorded .', 'Cardiorespiratory parameters', 'bispectral index', 'The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .', 'Numerical Pain Rating Scale ( NRS )', 'recovery level', 'return of psychomotor efficiency', 'Aldrete scale', 'Modified Post Anesthesia Discharge Scoring ( MPADS ) system', '( NRS', 'pain intensity score', 'pain intensity score', 'maximum MPADS score', 'maximum MPADS score', 'mean arterial pressure and heart rate and signs of respiratory depression', 'mean arterial pressure and heart rate and signs of respiratory depression', 'sufficient analgesia', 'hemodynamic stability', 'respiratory depression', 'rapid recovery', 'analgesia', 'hemodynamic stability', 'respiratory depression', 'rapid recovery']","[0, 4, 4, 4, 5, 5, 5, 5, 5, 5, 7, 8, 8, 9, 9, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",12709693
29,"['Twenty-nine IDDM patients with borderline hypertension', 'Twenty-nine IDDM patients with borderline hypertension', 'diabetic patients with borderline hypertension .', 'diabetic patients with borderline hypertension .', 'borderline hypertensive patients with IDDM-type diabetes mellitus .', 'borderline hypertensive patients with IDDM-type diabetes mellitus .']","[0, 0, 9, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['placebo', 'nitrendipine', 'placebo', 'nitrendipine', 'Nitrendipine', 'Nitrendipine', 'placebo', 'placebo', 'nitrendipine', 'nitrendipine', 'nitrendipine', 'nitrendipine', 'nitrendipine', 'nitrendipine', 'dihydropyridine calcium channel blocker :', 'nitrendipine', 'dihydropyridine calcium channel blocker', 'nitrendipine']","[0, 0, 0, 0, 1, 1, 5, 5, 7, 7, 8, 8, 9, 9, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['Stimulated platelet thromboxane formation', 'non exhausting exercise', 'Stimulated platelet thromboxane formation', 'plasma levels of platelet factor 4 and aggregation responses to collagen and ADP', 'plasma levels of platelet factor 4 and aggregation responses to collagen and ADP', 'thromboxane formation', 'thromboxane formation', 'Exercise induced change of thromboxane synthesis', 'Exercise induced change of thromboxane synthesis', 'PF4 plasma levels', 'PF4 plasma levels', 'Whole blood aggregation after collagen stimulation', 'aggregation', 'Whole blood aggregation after collagen stimulation', 'aggregation', 'collagen dependent platelet activation', 'collagen dependent platelet activation', 'platelet thromboxane formation', 'platelet thromboxane formation']","[2, 2, 2, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 7, 7, 9, 9, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",1286547
30,"['control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .', 'infants with different gastrointestinal diseases', '21 patients ( age 0-2 months ) and 40 healthy infants ( age 0-2 months )', '21 patients', 'age 0-2 months', '40 healthy infants', 'age 0-2 months', 'patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting', 'patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting', 'infants with partial or total intestinal obstruction', 'infants with gastrointestinal diseases', 'infants', 'gastrointestinal diseases']","[3, 3, 4, 4, 4, 4, 4, 5, 5, 10, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['Epigastric impedance', 'Epigastric impedance', 'epigastric impedance', 'epigastric impedance', 'epigastric impedance', 'epigastric impedance', 'epigastric impedance']","[2, 2, 3, 3, 10, 10, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i']","['myoelectrical dysrhythmia', 'gastric electrical activity', 'gastric myoelectrical activity and dysrhythmia', 'electrogastrography', 'Epigastric impedance', 'gastric emptying time and gastric phasic activity .', 'gastric dysrhythmia', 'epigastric impedance', 'gastric rhythms', 'impedance gastrography', 'epigastric impedance', 'phasic activity', 'frequency phasic activity', 'phasic activity', 'frequency phasic activity', 'phasic activity', 'phasic activity', 'epigastric impedance', 'gastric phasic activity patterns', 'Gastric dysrhythmia', 'epigastric impedance .']","[0, 0, 1, 1, 2, 2, 3, 3, 3, 3, 3, 8, 8, 8, 8, 9, 9, 10, 11, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",12960652
31,"['in vitro fertilization ( IVF )', 'in vitro fertilization ( IVF )', 'Aberdeen Assisted Reproduction Unit .', 'Forty-eight patients having IVF for the first time', 'Forty-eight patients having IVF for the first time', 'patients undergoing IVF .', 'undergoing IVF', 'in vitro fertilization']","[0, 0, 2, 3, 3, 6, 6, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p']","['gonadotropin-releasing hormone agonist ( GnRH-a )', 'gonadotropin-releasing hormone agonist ( GnRH-a )', 'GnRH-a .', 'GnRH-a .', 'gonadotropin-releasing hormone agonist', 'gonadotropin-releasing hormone agonist']","[0, 0, 1, 1, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['usefulness', 'usefulness', 'Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .', 'Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .', 'ovulation induction , fertilization , and pregnancy rates', 'LH surge .', 'ovulation induction , fertilization , and pregnancy rates', 'LH surge .', 'ovarian stimulation']","[0, 0, 4, 4, 5, 5, 5, 5, 6]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",1459268
32,"['patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .', 'patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .', 'Patients with bidimensionally measurable disease', 'Patients with bidimensionally measurable disease', 'A total of 226 patients were evaluable for response .', '226', 'ovarian cancer .', 'ovarian cancer .', 'advanced epithelial ovarian carcinoma .', 'advanced epithelial ovarian carcinoma .']","[0, 0, 1, 1, 4, 4, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel', 'Topotecan', 'paclitaxel', 'Topotecan', 'paclitaxel', 'topotecan', 'topotecan', 'topotecan', 'paclitaxel', 'topotecan', 'paclitaxel']","[0, 0, 0, 0, 1, 1, 1, 1, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 10, 10, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['survival', 'The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire', '( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia )', 'European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire', 'pain', 'anorexia', 'diarrhoea', 'fatigue', 'nausea', 'vomiting', 'dyspnea', 'constipation', 'insomnia', 'EORTC QOL-30 questionnaire .', 'progression', 'progression', 'median survival', 'median survival', 'efficacy', 'survival', 'haematological toxicity .', 'efficacy', 'survival', 'haematological toxicity .', 'Non-haematological toxicity', 'Non-haematological toxicity', 'long-term survival rate', 'Long-term survival']","[0, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 5, 6, 6, 7, 7, 8, 8, 8, 8, 8, 8, 9, 9, 10, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",14679127
33,"['healthy young subjects', 'healthy young', 'Five groups of 8 subjects each', 'Five groups of 8 subjects each']","[0, 0, 1, 1]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 )', 'cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib', 'placebo', 'torcetrapib', 'placebo', 'torcetrapib', 'Torcetrapib', 'Torcetrapib', 'torcetrapib .', 'torcetrapib .']","[0, 0, 1, 1, 1, 1, 2, 2, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['high-density lipoprotein cholesterol ( HDL-C ) levels', 'plasma drug levels', 'plasma drug levels', 'HDL-C', 'Total plasma cholesterol', 'nonHDL-C', 'low-density lipoprotein cholesterol', 'Total plasma cholesterol', 'nonHDL-C', 'low-density lipoprotein cholesterol', 'Apolipoprotein A-I and E', 'apoB', 'Apolipoprotein A-I and E', 'apoB', 'Cholesteryl ester content', 'triglyceride', 'nonHDL', 'HDL .', 'Cholesteryl ester content', 'triglyceride', 'high-density lipoprotein']","[0, 3, 3, 4, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",14739125
34,"['patients on continuous ambulatory peritoneal dialysis ( CAPD ) .', 'patients on continuous ambulatory peritoneal dialysis ( CAPD ) .', '24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ]', '24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women', 'LVMi > 137 g/m2 for men', 'CAPD patients with LVH', 'left ventricular hypertrophy', 'left ventricular hypertrophy']","[0, 0, 1, 1, 1, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['selective angiotensin II receptor blocker ( ARB )', 'selective angiotensin II receptor blocker ( ARB )', 'ARB valsartan', 'placebo', 'ARB valsartan', 'placebo', 'ARB .', 'ARB .', 'ARB', 'placebo', 'ARB', 'placebo', 'ARB', 'ARB', 'Valsartan', 'Valsartan']","[0, 0, 1, 1, 1, 1, 6, 6, 7, 7, 7, 7, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['regressive effect on left ventricular hypertrophy ( LVH )', '[ left ventricular mass index ( LVMi )', 'LVMi', 'target blood pressure ( BP )', 'blood pressure ( BP )', 'aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography .', 'aortic and large-artery compliance', 'arterial wave reflections [ pulse wave velocity ( PWV )', 'augmentation index ( AI ) application tonometry ]', 'cardiac echocardiography .', 'body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .', 'body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .', 'Systolic and diastolic BP', 'Systolic and diastolic BP', 'LVMi', 'LVMi', 'LVMi', 'PWV', 'AI .', 'LVMi', 'PWV', 'AI', 'LVMi', 'arterial hemodynamics .', 'LVMi', 'regression of left ventricular hypertrophy', 'arterial stiffness .']","[0, 1, 1, 2, 2, 3, 3, 3, 3, 3, 4, 4, 6, 6, 7, 7, 8, 8, 8, 8, 8, 8, 9, 9, 9, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",14763035
35,"['Nearly 2000 patients with stage IIB and III melanoma', 'Nearly 2000 patients with stage IIB and III melanoma', 'patients with high-risk resected melanoma', 'patients with high-risk resected melanoma']","[0, 0, 9, 9]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['IFN-alpha 2b', 'IFN-alpha 2b', 'observation ( Obs )', 'IFN-alpha 2b ( HDI )', 'Obs', 'IFN-alpha 2b ( HDI )', 'Obs', 'HDI', 'Obs .', 'HDI', 'Obs', 'HDI', 'Obs', 'HDI', 'Obs', 'interferon', 'interferon']","[0, 0, 4, 4, 4, 4, 4, 6, 6, 6, 6, 8, 8, 8, 8, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['prognostic factors and treatment effects', 'prognostic factors using optimized statistical models', 'treatment effects versus observation ( Obs )', 'relapse-free survival ( RFS ) -but', 'overall survival ( OS ) -was', 'relapse-free survival ( RFS )', 'overall survival ( OS )', 'prognostic factors', 'ulceration , recurrent disease at entry', 'age', 'RFS', 'OS', 'RFS', 'OS', 'RFS', 'OS', 'RFS', 'OS', 'predictors of relapse and response']","[1, 3, 4, 6, 6, 6, 6, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 10]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",15014018
36,"['Thirty-four consecutive patients', 'Thirty-four consecutive patients', 'biventricular implantation procedures .', 'biventricular implantation']","[4, 4, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['catheters ( guiding catheter alone', 'electrophysiology catheter advanced', '( electrophysiology catheter aided', 'catheters', 'guiding catheter alone', 'GCA', 'electrophysiology catheter advanced', 'electrophysiology catheter aided', 'EPA', 'GCA', 'EPA', 'GCA', 'GCA', 'EPA', 'GCA', 'EPA', 'EPA', 'GCA', 'EPA', 'GCA', 'EPA', 'GCA', 'EPA', 'GCA', 'EPA', 'GCA', 'EPA', 'GCA']","[2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['CS cannulation time', 'CS cannulation time', 'Time to successful catheterization of CS', 'Time to successful catheterization of CS', 'Fluoroscopy time', 'Fluoroscopy time', 'contrast dye volume', 'contrast dye volume', 'procedural time , fluoroscopy time and contrast dye volume', 'procedural time , fluoroscopy time', 'contrast dye volume']","[3, 3, 5, 5, 6, 6, 7, 7, 8, 8, 8]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",15133359
37,"[""peers '"", 'child with autism .', 'peers', 'child with autism .', 'Children ( N = 576 ; M age = 10.06 )', 'Children', '576', 'M age = 10.06', ""children 's"", ""children 's"", ""peers '"", 'peers']","[0, 0, 0, 0, 1, 1, 1, 1, 6, 6, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['descriptive and explanatory information', 'descriptive ( AUT-D )', 'descriptive and explanatory information ( AUT-D + E ) .', 'descriptive ( AUT-D )', 'descriptive and explanatory information ( AUT-D + E ) .', 'descriptive information', 'combination of descriptive and explanatory information', 'combination of descriptive and explanatory information', 'descriptive and explanatory information', 'Combined descriptive and explanatory information']","[0, 1, 1, 1, 1, 4, 4, 6, 6, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i']","[""peers ' perceptions and behavioral intentions"", ""peers ' perceptions"", 'behavioral intentions', 'measures of attitudes ( Adjective Checklist ) and behavioral intentions ( Shared Activities Questionnaire ) .', '( Adjective Checklist )', '( Shared Activities Questionnaire )', 'behavioral intentions', 'academic intentions .', ""children 's attitudes and behavioral intentions ."", ""children 's attitudes"", 'behavioral intentions', ""peers ' perceptions"", ""peers ' perceptions""]","[0, 0, 0, 2, 2, 2, 5, 5, 6, 6, 6, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",15193668
38,"['adults with autism .', 'adults with autism .', 'adults with autism', 'adults with autism', 'adults with autism', 'adults with autism', 'adults with autism .', 'adults with autism .']","[1, 1, 2, 2, 3, 5, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p']","['visual search', 'visual search']","[0, 0]","['ss_i', 'ss_i']","['visual search tasks', 'searching for targets .', 'searching for targets .', 'visual search performance', 'visual discrimination ability .', 'visual search performance', 'visual discrimination ability .', 'unique item detection', 'discrimination', 'unique item detection']","[0, 2, 2, 3, 3, 3, 3, 5, 5, 5]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",15358868
39,"['post-acute hemiparetic patients', 'post-acute hemiparetic patients', 'Twenty-six patients within 3 months of onset of stroke', 'Twenty-six patients within 3 months of onset of stroke', 'stroke patients ]', 'stroke patients ]']","[0, 0, 1, 1, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['conventional physical therapy alone', 'with a specialised balance retraining program .', 'conventional physical therapy alone', 'specialised balance retraining program', 'physical therapy', 'therapy and retraining', 'physical therapy', 'therapy and retraining', 'conventional therapy', 'therapy combined with standing balance training by biofeedback ( BPM Monitor ) .', 'conventional therapy', 'therapy', 'standing balance training by biofeedback ( BPM Monitor )', 'conventional therapy .', 'conventional therapy .']","[0, 0, 0, 0, 1, 1, 1, 1, 3, 3, 3, 3, 3, 12, 12]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['gait improvement', 'gait improvement', 'Clinical measures', 'Gait spatiotemporal parameters', 'Gait spatiotemporal parameters', 'clinical scores', 'clinical scores', 'time between stroke and the beginning of walking', 'time between stroke and the beginning of walking', 'Gait velocity', 'Gait velocity', 'walking pattern', 'duration of the paretic limb single stance .', 'walking pattern', 'duration of the paretic limb single stance .', 'duration of the reception double stance on the paretic limb', 'duration of the reception double stance on the paretic limb', 'anticipation equilibrium']","[0, 0, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 9, 9, 10, 10, 12]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",15848261
40,"['98 patients', 'flexible nasendoscopy .', '98 patients', 'flexible nasendoscopy .', 'flexible nasendoscopy .', 'flexible nasendoscopy .', 'flexible nasendoscopy :', 'flexible nasendoscopy :']","[1, 1, 1, 1, 6, 6, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['cophenylcaine', 'placebo', 'cophenylcaine', 'placebo', 'cophenylcaine', 'cophenylcaine', 'cophenylcaine', 'cophenylcaine', 'Cophenylcaine spray', 'placebo', 'Cophenylcaine', 'placebo']","[1, 1, 1, 1, 4, 4, 6, 6, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['visual analogue scale ( 1-100 ) was used to record pain , unpleasantness of taste and overall discomfort experienced .', 'pain , unpleasantness of taste and overall discomfort experienced .', 'pain and discomfort', 'pain and discomfort', 'pain or overall discomfort', 'sensation of bad taste', 'pain or overall discomfort', 'sensation of bad taste', 'unpleasantness', 'pain', 'unpleasantness of taste .', 'unpleasantness', 'pain', 'unpleasantness of taste .']","[2, 2, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o']",15854186
41,"['acute childhood diarrhoea', 'children with acute diarrhoea .', 'children with acute diarrhoea .', 'Two hundred children', 'Two hundred children', 'acute diarrhoea in children', 'acute diarrhoea in children', 'children with acute diarrhoea .', 'children', 'acute diarrhoea']","[1, 2, 2, 3, 3, 10, 10, 0, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['Saccharomyces boulardii .', 'Saccharomyces boulardii .', 'S. boulardii', 'S. boulardii', 'S. boulardii', '( S. boulardii', 'placebo ( placebo', 'S. boulardii', 'S. boulardii', 'placebo', 'placebo', 'S. boulardii', 'placebo', 'S. boulardii', 'placebo', 'S. boulardii', 'placebo', 'S. boulardii', 'placebo', 'S. boulardii', 'S. boulardii', 'S. boulardii', 'placebo', 'S. boulardii', 'placebo', 'placebo', 'S. boulardii', 'placebo', 'S. boulardii', 'S. boulardii', 'S. boulardii', 'S. boulardii', 'S. boulardii', 'Saccharomyces boulardii', 'Saccharomyces boulardii']","[1, 1, 2, 2, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['effect', 'average stool frequency', 'average stool frequency', 'duration of diarrhoea', 'duration of diarrhoea', 'effect', 'duration of hospital stay', 'duration of hospital stay', 'duration of acute diarrhoea and the duration of hospital stay .', 'duration of acute diarrhoea', 'duration of hospital stay']","[2, 4, 4, 5, 5, 6, 7, 7, 9, 9, 9]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",15858959
42,"['German', 'Schizophrenia', 'patients in the "" early initial prodromal state "" .', '"" early initial prodromal state ""', 'patients in the "" late initial prodromal state ""', '"" late initial prodromal state ""', '1212 individuals seeking help for mental health problems', 'four university centres .', '1212 individuals seeking help for mental health problems', 'More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .', 'More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .', 'people at increased risk of developing psychosis .', 'initial prodromal states of psychosis in Germany :', 'initial prodromal states of psychosis', 'Germany']","[0, 0, 3, 3, 4, 4, 6, 6, 6, 7, 7, 8, 0, 0, 0]","['ss_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['Comprehensive cognitive-behavioural therapy', 'Comprehensive cognitive-behavioural therapy', 'atypical neuroleptic amisulpride', 'atypical neuroleptic amisulpride']","[3, 3, 4, 4]","['ss_i', 'hl_i', 'ss_i', 'hl_i']",[],[],[],16055807
43,"['digestive surgery patients .', 'digestive surgery patients .', 'Forty patients who underwent digestive surgery', 'Forty patients who underwent digestive surgery', 'digestive surgery patients .', 'digestive surgery patients .', 'after digestive surgery ]', 'after digestive surgery ]']","[0, 0, 1, 1, 7, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['branch chain amino acid ( BCAA ) enriched formula', 'branch chain amino acid ( BCAA ) enriched formula', 'BCAA enriched', 'routine amino acid', 'BCAA enriched', 'routine amino acid', 'BCAA', 'BCAA', 'BCAA-enriched', 'BCAA-enriched', 'BCAA enriched formula', 'BCAA enriched formula', 'branch chain amino acid enriched formula', 'amino acid enriched formula']","[0, 0, 1, 1, 1, 1, 3, 3, 6, 6, 7, 7, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['nutritional status', 'postoperative fatigue', 'nutritional status', 'postoperative fatigue', 'Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score', 'Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score', 'cumulative postoperative fatigue scores', 'cumulative postoperative fatigue scores', 'nitrogen balance', 'cumulative nitrogen balance', 'nitrogen balance', 'cumulative nitrogen balance', 'serum total protein , albumin , prealbumin , transferrin', 'serum total protein , albumin , prealbumin , transferrin', 'serum level of retinol binding protein', 'serum level of retinol binding protein', 'postoperative fatigue score', 'nutritional status', 'postoperative fatigue score', 'nutritional status', 'postoperative fatigue and nutritional status', 'postoperative fatigue', 'nutritional status']","[0, 0, 0, 0, 2, 2, 3, 3, 4, 4, 4, 4, 5, 5, 6, 6, 7, 7, 7, 7, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",16167234
44,"['Parents of children who receive the diagnosis of autistic spectrum disorder ( ASD )', 'Parents of children', 'diagnosis of autistic spectrum disorder ( ASD )', 'parents of children with ASD', 'parents of children with ASD', 'parents of children with autistic spectrum disorder .', 'parents of children', 'autistic spectrum disorder']","[0, 0, 0, 1, 1, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['nursing intervention', 'nursing intervention', 'post-diagnosis nursing intervention', 'post-diagnosis nursing intervention', 'usual care', 'contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan .', 'usual care', 'contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan', 'usual care', 'consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan', 'usual care', 'consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan', 'nursing intervention', 'nursing intervention .', 'Intervention', 'Intervention']","[1, 1, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 7, 8, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['effects', ""parents ' reports of stress , impact of event ( diagnosis ) , and use of services"", ""parents ' reports of stress"", 'impact of event ( diagnosis )', 'use of services', '"" impact of event ""', '"" perceived stress ""', '"" impact of event ""', '"" perceived stress ""']","[2, 2, 2, 2, 2, 5, 5, 5, 5]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",16295154
45,"['human', 'human']","[0, 0]","['ss_p', 'hl_p']","['melatonin', 'melatonin', 'Melatonin', 'placebo', 'Melatonin', 'placebo', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin', 'melatonin']","[1, 1, 2, 2, 2, 2, 4, 4, 5, 5, 6, 6, 7, 7, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['brain activities', 'induction of sleepiness', 'task-related activity', 'task-related activity', 'subjective measurements of fatigue .', 'subjective measurements of fatigue .', 'activation in the left parahippocampus', 'activation in the left parahippocampus', 'brain activity', 'brain activity', 'fatigue', 'effect', 'brain activity', 'fatigue', 'sleep-associated brain activation', 'effects', 'effects']","[1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 6, 6, 6, 6, 7, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",16427787
46,"['patients with cancer-associated anemia .', 'patients with cancer-associated anemia .', 'Three hundred sixty-five patients', 'Three hundred sixty-five patients', 'anemic patients with cancer .', 'anemic patients with cancer .']","[0, 0, 2, 2, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa', 'epoetin alfa .', 'epoetin alfa .', 'erythropoietin', 'erythropoietin']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 8, 8, 9, 9, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['requiring transfusions', 'requiring transfusions', 'hemoglobin ( Hb ) increment', 'drug dose', 'Hb', 'Hb', 'hemoglobin ( Hb ) increment', 'drug dose', 'Hb', 'Hb', 'Toxicities , including thromboembolism', 'overall survival', 'Toxicities', 'thromboembolism', 'overall survival', 'global quality of life ( QOL )', 'global QOL', 'QOL', 'global quality of life ( QOL )', 'global QOL', 'QOL', 'safely', 'transfusion needs', 'QOL .', 'transfusion needs', 'QOL .', 'Hb increment', 'Hb increment']","[4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 9, 9]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",16505427
47,"['10 patients with asthma due to HDM', '10 patients with asthma due to HDM', 'asthma due to HDM .', 'asthma due to house dust mite Dermatophagoides pteronyssinus :']","[0, 0, 6, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p']","['local immunotherapy', 'powder extract of house dust mite ( HDM )', 'parenteral immunotherapy ( PI )', 'local immunotherapy', 'powder extract of house dust mite ( HDM )', 'parenteral immunotherapy ( PI )', 'placebo', 'lactose', 'placebo', 'lactose', 'disodium cromoglycate ( DSCG )', 'disodium cromoglycate ( DSCG )', 'DSCG', 'immunotherapy', 'immunotherapy']","[0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 2, 2, 7, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'tolerability', 'efficacy', 'tolerability', 'symptoms score', 'peak expiratory flow ( PEF ) -derived parameters', 'bronchial response', 'symptoms score', 'peak expiratory flow ( PEF ) -derived parameters', 'bronchial response', 'bronchial responsiveness', 'immunologic humoral and cellular parameters in peripheral blood', 'bronchial responsiveness', 'immunologic humoral and cellular parameters in peripheral blood', 'local important adverse reactions', 'systemic side effects', 'local important adverse reactions', 'systemic side effects', 'effective', 'tolerated', 'systemic side effects .', 'systemic side effects .']","[0, 0, 0, 0, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 7, 7, 7]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",1669598
48,"['patients with C. difficile-associated diarrhea ( CDAD )', 'patients with C. difficile-associated diarrhea ( CDAD )', '77 patients with CDAD', '77 patients with CDAD', 'patients with CDAD .', 'patients with CDAD .', 'individuals with CDAD', 'individuals with CDAD']","[0, 0, 2, 2, 3, 3, 4, 4]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['whey protein concentrate', 'immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B', 'whey protein concentrate', 'immunized against Clostridium difficile ( C.', 'anti-C. difficile whey protein concentrate ( anti-CD WPC )', 'anti-CD WPC', 'regular whey protein concentrate .', 'anti-C. difficile whey protein concentrate ( anti-CD WPC )', 'anti-CD WPC', 'regular whey protein concentrate .', 'anti-CD WPC', 'anti-CD WPC', 'anti-CD WPC', 'anti-CD WPC', 'anti-CD WPC', 'anti-CD WPC', 'whey protein concentrate', 'whey protein concentrate']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 2, 2, 3, 3, 4, 4, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['safety', 'safety', 'relapse of the infection .', 'adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments', 'safe', 'safe', 'safe', 'safe', 'safety']","[1, 2, 2, 3, 3, 3, 4, 4, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",17293018
49,"['patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .', 'patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .', 'patients with AML or MDS who received chemotherapy', 'patients with AML or MDS who received chemotherapy', 'patients with acute myeloid leukemia and myelodysplastic syndromes :', 'Japanese', 'patients with acute myeloid leukemia and myelodysplastic syndromes :', 'Japanese']","[0, 0, 5, 5, 0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['fluconazole', 'itraconazole', 'fluconazole', 'itraconazole', 'itraconazole', 'fluconazole', 'itraconazole', 'fluconazole', 'itraconazole', 'fluconazole', 'fluconazole', 'itraconazole', 'itraconazole', 'fluconazole .', 'itraconazole', 'fluconazole', 'itraconazole', 'fluconazole']","[0, 0, 0, 0, 1, 1, 1, 1, 3, 3, 4, 4, 5, 5, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['prophylactic effects', 'Adverse events', 'Adverse events', 'cases with probable or possible infections', 'probable or possible infections', 'frequency of infection', 'frequency of infection', 'efficacy', 'prophylactic effect']","[0, 2, 2, 3, 3, 4, 4, 5, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",17321989
50,"['pospartal anemia', 'Prague', 'Prague .', 'Prague', 'Prague', '50 women with clinical and lab signs of postpartal anemia .', '50 women', 'clinical and lab signs of postpartal anemia', 'pospartal anemia', 'postpartum anemia', 'postpartum']","[0, 2, 2, 2, 2, 3, 3, 3, 7, 0, 0]","['ss_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['trivalent ferrum preparation .', 'trivalent ferrum preparation .', 'sacharose ferric oxide ( Venofer )', 'sacharose ferric oxide ( Venofer )', 'Venofer', 'Venofer', 'trivalent saccharose ferric oxide', 'trivalent saccharose ferric oxide', 'trivalent ferrum preparation ]', 'trivalent ferrum preparation ]']","[0, 0, 3, 3, 7, 7, 8, 8, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['effectivity', 'safeness', 'effectivity', 'safeness', 'values of red blood count', 'values of red blood count', 'serum values of soluble transferrin receptors and ferritin', 'iron cell saturation and body iron reserves', 'serum values of soluble transferrin receptors and ferritin', 'iron cell saturation', 'body iron reserves', 'adverse events', 'adverse events', 'effective', 'effective', 'serious adverse event', 'serious adverse event']","[0, 0, 0, 0, 4, 4, 5, 5, 5, 5, 5, 6, 6, 7, 7, 8, 8]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",17616069
51,"['98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .', '98', 'aged between 18 and 75', 'pain-inflammatory pathologies of ENT nature .', 'pain-inflammatory pathologies of the ear , nose , and throat ]']","[1, 1, 1, 1, 0]","['ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p']","['non-steroid anti-inflammatory drug .', 'Nimesulide', 'flurbiprofen', 'Nimesulide', 'flurbiprofen', 'Nimesulide', 'Nimesulide', 'nimesulide', 'nimesulide']","[0, 1, 1, 1, 1, 3, 3, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['efficacy', 'tolerability', 'efficacy', 'tolerability', 'anti-inflammatory , analgesic and antipyretic activity', 'symptoms of the inflammatory state', 'anti-inflammatory , analgesic and antipyretic activity', 'symptoms of the inflammatory state', 'duration', 'duration', 'effectiveness', 'tolerability', 'effectiveness', 'tolerability', 'efficacy', 'tolerance', 'efficacy', 'tolerance']","[0, 0, 0, 0, 2, 2, 2, 2, 3, 3, 4, 4, 4, 4, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",1780092
52,"['patients with asthma poorly controlled on low dose inhaled corticosteroids', 'patients with asthma', 'adult asthmatics .', 'adult asthmatics .', 'Sixty-six subjects', 'Sixty-six subjects', 'asthma .']","[0, 0, 1, 1, 2, 2, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p']","['corticosteroids', 'salmeterol', 'fluticasone propionate ( FP ) ( Seretide ; SFC )', 'FP', 'montelukast ( FP/M )', 'salmeterol', 'fluticasone propionate ( FP ) ( Seretide ; SFC )', 'FP', 'montelukast ( FP/M )', 'SFC', 'FP/M', 'SFC', 'FP/M', 'SFC', 'FP/M .', 'SFC', 'FP/M .', 'FP/M', 'SFC', 'FP/M', 'SFC', 'SFC .', 'SFC .', 'Salmeterol', 'fluticasone propionate', 'fluticasone propionate', 'montelukast :', 'Salmeterol', 'fluticasone propionate', 'fluticasone propionate', 'montelukast :']","[0, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i']","['sputum inflammatory markers , airway responsiveness , lung function , and symptoms', 'sputum inflammatory markers', 'airway responsiveness , lung function', 'symptoms', 'changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .', 'changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .', 'change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .', 'change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .', 'induced sputum inflammatory cells', 'sputum eosinophils .', 'sputum inflammatory', 'sputum eosinophils .', 'airway responsiveness', 'symptom control and lung function', 'airway responsiveness', 'symptom control and lung function', 'sputum cysteinyl leukotrienes', 'sputum cysteinyl leukotrienes', 'eosinophilic airway inflammation', 'symptom control', 'eosinophilic airway inflammation', 'effects on airway inflammation', 'airway inflammation']","[1, 1, 1, 1, 3, 3, 4, 4, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 8, 8, 8, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",17897478
53,"['subjects > or =50 years of age .', 'subjects > or =50 years of age .', 'Subjects with a negative history for HZ', 'Subjects with a negative history for HZ', 'Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years )', 'Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years )']","[1, 1, 2, 2, 3, 3]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Zostavax', 'Zostavax', '( Zostavax', '( Zostavax', 'Zostavax', 'Zostavax', 'Zostavax', 'Zostavax', 'Zostavax .', 'Zostavax .']","[0, 0, 1, 1, 1, 1, 12, 12, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['safety', 'immunogenicity', 'safety', 'immunogenicity', 'Safety', 'Safety', 'Varicella-zoster virus ( VZV ) antibody responses', 'glycoprotein enzyme-linked immunosorbent assay ( gpELISA ) .', 'Varicella-zoster virus ( VZV ) antibody responses', 'VZV antibody geometric mean titer ( GMT ;', 'VZV antibody geometric mean rise ( GMR ;', 'incidence of vaccine-related serious adverse experiences ( AEs )', 'VZV antibody geometric mean titer ( GMT', 'VZV antibody geometric mean rise ( GMR', 'incidence of vaccine-related serious adverse experiences ( AEs )', 'GMTs', 'gpELISA', 'GMT', 'GMTs', 'GMT', 'GMRs', 'GMRs', 'vaccine-related serious AEs', 'safety', 'vaccine-related serious AEs', 'safety', 'injection-site AEs', 'injection-site AEs', 'systemic AEs', 'vaccine-related AEs', 'systemic AEs', 'vaccine-related AEs', 'safety', 'immunogenic', 'safety', 'immunogenic', 'safety', 'immunogenicity']","[1, 1, 1, 1, 4, 4, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 9, 10, 10, 11, 11, 11, 11, 12, 12, 12, 12, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o']",18077611
54,"['patients with early breast cancer', 'patients with early breast cancer', 'patients with early breast cancer :', 'European', 'patients with early breast cancer :']","[0, 0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['epirubicin', 'epirubicin', 'fluorouracil/epirubicin/cyclophosphamide ( FEC )', 'FEC ( 60 )', 'FEC ( 100 )', 'fluorouracil/epirubicin/cyclophosphamide ( FEC )', 'FEC ( 100 )', 'FEC', 'FEC', 'FEC ( 75 )', 'FEC ( 90 )', 'FEC ( 75 )', 'FEC ( 90 )', 'pegfilgrastim', 'pegfilgrastim', 'FEC ( 75 )', 'FEC ( 90 )', 'FEC ( 75 )', 'FEC ( 90 )', 'FEC ( 75 )', 'FEC ( 90 )', '( FEC ( 90 ) )', 'FEC ( 90 )', 'FEC ( 90 )', 'FEC ( 90 )', '( FEC ( 90 ) )', '( FEC ( 90 ) )', 'FEC ( 75', 'FEC ( 90 )', 'pegfilgrastim', 'FEC ( 75', 'FEC ( 90 )', 'FEC', 'FEC']","[0, 0, 1, 1, 1, 1, 1, 2, 2, 3, 3, 3, 3, 4, 4, 5, 5, 6, 6, 6, 6, 8, 8, 9, 9, 12, 12, 13, 13, 13, 13, 13, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['feasibility', 'efficacy', 'proportion of subjects receiving > or =85 % relative dose intensity', 'proportion of subjects receiving > or =85 % relative dose intensity', 'adverse events', 'adverse events', 'diarrhoea .', 'diarrhoea .', 'haematological toxicities', 'haematological toxicities', 'febrile neutropenia', 'febrile neutropenia', 'adverse events', 'increases in liver enzymes and gastrointestinal events ;', 'liver enzymes and gastrointestinal events', 'serious adverse events ( vomiting and throat oedema ) .', 'serious adverse events ( vomiting and throat oedema ) .', 'feasible', 'Feasibility']","[2, 5, 5, 5, 7, 7, 8, 8, 9, 9, 10, 10, 11, 11, 11, 12, 12, 13, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",18189160
55,"['preschool children with autism', 'preschool children with autism', 'Participants were 58 children ( 46 boys ) with autism between 3 and 4 years of age .', '58 children', '46', 'autism between 3 and 4 years of age', 'young children with autism .', 'young children with autism .', 'autism :', 'autism :']","[0, 0, 1, 1, 1, 1, 7, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['joint attention ( JA )', 'symbolic play ( SP )', 'joint attention ( JA )', 'symbolic play ( SP )', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'JA', 'SP', 'joint attention', 'play interventions .', 'joint attention', 'play interventions .']","[0, 0, 0, 0, 2, 2, 2, 2, 4, 4, 4, 4, 6, 6, 6, 6, 7, 7, 7, 7, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['language outcome', 'language outcome', 'JA skills , SP skills , mother-child interactions , and language development', 'JA skills , SP skills , mother-child interactions , and language development', 'expressive language gains', 'expressive language gains', 'language outcome', 'language outcome', 'Language outcome', 'Language outcome']","[0, 0, 4, 4, 5, 5, 6, 6, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",18229990
56,"['GABHS pharyngitis .', 'school-based clinic in New Zealand .', 'school-based clinic in New Zealand', 'Children presenting with GABHS pharyngitis', 'Children', 'GABHS pharyngitis', '353 children with positive throat swabs for GABHS', '353 children with positive throat swabs for GABHS', 'GABHS in children with pharyngitis .', 'GABHS in children with pharyngitis .', 'group A beta-haemolytic streptococcal pharyngitis .', 'beta-haemolytic streptococcal pharyngitis .']","[1, 2, 2, 3, 3, 3, 8, 8, 13, 13, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['amoxicillin', 'penicillin V', 'amoxicillin', 'penicillin V', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin .', 'amoxicillin .', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin', 'amoxicillin', 'penicillin V', 'amoxicillin', 'penicillin V']","[1, 1, 1, 1, 3, 3, 3, 3, 7, 7, 7, 7, 8, 8, 8, 8, 10, 10, 10, 10, 12, 12, 13, 13, 13, 13, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['non-inferiority', 'non-inferiority', 'non-inferiority', 'non-inferiority', 'medication and weekend diary cards', 'Eradication of GABHS', 'follow-up throat cultures', 'Eradication of GABHS', 'GABHS isolates were serotyped', 'bacteriological treatment failures', 'relapses )', 'new acquisitions .', 'bacteriological treatment failures', 'relapses', 'Non-inferiority', 'upper 95 % confidence limit ( CL ) for the difference in success of eradication', 'Non-inferiority', 'upper 95 % CL', 'Treatment failures', 'relapses )', 'Treatment failures', 'relapses', 'resolution of symptoms', 'resolution of symptoms', 'not inferior']","[1, 1, 2, 2, 4, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 9, 10, 10, 10, 10, 11, 11, 13]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",18337284
57,"['children with Asperger syndrome ( AS ) :', 'children', 'Asperger syndrome ( AS )', 'Forty-nine children with AS', 'Forty-nine children with AS', 'children with AS .', 'children with AS .', 'children with Asperger syndrome :', 'children', 'Asperger syndrome']","[0, 0, 0, 2, 2, 8, 8, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['multi-component social skills intervention', 'multi-component social skills intervention', 'small group sessions , parent training sessions', 'teacher handouts .', 'Junior Detective Training Program', 'Junior Detective Training Program', 'multi-component social skills intervention', 'Junior Detective Training Program .', 'multi-component social skills intervention', 'Junior Detective Training Program .']","[0, 0, 1, 1, 8, 8, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['effectiveness', 'effectiveness', 'improvements in social skills', 'parent-report measures .', 'improvements in social skills', 'Teacher-report data', 'social functioning', 'social functioning', 'emotion-management strategies', 'emotion-management strategies', 'facial expression and body-posture recognition measures .', 'facial expression and body-posture recognition measures .', 'effective', 'social skills and emotional understanding', 'social skills and emotional understanding']","[0, 0, 3, 3, 3, 4, 4, 4, 5, 5, 6, 6, 8, 8, 8]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",18503531
58,"['school-aged children .', '30 healthy children .', '30 healthy', 'school-aged children', 'school-aged children']","[0, 1, 1, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS )', 'LGG', 'Lactobacillus GG ( LGG )', 'galacto-oligosaccharides ( GOS )', 'LGG', 'LGG', 'LGG', 'GOS .', 'LGG', 'LGG', 'GOS .', 'LGG + GOS', 'LGG', 'LGG + GOS', 'LGG', 'LGG', 'LGG', 'LGG', 'GOS', 'LGG', 'GOS', 'LGG', 'GOS', 'LGG', 'GOS', 'GOS .', 'GOS .', 'galacto-oligosaccharides and Lactobacillus GG', 'Lactobacillus GG', 'galacto-oligosaccharides', 'Lactobacillus GG', 'Lactobacillus GG']","[0, 0, 0, 0, 0, 3, 3, 3, 3, 3, 3, 6, 6, 6, 6, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['intestinal microbiota', 'Symptom', 'Fecal samples', 'amount of bifidobacteria', 'amount of bifidobacteria', 'lactobacilli', 'gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation', 'lactobacilli', 'gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation', 'bifidobacteria', 'prebiotic effect', 'bifidobacteria', 'tolerated', 'bifidobacteria']","[0, 4, 5, 6, 6, 7, 7, 7, 7, 8, 8, 8, 9, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",18544974
59,"['auditory stimulation', 'Subjects', 'Vibrotactile -- auditory interactions']","[2, 5, 0]","['ss_p', 'hl_p', 'ss_p']","['Vibrotactile stimuli', 'Vibrotactile stimuli', 'vibrotactile stimulus', 'vibrotactile stimulus', 'vibrotactile stimulus', 'vibrotactile stimulus', 'vibrotaction', 'vibrotaction', 'vibrotactile stimuli .', 'vibrotaction', 'vibrotaction', 'vibrotactile stimuli .', 'vibrotaction', 'vibrotaction', 'vibrotaction', 'vibrotaction']","[0, 0, 1, 1, 3, 3, 5, 5, 5, 5, 5, 5, 6, 6, 7, 7]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['compelling auditory sensations', 'auditory tones', 'auditory stimulation ( no tone , tone at detection threshold , tone at 5 dB above threshold , and tone at 10 dB above threshold ) .', 'auditory tones', 'auditory tones', 'nature of this cross-modal interaction .', 'auditory tone .']","[0, 1, 2, 3, 3, 4, 6]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",18773733
60,"['Madison , WI , USA .', 'Madison , WI , USA', '403 adult , daily smokers without contraindications to bupropion SR use .', '403 adult , daily smokers without contraindications to bupropion SR use', 'smoking cessation .']","[3, 3, 4, 4, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p']","['bupropion sustained-release ( SR )', 'bupropion sustained-release ( SR )', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'placebo', 'bupropion SR', 'placebo', 'bupropion SR', 'Bupropion SR', 'Bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion SR', 'bupropion sustained-release', 'bupropion sustained-release']","[0, 0, 1, 1, 2, 2, 4, 4, 5, 5, 5, 5, 7, 8, 8, 9, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['putative mediators', 'post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .', 'specificity', 'Ecological momentary assessment ratings of smoking behavior and putative mediators', 'Ecological momentary assessment ratings of smoking behavior and putative mediators', 'short-term abstinence', 'withdrawal distress', 'subjective effects of a lapse cigarette', 'cigarette craving reduction', 'positive affect .', 'short-term abstinence', 'cigarette craving reduction', 'positive affect .', 'point-prevalence abstinence', 'motivation', 'self-efficacy .', 'abstinence', 'efficacy .', 'Psychological mediators']","[0, 0, 1, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 9, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",18783504
61,"['patients with metastatic breast cancer ( MBC ) .', 'patients with metastatic breast cancer ( MBC ) .', 'MBC ( n = 509 )', 'MBC patients', 'patients', 'metastatic breast cancer', 'metastatic breast cancer']","[0, 0, 1, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['doxorubicin ( DOX )', 'pegylated liposomal formulation ( PLD )', 'doxorubicin ( DOX )', 'pegylated liposomal formulation ( PLD )', 'DOX', 'PLD', 'DOX', 'PLD', 'DOX', 'PLD', 'DOX', 'PLD', 'PLD )', 'doxorubicin', 'pegylated liposomal doxorubicin :', 'doxorubicin', 'pegylated liposomal doxorubicin']","[0, 0, 0, 0, 1, 1, 1, 1, 7, 7, 7, 7, 10, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['cycle-based risk prediction model for neutropenic complications ( NC )', 'neutropenic complications ( NC )', 'NC', 'absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .', 'NC', 'absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L', 'febrile neutropenia or neutropenia with a documented infection .', 'Patient and hematologic factors potentially associated with NC', 'risk scoring algorithm', 'Risk factors', 'poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L', 'age .', 'poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L', 'age', 'precycle risk score', 'precycle risk score', 'risk', 'NC', 'risk', 'NC', 'NC', 'Identifying patients at high risk for neutropenic complications', 'neutropenic complications']","[0, 0, 3, 3, 3, 3, 3, 4, 6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",18845996
62,"['individuals with autism spectrum disorders ( ASD ) .', 'individuals with autism spectrum disorders ( ASD ) .', 'Children with ASD and typically developing ( TD ) children', 'Children', 'ASD and typically developing ( TD ) children', 'autism']","[1, 1, 4, 4, 4, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p']","[""images of the subjects ' own face and to faces of others ."", 'their own face and a gender-matched other face', 'their own face and a gender-matched other face', 'images', 'self- and other-processing', 'images']","[3, 4, 4, 5, 6, 6]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i']","['neural mechanisms', 'fMRI', ""brain responsiveness to images of the subjects ' own face and to faces of others ."", 'brain responsiveness', 'right premotor/prefrontal system', 'right premotor/prefrontal system', 'system', 'neural representations for self and others', 'Neural basis of self and other representation', 'FMRI', 'self-face recognition .', 'self-face recognition']","[2, 3, 3, 3, 5, 5, 6, 7, 0, 0, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",18958161
63,"['10 patients in each group .', '10 patients in each group .']","[2, 2]","['ss_p', 'hl_p']","['iopamidol', 'iopamidol', 'iopamidol', 'iopamidol', 'iopamidol', 'iopamidol']","[1, 1, 1, 1, 1, 1]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['difference', 'difference', 'Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein', 'four-channel MDCT .', 'Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein', 'arteriovenous contrast at the cavernous portion .', 'arteriovenous contrast', 'CT value', 'CT value', 'ICA attenuation', 'intracavernous attenuation', 'ICA attenuation', 'intracavernous attenuation', 'intracranial arteriovenous contrast', 'intracranial arteriovenous contrast']","[0, 0, 3, 3, 3, 4, 4, 5, 5, 6, 6, 6, 6, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",18975051
64,"['children with pervasive developmental disorders .', 'children', 'pervasive developmental disorders']","[0, 0, 0]","['ss_p', 'hl_p', 'hl_p']","['risperidone', 'structured parent training', 'risperidone', 'risperidone', 'structured parent training', 'risperidone', 'medication', 'parent training', 'medication', 'medication', 'parent training', 'medication', 'parent training']","[0, 0, 0, 0, 0, 0, 2, 2, 3, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['noncompliance , irritability and adaptive functioning .', 'noncompliance', 'irritability', 'adaptive functioning', 'tantrums , aggression and self-injury ;', 'noncompliance and adaptive functioning .', 'tantrums', 'aggression', 'self-injury', 'noncompliance and adaptive functioning .', 'symptom', 'functional', 'symptom', 'functional', 'effects']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 4, 4, 4, 4, 5]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",19096921
65,"['breast cancer surgery in Japanese patients .', 'breast cancer surgery in Japanese patients .', 'Japanese women', 'Japanese women', 'A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg )', '100', 'mean [ SD ] age , 52 [ 7 ] years', 'height , 154 [ 6 ] cm', 'weight , 54 [ 7 ] kg', 'Japanese women who underwent breast cancer surgery .', 'breast cancer surgery :', 'Japanese patients .', 'breast cancer surgery :', 'Japanese patients .']","[3, 3, 4, 4, 9, 9, 9, 9, 9, 15, 0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['propofol', 'placebo', 'propofol', 'placebo', 'propofol', 'droperidol', 'metoclopramide', 'propofol', 'droperidol', 'metoclopramide', 'propofol', 'droperidol', 'metoclopramide', 'placebo ( isotonic saline )', 'propofol', 'droperidol', 'metoclopramide', 'placebo ( isotonic saline )', 'sevoflurane', 'oxygen', 'propofol', 'droperidol', 'metoclopramide', 'placebo', 'propofol', 'droperidol', 'metoclopramide', 'placebo', 'propofol', 'droperidol', 'propofol', 'droperidol', 'metoclopramide', 'propofol', 'droperidol', 'propofol', 'droperidol', 'metoclopramide', 'propofol', 'droperidol', 'propofol', 'droperidol', 'propofol', 'droperidol', 'metoclopramide', 'placebo .', 'propofol', 'droperidol', 'metoclopramide', 'placebo .', 'propofol , droperidol', 'metoclopramide', 'propofol', 'droperidol', 'metoclopramide']","[2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 15, 15, 15, 15, 16, 16, 16, 16, 16, 16, 16, 16, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['incidence of postoperative nausea and vomiting ( PONV ) .', 'postoperative nausea and vomiting ( PONV )', 'PONV .', 'PONV .', 'PONV', 'PONV', 'efficacy', 'prophylaxis of PONV', 'efficacy', 'PONV', 'episodes of PONV during the first 24 hours after anesthesia administration', 'PONV', 'extrapyramidal symptoms .', 'extrapyramidal symptoms .', 'patient demographics , surgery type , or awakening time .', 'prevalences of PONV 0 to 24 hours', 'PONV', 'prevalence of PONV', 'prevalences of PONV', 'PONV', 'PONV', 'Extrapyramidal symptoms', 'Extrapyramidal symptoms', 'prevalences of PONV', 'PONV', 'prevalences of PONV', 'PONV', 'prophylaxis of postoperative nausea and vomiting', 'postoperative nausea and vomiting']","[0, 0, 1, 1, 2, 2, 3, 3, 3, 3, 6, 6, 7, 7, 11, 12, 12, 13, 13, 13, 13, 14, 14, 15, 15, 16, 16, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",19108790
66,"[""primary Raynaud 's phenomenon ( RP ) in Korea ."", 'Ninety-three subjects', 'Ninety-three subjects', 'primary RP in Korean patients .', 'Korean patients .', 'primary RP patients .', 'RP patients .', ""patients with primary Raynaud 's phenomenon in South Korea ;"", ""patients with primary Raynaud 's phenomenon in South Korea ;""]","[0, 4, 4, 7, 7, 8, 8, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['nifedipine sustained release ( nifedipine SR )', 'Ginkgo biloba extract', 'nifedipine sustained release ( nifedipine SR )', 'Ginkgo biloba extract', 'nifedipine SR', 'Ginkgo biloba extract', 'nifedipine SR', 'Ginkgo biloba extract', 'nifedipine SR', 'Ginkgo biloba extract', 'nifedipine SR', 'Ginkgo biloba extract', 'nifedipine sustained release', 'Ginkgo biloba extract', 'nifedipine sustained release', 'Ginkgo biloba extract']","[0, 0, 0, 0, 1, 1, 1, 1, 7, 7, 7, 7, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'safety', 'efficacy', 'safety', 'percent improvement of the RP attack rate between before and after the 8-week treatment .', 'percent improvement of the RP attack rate', 'percent improvement', 'serious adverse events', 'adverse events', 'serious adverse events', 'adverse events', 'effective', 'effective', 'tolerable', 'tolerable', 'efficacy', 'safety', 'efficacy', 'safety']","[0, 0, 0, 0, 3, 3, 5, 6, 6, 6, 6, 7, 7, 8, 8, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",19159999
67,"['61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA )', '61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA )', 'after total knee arthroplasty ( TKA ) .', 'total knee arthroplasty ( TKA ) .']","[4, 4, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['femoral nerve block ( FNB )', 'femoral nerve block ( FNB )', 'continuous epidural infusion ( CEI )', 'continuous femoral nerve block ( CFNB )', 'continuous epidural infusion ( CEI )', 'continuous femoral nerve block ( CFNB )', '( CEI )', 'levobupivacaine', 'morphine', '( CFNB )', 'levobupivacaine', '( CEI )', 'levobupivacaine', 'morphine', '( CFNB )', 'levobupivacaine', 'CFNB', 'CEI', 'CFNB', 'CEI', 'CEI', 'CFNB', 'CEI', 'CFNB', 'CFNB', 'CFNB', 'CFNB', 'CFNB', 'continuous femoral nerve block ( CFNB )', 'continuous epidural infusion ( CEI )', 'continuous femoral nerve block ( CFNB )', 'continuous epidural infusion ( CEI )']","[0, 0, 3, 3, 3, 3, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['pain relief', 'side effects', 'nausea , vomiting , pruritus , dizziness , and hypotension .', 'postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .', 'postoperative analgesic efficacy', 'side effects', 'postoperative knee rehabilitation', 'hospital length of stay ( LOS )', 'VAS scores', 'tramadol IV requirement', 'VAS scores', 'tramadol IV requirement', 'dizziness , pruritus , and PONV', 'dizziness', 'pruritus', 'PONV', 'Patient satisfaction', 'postoperative knee rehabilitation and the hospital LOS', 'Patient satisfaction', 'postoperative knee rehabilitation', 'hospital LOS', 'side effects', 'patient , satisfaction .', 'side effects', 'patient , satisfaction', 'rehabilitation indices and duration of hospital stay', 'rehabilitation indices', 'duration of hospital stay']","[0, 0, 0, 3, 3, 3, 3, 3, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 9, 10, 10, 10, 10, 11, 11, 11]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",19301724
68,"['patients with atrial fibrillation ( AF )', 'atrial fibrillation', 'AF', 'patients with nonvalvular AF and at least 1 risk factor for stroke .', 'Recruitment concluded with a total of 18,113 patients .', '18,113', 'Patients who were VKA-naive and experienced are included in balanced proportions .']","[0, 0, 0, 4, 5, 5, 6]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p']","['Vitamin K antagonists', 'Dabigatran etexilate', 'dabigatran .', 'Dabigatran etexilate', 'dabigatran .', 'warfarin', 'warfarin', 'dabigatran', 'dabigatran', 'dabigatran', 'dabigatran', 'warfarin', 'dabigatran .', 'warfarin', 'dabigatran .']","[0, 1, 1, 1, 1, 2, 2, 3, 3, 12, 12, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['stroke prevention', 'stroke ( including hemorrhagic ) or systemic embolism .', 'stroke ( including hemorrhagic )', 'systemic embolism', 'Safety', 'bleeding , liver function abnormalities , and other adverse events .', 'bleeding', 'liver function abnormalities', 'other adverse events', 'stroke']","[0, 7, 7, 7, 8, 8, 8, 8, 8, 11]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o']",19376304
69,"['ten normotensive and seven hypertensive subjects', 'ten normotensive', 'seven hypertensive', '( hypertensive and normotensive subjects']","[0, 0, 0, 1]","['ss_p', 'hl_p', 'hl_p', 'ss_p']","['self-inflation of the cuff', 'just wearing the inflated cuff', 'self-inflation of the cuff', 'just wearing the inflated cuff', 'Inflating the cuff', 'Inflating the cuff', 'inflated cuff', 'inflated cuff', 'cuff inflation .', 'cuff inflation .', 'cuff inflation .', 'inflate their cuff', 'cuff inflation']","[0, 0, 0, 0, 1, 1, 2, 2, 3, 3, 4, 5, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","[""continuously recorded 'Finapres ' finger blood pressure"", ""'Finapres ' finger blood pressure"", 'systolic blood pressure', 'systolic blood pressure', 'blood pressure .', 'blood pressure .', 'pressure', 'pressure', 'Systolic blood pressure', 'Systolic blood pressure', 'self-recorded systolic blood pressure', 'self-recorded systolic blood pressure', 'self-recorded blood pressure .', 'self-recorded blood pressure .']","[0, 0, 1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",1968178
70,"['100 patients with gastric ulcer aged from 16 to 60 years .', '100 patients with gastric ulcer aged from 16 to 60 years', 'patients with gastric ulcer ]', 'patients with gastric ulcer ]']","[0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['traditional treatment', 'transcranial electrotherapy', 'traditional treatment', 'transcranial electrotherapy', '( traditional therapy plus electrostimulation )', '( traditional therapy', 'electrostimulation', 'transcranial electrostimulation', 'transcranial electrostimulation']","[1, 1, 1, 1, 3, 3, 3, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['Laboratory studies', 'measurements of lactoferrin ( LF ) and tumour necrosis factor-alpha ( TNF-alpha ) , besides standard analyses .', 'lactoferrin ( LF )', 'tumour necrosis factor-alpha ( TNF-alpha )', 'duration of the main symptoms of the gastric ulcer', ""patients ' age and sex ."", 'duration of the main symptoms', 'ulcer scarring', 'serum LF and TNF-alpha levels .', 'ulcer scarring', 'serum LF and TNF-alpha levels .']","[2, 2, 2, 2, 3, 3, 3, 4, 4, 4, 4]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",19708562
71,"['autistic children', 'autistic children', '81 cases of autistic children were selected', '81 cases of autistic children', 'autistic children', 'autistic children', 'autistic children ]', 'autistic children']","[0, 0, 1, 1, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['auditory integrative training', 'auditory integrative training', 'auditory integrative training', 'auditory integrative training', 'auditory integrative training', 'auditory integrative training', 'auditory integrative training ( AIT )', 'auditory integrative training ( AIT )', 'auditory integrative training', 'auditory integrative training']","[0, 0, 2, 2, 6, 6, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['effect', 'clinical manifestation and Autism Behavior Checklist ( ABC ) and intelligence quotient ( IQ )', 'clinical manifestation', 'Autism Behavior Checklist ( ABC )', 'intelligence quotient ( IQ )', 'changes of clinical manifestations and scores of ABC and IQ .', 'changes of clinical manifestations', 'ABC', 'IQ .', 'changes of scores of IQ were determined with Gesell and WPPSI or WISC-R .', 'IQ', 'disorders of their language , social interactions and typical behavior symptoms', 'abnormal behaviors .', 'disorders of their language', 'social interactions', 'typical behavior symptoms', 'abnormal behaviors .', 'scores of IQ or DQ', 'scores of ABC', 'scores of IQ or DQ', 'ABC', 'ABC scores', 'IQ scores', 'ABC scores', 'ABC scores', 'IQ scores', 'ABC scores', 'language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels', 'effect .', 'language disorders', 'difficulties of social interactions', 'typical behavior symptoms', 'developmental levels']","[0, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",19727232
72,"['223 postmenopausal breast cancer survivors .', '223 postmenopausal breast cancer survivors', 'postmenopausal breast cancer survivors ( BCS ) with bone loss', 'postmenopausal breast cancer survivors ( BCS ) with bone loss', 'Postmenopausal BCS ( 223 )', 'Postmenopausal BCS', '223', 'postmenopausal BCS at risk for bone loss .', 'postmenopausal breast cancer survivors with bone loss :', 'postmenopausal breast cancer survivors with bone loss :']","[0, 0, 2, 2, 3, 3, 3, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['weight training exercises', 'weight training exercises', 'risedronate , calcium', 'vitamin D', 'strength/weight training ( ST ) exercises', 'risedronate', 'calcium', 'vitamin D', 'strength/weight training ( ST ) exercises', 'exercise plus medication', 'medication', 'exercise', 'medication', 'medication', 'calcium', 'vitamin D', 'risedronate', 'exercise', 'ST exercises', 'calcium', 'vitamin D', 'risedronate', 'exercise', 'ST exercises', 'medications', 'exercising', 'medications', 'exercising', 'exercised', 'exercised', 'exercise', 'exercise', 'exercise', 'Strength/weight training exercises', 'Strength/weight training exercises', 'weight training', 'weight training']","[0, 0, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 7, 8, 8, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['effectiveness', 'bone mineral density ( BMD )', 'bone mineral density ( BMD )', 'BMD', 'BMD .', 'BMD', 'BMD .', 'bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius', 'bone turnover ;', 'BMD', 'bone turnover ;', 'BMD .', 'bone mineral density ( BMD )', 'bone turnover ;', 'BMD', 'bone turnover ;', 'BMD .', 'BMD', 'Alkphase B', 'serum NTx', 'BMD', 'Alkphase B', 'serum NTx', 'BMD', 'Alkphase B', 'Serum NTx', 'BMD', 'Alkphase B', 'Serum NTx', 'changes in BMD and bone turnover', 'BMD', 'bone turnover', 'BMD', 'BMD', 'BMD', 'BMD', 'bone mineral density and bone turnover', 'bone mineral density', 'bone turnover']","[0, 0, 0, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",19802506
73,"['in chemo-naïve non-small cell lung cancer patients', 'chemo-naïve non-small cell lung cancer patients', 'METHODS Patients with chemo-naïve stage IIIB/IV non-small cell lung cancer', 'chemo-naïve stage IIIB/IV non-small cell lung cancer', 'RESULTS A total of 80 patients were entered in this trial', '80', 'chemo-naïve patients with advanced non-small cell lung cancer', 'chemo-naïve', 'advanced non-small cell lung cancer']","[0, 0, 1, 1, 4, 4, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['of gemcitabine', 'with S-1', 'gemcitabine', 'S-1', 'oral S-1', 'with gemcitabine', 'S-1', 'gemcitabine', 'of gemcitabine and S-1', 'gemcitabine', 'S-1', 'gemcitabine', 'S-1', 'gemcitabine', 'S-1']","[0, 0, 0, 0, 2, 2, 2, 2, 11, 11, 11, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['the efficacy and safety', 'to compare dosing schedules', 'efficacy', 'safety', 'was response rate', 'response rate', 'The response rates', '0.606 ) .', 'response rates', 'Median time to treatment failure', 'B .', 'Median time to treatment failure', 'Median time to progression', 'B .', 'Median time to progression', 'Median survival time', 'Median survival time', 'The toxicity profile', 'toxicity profile', 'be feasible and effective', 'feasible', 'effective', 'higher response rate and survival data', 'response rate', 'survival data']","[0, 0, 0, 0, 5, 5, 6, 6, 6, 7, 7, 7, 8, 8, 8, 9, 9, 10, 10, 11, 11, 11, 12, 12, 12]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",20147856
74,"['ST-elevation myocardial infarction', '333 consecutive adult patients with a suspected first acute myocardial infarction', '333 consecutive adult patients with a suspected first acute myocardial infarction', '82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up', '82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up', 'patients with acute myocardial infarction :', 'patients with acute myocardial infarction :']","[1, 2, 2, 7, 7, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Remote ischaemic preconditioning', 'Remote ischaemic preconditioning', 'remote ischaemic conditioning', 'remote ischaemic conditioning', 'remote conditioning', 'remote conditioning', 'remote conditioning', 'remote conditioning', 'remote conditioning', 'remote conditioning', 'Remote ischaemic conditioning', 'Remote ischaemic conditioning', 'remote conditioning', 'remote conditioning', 'Remote ischaemic conditioning', 'Remote ischaemic conditioning']","[0, 0, 1, 1, 2, 2, 4, 4, 8, 8, 10, 10, 11, 11, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['myocardial salvage .', 'myocardial salvage .', 'myocardial salvage index at 30 days after primary percutaneous coronary intervention , measured by myocardial perfusion imaging', 'proportion of the area at risk salvaged by treatment ;', 'myocardial salvage index', 'myocardial perfusion imaging', 'salvage index .', 'Median salvage index', 'median difference', 'mean salvage index', 'mean difference', 'Median salvage index', 'mean salvage index', 'Major adverse coronary events', 'death', 'reinfarction', 'heart failure', 'Major adverse coronary events', 'death', 'reinfarction', 'heart failure', 'myocardial salvage', 'safety profile .', 'myocardial salvage', 'safety', 'myocardial salvage', 'myocardial salvage']","[1, 1, 5, 5, 5, 5, 7, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",20189026
75,"['296 patients with visible endoluminal tumor lesions were included', 'bronchoscopy unit of a university hospital .', '296 patients with visible endoluminal tumor lesions were included', 'bronchoscopy unit of a university hospital .', 'endobronchial tumor lesions .', 'endobronchial tumor lesions .']","[4, 4, 4, 4, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['cryoprobe', '"" cryobiopsies', 'cryoprobe', 'cryobiopsy', 'forceps biopsy .', 'cryobiopsy', 'forceps biopsy .', 'forceps biopsy and cryobiopsy', 'forceps biopsy', 'cryobiopsy', 'cryobiopsy .', 'cryobiopsy .', 'cryobiopsy', 'forceps biopsy', 'cryobiopsy', 'forceps biopsy', 'cryobiopsy', 'forceps biopsy', 'cryobiopsy', 'forceps biopsy', 'cryobiopsy', 'cryobiopsy', 'Cryobiopsy', 'Cryobiopsy', 'Cryoprobe biopsy', 'Cryoprobe biopsy']","[2, 2, 2, 3, 3, 3, 3, 5, 5, 5, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 12, 12, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['diagnostic yield .', 'diagnostic yield', 'safety', 'Pathologic and quantitative image analyses', 'size and quality of the obtained specimens .', 'safety', 'diagnostic yield', 'feasibility', 'safety', 'diagnostic yield', 'diagnostic yield', 'diagnostic yield', 'quantitative image analysis', 'size', 'size', 'overall diagnostic yield', 'diagnostic yield', 'bleeding', 'bleeding', 'bleeding', 'bleeding', 'bleeding', 'bleeding', 'safe', 'diagnostic yield', 'safe', 'diagnostic yield', 'feasible', 'feasible', 'diagnostic yield']","[1, 3, 3, 6, 6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 10, 10, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 13, 13, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",20226474
76,"['21 hospitalized trauma patients', '21 hospitalized trauma patients', 'physical trauma .', 'physical trauma .']","[2, 2, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['virtual reality hypnosis ( VRH ) -hypnotic induction', 'virtual reality hypnosis ( VRH ) -hypnotic induction', 'VRH', 'VR without hypnosis', 'standard care', 'VRH', 'VRH', 'VRH', 'Virtual reality hypnosis', 'Virtual reality hypnosis']","[2, 2, 3, 3, 3, 4, 5, 5, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['analgesic efficacy', 'analgesic suggestion', 'Subjective pain ratings', 'Subjective pain ratings', 'pain intensity', 'pain unpleasantness', 'pain intensity', 'pain unpleasantness', 'pain management', 'pain management']","[2, 2, 3, 3, 4, 4, 4, 4, 5, 5]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",20509069
77,"['male adolescents', 'male adolescents', 'adolescents', 'adolescents', '18 male adolescents', '18 male adolescents']","[0, 0, 1, 1, 2, 2]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Maillard reaction products ( MRP )', 'Maillard reaction products ( MRP )', 'white diet ( WD )', 'brown diet ( BD )', 'MRP', 'white diet ( WD )', 'brown diet ( BD )', 'MRP', 'MRP', 'MRP', 'Maillard reaction products', 'Maillard reaction products']","[1, 1, 2, 2, 2, 2, 2, 2, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['calcium availability', 'calcium availability', 'fasting blood samples', 'fasting blood samples', 'Calcium solubility and absorption across Caco-2 cells', 'Calcium solubility', 'absorption across Caco-2 cells', 'solubility', 'solubility', 'calcium bioavailability', 'calcium bioavailability', 'Serum and urine biochemical parameters related to calcium status and bone metabolism', 'Serum and urine biochemical parameters related to calcium status and bone metabolism', 'deoxypyridinoline', 'bone turnover', 'deoxypyridinoline', 'bone turnover', 'calcium bioavailability .', 'calcium bioavailability .']","[1, 1, 3, 3, 4, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 8, 8, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",20560622
78,"['Eighty depressed patients undergoing standard antidepressant treatment', 'Eighty depressed patients undergoing standard antidepressant treatment', 'patients with depression :', 'patients with depression :']","[3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['Mediterranean diet', 'antidepressant', 'hygienic-dietary recommendations', 'hygienic-dietary recommendations', 'hygienic-dietary recommendations', 'hygienic-dietary recommendations']","[0, 3, 3, 3, 0, 0]","['hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['efficacy', 'Outcome measures', 'depressive symptoms .', 'depressive symptoms .', 'Effectiveness', 'Effectiveness']","[0, 4, 5, 5, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",20618920
79,"['46 upper and lower molars with furcation grade II involvement', '16 patients with periodontal disease .', '46 upper and lower molars with furcation grade II involvement', '16 patients with periodontal disease', 'periodontal furcation pockets .', 'periodontal furcation pockets .']","[0, 0, 0, 0, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['tetracycline-immobilized cross-linked collagen film ( TC film )', 'root planing treatment ( RP', '( TC + RP', 'tetracycline-immobilized cross-linked collagen film ( TC film )', 'root planing treatment ( RP', 'TC + RP', 'RP', 'TC + RP', 'RP', 'TC + RP', 'TC + RP', 'TC + RP', 'root planning', 'TC films .', 'TC', 'tetracycline-immobilized collagen film and root planing', 'tetracycline-immobilized collagen film', 'root planing']","[1, 1, 1, 1, 1, 1, 4, 4, 4, 4, 5, 5, 6, 6, 6, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i']","['therapeutic effects', 'plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts', 'plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts', 'probing depth and density of micro-organisms', 'probing depth and density of micro-organisms', 'rate of bleeding on pocket probing', 'probing attachment gain .', 'rate of bleeding on pocket probing', 'probing attachment gain .', 'Therapeutic effects']","[2, 3, 3, 4, 4, 5, 5, 5, 5, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",2066441
80,"['patients with chronic immune thrombocytopenia', 'patients with chronic immune thrombocytopenia', ""adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per μL"", 'adults', ""previously treated immune thrombocytopenia of more than 6 months ' duration"", 'baseline platelet counts lower than 30,000 per μL', 'FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients', '197', 'chronic immune thrombocytopenia', 'chronic immune thrombocytopenia']","[1, 1, 2, 2, 2, 2, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Eltrombopag', 'Eltrombopag', 'eltrombopag', 'placebo', 'eltrombopag', 'placebo', 'placebo-controlled', 'mg eltrombopag', 'matching placebo', 'eltrombopag', 'placebo', 'response to eltrombopag versus placebo', 'eltrombopag', 'placebo', '( 135 eltrombopag , 62 placebo )', 'eltrombopag', 'placebo', 'in the eltrombopag', 'in the placebo', 'eltrombopag', 'in the eltrombopag', 'in the placebo', 'eltrombopag', 'placebo', 'receiving eltrombopag', 'receiving', 'eltrombopag', 'receiving eltrombopag', 'receiving', 'eltrombopag', 'patients receiving eltrombopag', 'patients', '.', 'eltrombopag', 'Nine ( 7 % ) eltrombopag-treated', '( 3 % ) in the', 'and five ( 4 % ) eltrombopag-treated', 'allocated', 'eltrombopag-treated', 'eltrombopag-treated', 'patients taking', 'treated with eltrombopag', 'eltrombopag', 'INTERPRETATION Eltrombopag', 'Eltrombopag', 'associated with eltrombopag', 'eltrombopag', 'Eltrombopag', 'Eltrombopag']","[0, 0, 1, 1, 1, 1, 2, 3, 3, 3, 3, 7, 7, 7, 10, 10, 10, 11, 11, 11, 12, 12, 12, 12, 13, 13, 13, 14, 14, 14, 15, 15, 15, 15, 16, 16, 16, 16, 16, 16, 17, 17, 17, 18, 18, 19, 19, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['response', 'response', 'for response to treatment ( defined as a platelet count of 50,000-400,000 per', 'was the odds of response', 'response to treatment', 'platelet count', 'group responded', '.', 'responded to treatment', 'The odds of responding', 'eltrombopag reduced concomitant treatment', 'eltrombopag needed rescue', 'eltrombopag had thromboembolic', 'thromboembolic', 'increases in alanine aminotransferase concentration', 'increases in total', 'placebo had serious bleeding', 'serious bleeding', 'Eltrombopag is']","[1, 1, 7, 7, 7, 7, 11, 11, 11, 12, 13, 14, 15, 15, 16, 16, 17, 17, 18]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",20739054
81,"['children with autism spectrum disorder .', 'children', 'autism spectrum disorder', '50 children .', '50 children', 'children .', 'children with autism .', 'children with autism .', 'autism spectrum disorder .', 'autism spectrum disorder .']","[0, 0, 0, 1, 1, 4, 5, 5, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['acupuncture', 'sham acupuncture', 'acupuncture', 'sham acupuncture', 'tongue acupuncture', '( sham tongue acupuncture', 'tongue acupuncture', 'sham tongue acupuncture', 'acupuncture', 'acupuncture', 'acupuncture', 'sham acupuncture', 'acupuncture', 'sham acupuncture']","[0, 0, 0, 0, 2, 2, 2, 2, 5, 5, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'efficacy', 'eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .', 'eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale', 'sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale', 'Comprehension Language age in the Reynell Language Developmental Scale', 'Total Score and Mental Age in Symbolic Play Test', 'self-care and cognition domains of the Functional Independence Measure for children .', 'self-care and cognition domains of the Functional Independence Measure for children .', 'efficacy', 'efficacy']","[0, 0, 3, 3, 3, 3, 3, 4, 4, 5, 6]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",20804366
82,"['16 patients with localized juvenile periodontitis .', '16 patients with localized juvenile periodontitis', 'patients with localized juvenile periodontitis .', 'patients with localized juvenile periodontitis .', 'localized juvenile periodontitis .', 'localized juvenile periodontitis .']","[0, 0, 7, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['doxycycline', 'doxycycline', 'doxycycline', 'doxycycline', 'doxycycline', 'doxycycline']","[0, 0, 7, 7, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['immediate clinical and microbiological efficacy', 'immediate clinical and microbiological efficacy', 'gingival fluid flow , probing depths , bleeding on probing and suppuration', 'radiographic attachment loss', 'gingival fluid flow , probing depths , bleeding on probing and suppuration', 'Subgingival bacterial samples', 'Subgingival bacterial samples', 'Spirochaetes', 'dark-field microscopy .', 'Spirochaetes', 'dark-field microscopy .', 'Actinobacillus actinomycetemcomitans , pigmented and non-pigmented Bacteroides spp.', 'Capnocytophaga , Fusobacterium and Actinomyces spp .', 'Bacterial species', 'short-term clinical nor microbiological efficacy', 'short-term clinical nor microbiological efficacy', 'immediate efficacy', 'immediate efficacy']","[0, 0, 1, 1, 1, 2, 2, 3, 3, 3, 3, 4, 4, 6, 7, 7, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",2088233
83,"['Fifteen subjects with post-stroke hemiparesis .', 'Fifteen subjects with post-stroke hemiparesis', 'performance of patients with post-stroke hemiparesis', 'post-stroke hemiparesis', 'patients with chronic stroke .', 'patients with chronic stroke .']","[3, 3, 10, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['visual and kinesthetic locomotor imagery training', 'auditory step rhythm', 'visual and kinesthetic locomotor imagery training', 'auditory step rhythm', 'locomotor imagery trainings', 'visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm', 'kinesthetic locomotor imagery training with auditory step rhythm .', 'locomotor imagery trainings', 'visual locomotor imagery training', 'kinesthetic locomotor imagery training', 'visual locomotor imagery training with auditory step rhythm', 'kinesthetic locomotor imagery training with auditory step rhythm', 'visual locomotor imagery training', 'the kinesthetic locomotor imagery training with auditory step rhythm', 'visual locomotor imagery training', 'kinesthetic locomotor imagery training', 'auditory step rhythm', 'the kinesthetic locomotor imagery training', 'the visual locomotor imagery training', 'when auditory step rhythm', 'form of locomotor imagery training', 'kinesthetic locomotor imagery', 'visual locomotor imagery training', 'step rhythm', 'the visual locomotor imagery training', 'the kinesthetic locomotor imagery training with auditory step rhythm', 'visual locomotor imagery training', 'kinesthetic locomotor imagery training', 'auditory step rhythm', 'the kinesthetic locomotor imagery training', 'the visual locomotor imagery training', 'kinesthetic locomotor imagery training', 'visual locomotor imagery training', 'The auditory step rhythm', 'the locomotor imagery training', 'auditory step rhythm', 'locomotor imagery training', 'Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm', 'Visual and kinesthetic locomotor imagery training', 'auditory step rhythm']","[0, 0, 0, 0, 4, 4, 4, 4, 4, 4, 4, 4, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i']","['walking performance', 'walking performance', 'The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb', 'The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb', 'timed up-and-go test', 'timed up-and-go test', 'greater number of muscles', 'increased angular displacement of the knee and ankle joints', 'well as kinematic data of the knee joint', 'The therapeutic effect', 'the walking performance', 'walking performance']","[0, 0, 5, 5, 6, 6, 7, 7, 8, 9, 10, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",20943715
84,"['schizophrenics .', 'schizophrenics .', 'total of 81 schizophrenics', '81 schizophrenics', 'and psychiatric', 'schizophrenics :', 'schizophrenics']","[0, 0, 1, 1, 11, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['paliperidone', 'paliperidone', 'paliperidone', 'risperidone', 'paliperidone', 'risperidone', 'in either group', 'paliperidone', 'paliperidone']","[0, 0, 1, 1, 1, 1, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['efficacy', 'social functions', 'social functions', 'positive and negative symptoms scales ( PANSS ) , social disability screening schedule ( SDSS ) and treatment emergent symptom scale ( TESS )', 'positive and negative symptoms scales ( PANSS )', 'social disability screening schedule ( SDSS )', 'treatment emergent symptom scale ( TESS )', 'factors and total scores of PANSS', 'factors and total scores of PANSS', 'group , the positive factor , negative factor and total scores of', 'treatment , the factors and total scores', 'study group , the', 'In study group , the', 'weekend of treatment', '2.9 ) ( t = -4.49 , P < 0.05 )', 'extended-release tablets are effective', 'improve social functions', '[ Efficacy', 'social functions', 'social functions']","[0, 0, 0, 2, 2, 2, 2, 3, 3, 4, 5, 6, 7, 9, 9, 11, 11, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",21029638
85,"['Participants were 236 heavy drinking smokers', '236 heavy drinking smokers']","[4, 4]","['ss_p', 'hl_p']","['alcohol intervention', 'alcohol intervention']","[4, 4]","['ss_i', 'hl_i']","['depressive symptoms', 'depressive symptoms', 'abstinence and depressive symptom', 'time-varying abstinence and depressive symptom', 'depressive symptom', 'efficacy', 'Depressive symptoms and biochemically verified abstinence', 'Depressive symptoms', 'biochemically verified abstinence', 'depressive symptoms', 'depressive symptoms', 'time-varying abstinence ( vs. smoking )', 'level of depressive symptoms', 'depressive symptoms .', 'level of depressive symptoms', 'depressive symptoms .', 'depressive symptoms .', 'depressive symptoms .', 'depressive symptoms .', 'depressive symptoms .', 'depressive symptoms', 'depressive symptoms']","[0, 0, 1, 3, 3, 4, 5, 5, 5, 6, 6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",21106663
86,"['Beluga , Huso huso ( L. )', 'Beluga , Huso huso ( L. )', 'for blood', 'Beluga , Huso huso ( L. )', 'Beluga , Huso huso ( L. )']","[0, 0, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['anesthesia', 'anesthesia', 'anesthesia', 'l⁻¹ clove solution', 'anesthesia', 'anesthesia', 'Results suggest that', 'dose is better']","[0, 0, 0, 0, 0, 0, 6, 6]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i']","['serum parameters', 'respectively .', 'Blood samples', 'that cortisol and glucose levels', 'control .', 'Serum lactate levels', 'control group .', 'Lactate', 'differences in serum levels of cholesterol , total protein , lactate dehydrogenase , aspartate aminotransferase , alanine aminotransferase , Na⁺ , Cl⁻', 'anesthesia with lower dose', 'Serum biochemical characteristics']","[0, 0, 1, 2, 2, 3, 3, 4, 5, 6, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",21170734
87,"['360 diabetic patients with coronary artery disease', '360 diabetic patients with coronary artery disease', 'diabetic patients .', 'diabetic patients .', 'diabetic patients with coronary artery disease .', 'diabetic patients with coronary artery disease .', 'diabetic patients :', 'diabetic patients']","[3, 3, 10, 10, 11, 11, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['pioglitazone', 'pioglitazone', 'Pioglitazone', 'glimepiride', 'Pioglitazone', 'pioglitazone', 'glimepiride', '( Pioglitazone', 'pioglitazone', 'glimepiride', 'Pioglitazone-treated', 'Pioglitazone-treated', 'pioglitazone', 'glimepiride .', 'pioglitazone', 'glimepiride .', 'pioglitazone-induced', 'pioglitazone-induced', 'pioglitazone', 'pioglitazone', 'pioglitazone', '( Pioglitazone', 'pioglitazone']","[0, 0, 2, 2, 2, 3, 3, 3, 3, 3, 6, 6, 7, 7, 7, 7, 9, 9, 10, 10, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['effect', 'atheroma progression .', 'coronary atheroma progression .', 'progression', 'Coronary atheroma progression was evaluated by serial intravascular ultrasound .', 'Coronary atheroma progression', 'changes in biochemical parameters , percent atheroma volume , and total atheroma volume', 'changes in biochemical parameters', 'percent atheroma volume', 'total atheroma volume', 'high-density lipoprotein cholesterol ( HDL-C )', 'glycated hemoglobin , triglycerides , and C-reactive protein .', 'high-density lipoprotein cholesterol ( HDL-C )', 'glycated hemoglobin', 'triglycerides', 'C-reactive protein', 'percent atheroma volume and triglycerides', 'triglyceride/HDL-C ratio', 'glycated hemoglobin', 'low-density lipoprotein cholesterol', 'apolipoprotein B', 'apolipoprotein A-I', 'percent atheroma volume and triglycerides', 'triglyceride/HDL-C ratio', 'glycated hemoglobin', 'low-density lipoprotein cholesterol', 'apolipoprotein B', 'apolipoprotein A-I', 'Substantial atheroma regression', 'progression', 'HDL-C', 'triglycerides', 'triglyceride/HDL-C ratio', 'glycated hemoglobin', 'HDL-C', 'triglycerides', 'triglyceride/HDL-C ratio', 'glycated hemoglobin', 'triglyceride/HDL-C', 'percent atheroma volume', 'total atheroma volume', 'triglyceride/HDL-C', 'percent atheroma volume', 'total atheroma volume', 'triglyceride/HDL-C ratio', 'atheroma progression', 'triglyceride/HDL-C ratio', 'atheroma progression', 'triglyceride/high-density lipoprotein cholesterol ratio', 'progression of coronary atherosclerosis', 'triglyceride/high-density lipoprotein cholesterol ratio', 'coronary atherosclerosis']","[0, 0, 1, 2, 4, 4, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 0, 0, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",21211686
88,"['human', 'human']","[0, 0]","['ss_p', 'hl_p']","['perturbations to treadmill walking', 'perturbations to treadmill walking']","[4, 4]","['ss_i', 'hl_i']","['step frequency', 'human step frequency adjustments', 'quite quickly', 'human step frequency adjustments', 'smaller amplitude', 'tens of seconds', 'preferred step frequency']","[0, 5, 5, 5, 6, 6, 10]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o']",21393467
89,"['Twenty-four patients presenting with ≥12 teeth with probing depth ( PD ) ≥5 mm and bleeding on probing', 'Twenty-four patients', 'treatment of chronic periodontitis', 'chronic periodontitis :', 'chronic periodontitis :']","[1, 1, 13, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['chlorhexidine ( CHX )', 'chlorhexidine ( CHX )', 'prophylaxis , CHX chips ( test ) or placebo', 'placebo', 'treatment with', 'The use of', 'chlorhexidine', 'chlorhexidine']","[0, 0, 2, 2, 12, 13, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['clinical , microbiologic , and serologic effects', 'clinical', 'microbiologic', 'serologic effects', 'PD ≥5 mm .', 'Parameters', 'treatment .', 'Subgingival', 'treatment .', 'Periodontal pathogens Aggregatibacter actinomycetemcomitans , Porphyromonas gingivalis , Prevotella intermedia , Tannerella forsythia , and Treponema', 'analyzed .', 'Serum levels of high sensitive C-reactive and lipopolysaccharide-binding', 'changes of the parameters', 'tested by Mann-Whitney', 'RESULTS All clinical and serologic parameters', 'difference in clinical attachment level', 'clinical attachment level ( CAL )', 'a greater reduction of the microorganisms of the "" red', 'reduction of the microorganisms of the "" red', 'SRP improved', 'reduced the subgingival microorganisms of the red', 'subgingival microorganisms of the red']","[0, 0, 0, 0, 4, 5, 5, 6, 6, 7, 7, 8, 9, 9, 10, 11, 11, 12, 12, 13, 13, 13]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",21491990
90,"['49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .', '49', '70', '38-84 years of age', '55', 'Guatemala']","[4, 4, 4, 4, 4, 0]","['ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p']","['chimney woodstove', 'chimney woodstove', 'stove intervention', 'open fire', 'stove intervention', 'open fire', 'stove', 'open fires', 'chimney stoves', 'stove', 'open fires', 'chimney stoves', 'stoves .', 'stoves .', 'the trial , the stove', 'CONCLUSIONS The stove']","[1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 9, 12]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i']","['ST-segment depression', 'heart rate variability ( HRV ) .', 'ST-segment depression', 'heart rate variability ( HRV ) .', 'Electrocardiogram sessions', 'HRV and ST-segment values', 'HRV and ST-segment values', 'ST-segment depression was defined as an average value below -1.00 mm .', 'ST-segment depression', 'Personal fine PM [ aerodynamic diameter ≤ 2.5 μm ( PM₂.₅ ] exposures', 'before each electrocardiogram', 'RESULTS PM₂.₅', '0.08-0.90 ) for ST-segment', 'associated', 'of nonspecific ST-segment', 'ST-segment depression', 'ST-segment depression']","[2, 2, 2, 2, 4, 5, 5, 6, 6, 7, 7, 8, 9, 11, 12, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",21669557
91,"['with type 1 diabetes ( T1D )', 'type 1 diabetes ( T1D )', 'in 24 patients , 8-18 years old , with newly diagnosed T1D', '24', '8-18 years old', 'newly diagnosed T1D', 'in type 1 diabetes', 'type 1 diabetes']","[0, 0, 1, 1, 1, 1, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['starting insulin pump', 'daily insulin', 'comparing MDI', 'subcutaneous insulin therapy ( pump therapy )', 'insulin therapy ( pump therapy )', 'of pump therapy', 'in insulin', 'of insulin pump therapy', 'insulin pump therapy', 'Insulin pump', 'Insulin pump']","[0, 0, 1, 1, 1, 5, 6, 7, 7, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['the efficacy', '.', 'Preservation of insulin secretion , measured by mixed-meal-stimulated C-peptide secretion', 'Preservation of insulin secretion', 'by mixed-meal-stimulated C-peptide secretion', 'in glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction with therapy', 'glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction', 'higher mixed-meal tolerance test-stimulated C-peptide values', 'mixed-meal tolerance', 'C-peptide values', 'improved glycemic control', 'mean HbA1c )', 'greater satisfaction', 'glycemic control', 'improved glycemic control', 'improved patient satisfaction', 'glycemic control', 'preserve residual β-cell function', 'glycemic control and pancreatic β-cell function', 'glycemic control', 'pancreatic β-cell function']","[0, 2, 3, 3, 3, 4, 4, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 8, 0, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",21718094
92,"['endometriosis ( EMs ) -related infertility patients .', 'endometriosis ( EMs ) -related infertility patients .', '130 EMs-related infertility patients of blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery', '130 EMs-related infertility patients', 'blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery', 'EMs patients of blood stasis and toxin accumulation syndrome', 'EMs-related infertility .', 'endometriosis-related infertility patients', 'endometriosis-related infertility patients']","[0, 0, 1, 1, 1, 14, 15, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p']","['laparoscopic surgery', 'Quyu Jiedu Recipe ( QYJDR )', 'laparoscopic surgery', 'Quyu Jiedu Recipe ( QYJDR )', 'progesterone', 'progesterone', 'QYJDR', 'QYJDR', 'laparoscopic surgery', 'laparoscopic surgery', 'QYJDR', 'laparoscopic surgery', 'QYJDR', 'QYJDR', 'QYJDR', 'laparoscopic surgery', 'quyu jiedu recipe ]', 'laparoscopic surgery', 'quyu jiedu recipe ]']","[0, 0, 0, 0, 2, 2, 3, 3, 3, 14, 14, 14, 14, 15, 15, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['clinical efficacy', 'clinical efficacy', 'pregnancy rate within one year after laparoscopic surgery', 'pregnancy rate', 'Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels', 'Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels', 'pregnancy rate', 'pregnancy rate', 'Chinese medicine syndrome integral', 'Chinese medicine syndrome integral', 'Chinese medicine syndrome integral', 'Chinese medicine syndrome integral', 'integral', 'serum EMAb', 'serum EMAb', 'serum CA125 level', 'serum CA125 level', 'clinical symptoms', 'blood stasis and toxin accumulation syndrome', 'negative conversion of EMAb', 'serum CA125 levels', 'clinical pregnancy rate .', 'blood stasis', 'toxin accumulation syndrome', 'negative conversion of EMAb', 'serum CA125 levels', 'clinical pregnancy rate .']","[0, 0, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 10, 10, 11, 11, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",21866656
93,"['patients with moderate to severe congestive heart failure .', 'patients with moderate to severe congestive heart failure .', 'Seventeen patients on chronic digitalis and diuretic therapy', 'Seventeen patients on chronic digitalis and diuretic therapy', 'patients with moderate to severe chronic heart failure .', 'patients with moderate to severe chronic heart failure .', 'congestive heart failure .', 'congestive heart failure .']","[0, 0, 1, 1, 6, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['flosequinan', 'flosequinan', 'flosequinan', 'placebo', 'flosequinan', 'placebo', 'flosequinan-treated', 'Flosequinan', 'Flosequinan', 'flosequinan', 'flosequinan', 'flosequinan', 'flosequinan', 'flosequinan', 'flosequinan']","[0, 0, 1, 1, 1, 1, 3, 4, 4, 5, 5, 6, 6, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['long-term effect', 'clinical course', 'long-term effect', 'Changes in symptomatology , exercise performance , and left ventricular function', 'symptomatology', 'exercise performance', 'left ventricular function', 'symptom scores and functional classification', 'symptom scores', 'functional classification', 'maximal exercise capacity .', 'maximal exercise capacity .', 'resting heart rate', 'left ventricular systolic function .', 'resting heart rate', 'left ventricular systolic function .']","[0, 0, 0, 2, 2, 2, 2, 3, 3, 3, 4, 4, 5, 5, 5, 5]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",2188766
94,"['The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .', '186', 'mean age 70 years', '123', 'female', '130', 'trauma', 'referred for physiotherapy assessment/intervention']","[3, 3, 3, 3, 3, 3, 3, 3]","['ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p']","['physiotherapy', 'physiotherapy', 'physiotherapy service', 'physiotherapy service', 'physiotherapy assessment/intervention .', 'physiotherapy assessment/intervention', 'physiotherapy', 'physiotherapy assessment/intervention .', 'physiotherapy', 'physiotherapy assessment/intervention', 'physiotherapy', 'physiotherapy', 'A physiotherapy service', 'physiotherapy', 'physiotherapy service', 'physiotherapy service']","[0, 0, 1, 1, 3, 3, 6, 6, 6, 6, 7, 7, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .', 'rate of hospital admission', 'rate of re-presentation to the ED', 'visits to community healthcare practitioners', 'return to usual work/home/leisure activities', 'patient satisfaction', 'rate of admission to hospital', 'rate of re-presentation to the ED', 'rate of admission to hospital', 'rate of re-presentation to the ED', 'for use of community healthcare resources , return to usual work/home/leisure activities and satisfaction with their EECU care', 'the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources', 'the rate of return to usual work/home/leisure activities or patient satisfaction', 'admission rates to hospital :', 'admission rates to hospital :']","[1, 1, 1, 1, 1, 1, 7, 7, 7, 7, 8, 9, 9, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",21896676
95,"['Male students ( N=443 )', 'Male students', 'N=443']","[2, 2, 2]","['ss_p', 'hl_p', 'hl_p']","['public education about testicular cancer ( TC )', 'threat control strategies ( eg , testicular self-examination ; TSE )', 'testicular self-examination ;', 'TC', 'TC +TSE', 'TC', 'TC +TSE', 'TC+TSE', 'TC', 'TSE', 'TC', 'Cancer information']","[0, 1, 1, 2, 2, 2, 2, 3, 4, 4, 4, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i']","['anxiety .', 'anxiety', 'Anxiety levels', 'perceived message benefit', 'intention to self-examine', 'message denigration .', 'Anxiety levels', 'perceived message benefit', 'intention to self-examine', 'message denigration .', 'anxiogenic', 'acceptance of disease awareness information .', 'anxiety :', 'anxiety :']","[0, 1, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",21914768
96,"['ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .', 'ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .', '32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched', '122 and 865 controls', '32 cases with ischemic stroke', '234 cases with bleeding', 'lower in individual AF patients', 'atrial fibrillation patients :', 'atrial fibrillation patients :']","[1, 1, 3, 3, 3, 3, 8, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['Time in therapeutic range ( TTR )', 'Time in therapeutic range ( TTR )', 'mean TTR', 'TTR', 'CONCLUSIONS', 'Maintaining a high']","[0, 0, 5, 5, 8, 8]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i']","['Time in therapeutic range ( TTR )', 'stroke and bleeding', 'Time in therapeutic range ( TTR )', 'anticoagulation quality measures', 'the stroke analysis', 'the bleeding analysis', 'mean TTR', 'lower .', 'stroke and', 'Time below range for stroke', 'time above range for bleeding', 'spent more', 'CONCLUSIONS', 'Maintaining a high', 'treatment to prevent stroke and bleeding', 'risk of stroke and bleeding events']","[0, 0, 0, 2, 4, 4, 5, 5, 6, 6, 6, 7, 8, 8, 8, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",21924760
97,"['3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries .', '3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries', 'Among 1314 couples in which the HIV-1-seronegative partner was female', 'p=0·03 ) .', '1314 couples in which the HIV-1-seronegative partner', 'female', 'Among 2476 couples in which the HIV-1-seronegative partner']","[2, 2, 6, 6, 6, 6, 7]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p']","['Hormonal contraceptives', 'Hormonal contraceptives', 'hormonal contraceptive', 'hormonal contraceptive', 'hormonal contraceptive', 'hormonal contraceptive', 'used hormonal contraception', 'which women used hormonal contraception', 'women did not use hormonal', 'transmission with hormonal', 'Non-hormonal or low-dose hormonal', 'hormonal contraceptives', 'hormonal contraceptives']","[0, 0, 1, 1, 3, 3, 6, 7, 7, 9, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['risk of HIV-1 acquisition', 'HIV-1 transmission', 'rates of HIV-1 acquisition', 'HIV-1 transmission', 'HIV-1 seroconversion .', 'HIV-1 risk .', 'of HIV-1 acquisition', 'HIV-1 acquisition', 'months ) , rates of HIV-1 transmission', 'HIV-1 transmission', 'potentially increased risk of HIV-1 acquisition', 'risk of HIV-1 acquisition', 'risk of HIV-1 transmission :']","[1, 1, 3, 3, 4, 5, 6, 6, 7, 7, 9, 9, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",21975269
98,"['patients with heart failure ( HF ) .', 'patients with heart failure ( HF ) .', 'patients with class II to IV HF and ejection fraction < 35 % .', 'patients with class II to IV HF and ejection fraction < 35 % .', 'Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons .', '330', '23', 'In HF patients with chronic postinfarction cardiomyopathy', 'in HF patients with postinfarction cardiomyopathy', 'patients with chronic heart failure after myocardial infarction .', 'patients with chronic heart failure after myocardial infarction .']","[0, 0, 1, 1, 3, 3, 3, 7, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p']","['myoblasts', 'myoblasts', 'placebo', 'myoblasts', 'placebo', 'myoblasts', '( placebo )', '( placebo )', 'myoblast-treated', '( placebo )', 'myoblast-treated', '( placebo )', 'myoblast-treated', 'myoblast-treated', 'of myoblasts', 'myoblasts', 'by myoblast', 'of myoblast', 'skeletal myoblast implantation', 'skeletal myoblast implantation']","[0, 0, 1, 1, 1, 1, 4, 4, 5, 5, 5, 5, 6, 6, 7, 7, 8, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['safety', 'preliminary efficacy', 'safety', 'efficacy', 'frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .', 'frequency of serious adverse events ( safety )', 'changes in 6-minute walk test', 'Minnesota Living With HF score ( efficacy )', 'Ventricular tachycardia responsive', 'Ventricular tachycardia responsive', 'functional capacity', 'in Minnesota Living With HF scores', 'functional capacity', 'safety', 'cardiovascular effects', 'safety', 'cardiovascular effects']","[0, 0, 0, 0, 2, 2, 2, 2, 5, 5, 6, 6, 6, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",21982657
99,"['with 210 subjects ≥60 years', '210', '≥60 years', 'immunogenic in adults ≥60', 'healthy adults ≥60 years of age', 'healthy adults ≥60 years of age']","[2, 2, 2, 12, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['of zoster vaccine ( ZV )', 'of ZV', 'zoster vaccine ( ZV )', 'doses of', 'vs. placebo', 'placebo', 'in the', 'in the placebo', 'placebo', 'after', '( GMTs ) in', 'than in the', 'CONCLUSIONS', 'second', 'zoster vaccine', 'zoster vaccine']","[1, 1, 1, 2, 2, 2, 6, 8, 8, 9, 10, 10, 12, 13, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['compared immunity and safety profiles', 'placebo .', 'immunity', 'safety', 'Immunogenicity was evaluated using VZV interferon-gamma ( IFN-γ ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay .', 'Immunogenicity', 'Adverse experiences ( AEs )', 'on a standardized Vaccination Report', 'Adverse experiences ( AEs )', 'RESULTS No serious vaccine-related', 'occurred .', 'serious vaccine-related', 'VZV IFN-γ ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear', 'respectively', 'study .', 'The peak ELISPOT response', 'dose .', 'The gpELISA geometric mean titers', 'between the IFN-γ ELISPOT and gpELISA', 'was generally', 'VZV-specific', 'Safety , tolerability , and immunogenicity', 'Safety', 'tolerability', 'immunogenicity']","[2, 2, 2, 2, 3, 3, 4, 4, 4, 5, 5, 5, 6, 7, 8, 9, 9, 10, 11, 13, 13, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o']",22154769
100,"['60 elderly patients .', '60 elderly patients', 'elderly patients .', 'elderly patients .']","[0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['propofol', 'propofol', 'Propofol', 'Propofol', 'propofol', 'propofol']","[0, 0, 1, 1, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['loss of consciousness ( as judged by loss of verbal contact with the patient )', 'loss of consciousness', 'loss of verbal contact with the patient )', 'duration of induction', 'infusion rates', 'total dose', 'duration of induction', 'systolic and diastolic arterial pressure', 'systolic and diastolic arterial pressure', 'incidence of apnoea', 'incidence of apnoea']","[1, 1, 1, 2, 2, 2, 2, 3, 3, 4, 4]","['ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",2223363
101,"['adult acute nonlymphocytic leukemia ( ANLL )', 'adult acute nonlymphocytic leukemia ( ANLL )', 'The 101 eligible cases ( bestatin : 48 , control : 53 )', '101', '48', '53', 'acute nonlymphocytic leukemia in adults .', 'acute nonlymphocytic leukemia', 'adults']","[1, 1, 3, 3, 3, 3, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['bestatin', 'bestatin', 'bestatin', 'bestatin', 'bestatin', 'bestatin', '( bestatin :', 'bestatin', 'bestatin', 'bestatin', 'bestatin', 'bestatin', 'Bestatin', 'Bestatin', 'bestatin', 'bestatin']","[0, 0, 1, 1, 2, 2, 3, 3, 3, 3, 4, 4, 5, 5, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['longer remission', 'longer survival .', 'remission', 'survival .', 'prolongation of remission', 'prolongation of remission', 'prolonged survival and remission', 'side-effects .', 'survival', 'remission', 'side-effects .']","[3, 3, 3, 3, 4, 4, 5, 5, 5, 5, 5]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o']",2224060
102,"['autism .', 'autism .']","[0, 0]","['ss_p', 'hl_p']","['psychosocial interventions', 'psychosocial interventions', 'psychosocial interventions', 'psychosocial interventions']","[0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i']","['Goal attainment scaling ( GAS )', 'Goal attainment scaling ( GAS )', 'scaling level', 'inter-individual equivalence', 'comparability', 'reliability of coding across different behavioral observation methods .', 'assumptions of equality', 'measurability , equidistance , level of difficulty , comparability of behavior samples collected from teachers vs. researchers and live vs. videotape )', 'GAS', 'GAS', 'Goal attainment scaling', 'Goal attainment scaling']","[0, 0, 1, 1, 1, 1, 2, 2, 3, 4, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",22271197
103,"['infants undergoing the Norwood procedure', 'infants undergoing the Norwood procedure', '549 subjects ( follow-up , 2.7 ± 0.9 years )', '549', 'infants with single-ventricle lesions :', 'infants', 'single-ventricle lesions']","[0, 0, 3, 3, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['cardiac transplantation', 'cardiac transplantation', 'cardiac transplantation', 'cardiac transplantation', 'cardiac transplantation']","[0, 0, 1, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['factors associated with death and cardiac transplantation', 'death without transplantation , cardiac transplantation , and survival without transplantation .', 'Parametric time-to-event modeling and bootstrapping were used to identify independent predictors .', '.', 'Mortality risk', 'Mortality risk', 'with death', 'lower socioeconomic status', 'obstructed pulmonary venous return', 'smaller ascending aorta', 'and anatomic subtype', 'with death', 'with death included genetic syndrome', 'lower gestational age', 'with death', 'better survival', 'survival', 'Lower pre-Norwood right ventricular fractional area change , pre-Norwood surgery , and anatomy other than hypoplastic left heart syndrome', 'Independent risk factors for intermediate-term mortality', '.', 'Right ventricular function and anatomy', 'not shunt type', 'Intermediate-term mortality and cardiac transplantation', 'risk factors']","[0, 1, 2, 3, 4, 4, 5, 5, 5, 5, 5, 5, 6, 6, 6, 7, 7, 9, 10, 11, 12, 12, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",22341427
104,"['children', 'twenty-two 3- to 4-year-olds', 'twenty-two 3- to 4-year-olds', 'thirty-two 4- to 5-year-olds', 'thirty-two 4- to 5-year-olds', 'Preschoolers', 'Preschoolers']","[1, 2, 2, 5, 5, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['pretend play .', 'pretend play .', 'pretense', 'pretense', 'scenarios lacking pretend speech or sound effects .', 'scenarios lacking pretend speech or sound effects .', 'pretense .', 'pretense .']","[1, 1, 2, 2, 5, 5, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['general knowledge', 'generic knowledge', ""children 's responses"", 'responses', 'generic knowledge .', 'general knowledge']","[0, 1, 4, 4, 6, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",22416755
105,"['individuals formally diagnosed with autism spectrum disorder ( ASD ) .', 'individuals formally diagnosed with autism spectrum disorder ( ASD ) .', '20 children with ASD ( M age = 14.3 yr.', 'SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .', '20 children', 'ASD', 'M age = 14.3 yr.', 'SD = 4.2', '6', '14', '20', 'children', 'Inclusion/exclusion criteria were defined according to the clinical diagnosis of ASD , the presence or absence of additional or associated disability , previous training in referential communication , and any drug treatment .', 'individuals with ASD', 'individuals with ASD', 'individuals with autism spectrum disorder :', 'individuals with autism spectrum disorder :']","[0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 3, 9, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['referential communication training', 'referential communication training', 'referential communication', 'referential communication tasks ( task analysis , role taking', 'task evaluation )', 'communicative game', 'referential communication tasks ( task analysis , role taking', 'task evaluation )', 'communicative game', 'referential communication', 'referential communication', 'referential communicative skills', 'referential communicative skills']","[0, 0, 3, 7, 7, 7, 7, 7, 7, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['Linguistic age , cognitive level and autistic symptoms', 'Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .', 'Linguistic age , cognitive level and autistic symptoms', 'Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .', 'Communicative abilities', 'indexes related to message complexity and self-regulation .', 'Communicative abilities', 'complexity of emitted messages', 'complexity of emitted messages']","[5, 5, 5, 5, 6, 6, 6, 8, 8]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",22420121
106,"['Fifty children with high-functioning ASD and anxiety', 'Fifty children', 'high-functioning ASD and anxiety', 'RESULTS Forty-seven children completed either the CBT or TAU condition', 'Forty-seven children', 'for children with ASD', 'children with high-functioning autism spectrum disorders and anxiety :', 'children', 'high-functioning autism spectrum disorders and anxiety']","[4, 4, 4, 6, 6, 10, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['Cognitive behavioral therapies ( CBT )', 'Cognitive behavioral therapies ( CBT )', 'CBT', 'CBT', 'CBT', 'treatment-as-usual ( TAU )', 'CBT', 'treatment-as-usual ( TAU )', 'the CBT or TAU', 'CBT', 'TAU', 'the CBT', 'CBT', 'the CBT', 'the TAU', 'CBT', 'agroup CBT', 'CBT', 'Group cognitive behavior therapy', 'Group cognitive behavior therapy']","[2, 2, 3, 3, 4, 4, 4, 4, 6, 6, 6, 7, 7, 9, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['anxiety symptoms .', 'anxiety symptoms .', 'structured interviews ( Anxiety Disorders Interview Schedule – Parent Version ; ADIS-P )', 'in Clinician Severity Ratings , diagnostic status , and clinician ratings of global improvement', 'positive treatment response']","[2, 2, 5, 8, 9]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o']",22435114
107,"['patients with spotty calcification .', 'patients with spotty calcification .', 'A total of 1,347 stable patients with angiographic coronary artery disease', '1,347 stable patients with angiographic coronary artery disease', 'Patients with spotty calcification were identified based on the presence of lesions ( 1 to 4 mm in length ) containing an arc of calcification of < 90°', 'RESULTS Patients with spotty calcification were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68 % vs. 54 % ;', '0.001 )', 'attenuated in patients with spotty calcification']","[0, 0, 3, 3, 4, 6, 6, 9]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'ss_p']","['serial evaluation of atheroma burden with intravascular ultrasound imaging .', 'serial evaluation of atheroma burden with intravascular ultrasound imaging .']","[3, 3]","['ss_i', 'hl_i']","['atheroma progression', 'atheroma progression', 'spotty calcification', 'disease progression', 'disease progression', 'atheroma burden with intravascular ultrasound imaging .', 'atheroma burden', '.', 'Clinical characteristics and disease progression', 'on-treatment high-density lipoprotein cholesterol levels', 'greater percent atheroma volume ( PAV )', '0.001 ) and total atheroma volume', 'greater progression', 'greater progression', 'and diffuse coronary atherosclerosis', 'accelerated disease progression', 'coronary atherosclerosis', 'progression of coronary atherosclerosis :', 'progression of coronary atherosclerosis :']","[0, 0, 2, 2, 2, 3, 3, 4, 5, 6, 7, 7, 8, 8, 10, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",22538329
108,"['Fifty-six outpatients', 'Fifty-six outpatients', 'Thirty-nine subjects completed the study', 'Thirty-nine subjects completed the study', 'patients with inflammatory bowel disease .', 'patients with inflammatory bowel disease .']","[3, 3, 9, 9, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['relaxation-training sessions', 'relaxation-training sessions', 'relaxation-training', 'relaxation-training', 'patients may benefit from', 'relaxation training', 'relaxation training']","[4, 4, 10, 10, 11, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['quality of life ( QoL ) .', 'quality of life ( QoL ) .', 'state anxiety was assessed with the State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .', 'state anxiety', 'State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .', 'The Visual Analogue Scale assessed pain , depression , stress and mood .', 'Visual Analogue Scale', 'pain', 'depression', 'stress', 'mood', 'symptom monitoring diary .', 'interaction ) : anxiety', '( p < 0.01 ) , QoL', '( p < 0.05 ) , while levels of', 'anxiety', 'quality of life', 'anxiety', 'quality of life']","[0, 0, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 10, 10, 10, 0, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",22646975
109,"['preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .', 'preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .', 'Seventy-seven children', 'Seventy-seven children', 'preschool children who have ID and significant language impairments .', 'preschool children who have ID and significant language impairments .', 'preschool children who have intellectual disabilities .', 'preschool children who have intellectual disabilities .']","[0, 0, 1, 1, 6, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['enhanced milieu teaching ( EMT )', 'enhanced milieu teaching ( EMT )', '( parent + therapist EMT', 'therapist-only EMT )', 'parent + therapist EMT', 'therapist-only EMT', 'EMT', 'EMT', 'enhanced milieu teaching', 'enhanced milieu teaching']","[0, 0, 1, 1, 1, 1, 4, 4, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['language skills', 'standardized and observational measure', 'use of EMT strategies', 'EMT strategies', 'observational measures', 'observational measures']","[0, 3, 4, 4, 5, 5]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",22744141
110,"['patients with Posttraumatic stress disorder ( PTSD ) .', 'patients with Posttraumatic stress disorder ( PTSD ) .', 'PTSD', 'PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities', 'PTSD', 'five primary care clinics at four Veterans Affairs healthcare facilities', 'Participants were 195 Veterans .', '195 Veterans', 'Their average age was 45 years , 91 % were male , 58 % were white , 40 % served in Iraq or Afghanistan , and 42 % served in Vietnam .', 'average age was 45 years', '91 % were male', 'PTSD', 'PTSD']","[0, 0, 1, 3, 3, 3, 5, 5, 6, 6, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['collaborative care', 'Three Component Model ( 3CM )', 'usual care', 'Three Component Model ( 3CM )', 'usual care', 'usual care', 'usual care plus 3CM .', 'usual care', 'usual care', '3CM', 'usual care', '3CM', 'telephone care management .', '3CM', 'telephone care management .', '3CM', 'usual care', '3CM', '3CM', '3CM', '3CM', 'collaborative care']","[0, 1, 1, 1, 1, 3, 3, 3, 3, 3, 7, 8, 8, 8, 8, 12, 12, 13, 13, 14, 14, 15]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i']","['PTSD symptom severity', 'PTSD symptom severity', 'Depression , functioning , perceived quality of care , utilization , and costs', 'Depression', 'functioning', 'perceived quality of care', 'utilization', 'costs', 'symptoms or functioning .', 'symptoms', 'functioning .', 'mental health visit , fill an antidepressant prescription', 'adequate antidepressant refills .', 'mental health visit , fill an antidepressant prescription', 'adequate antidepressant refills .', 'mental health visits', 'outpatient pharmacy costs .', 'mental health visits', 'outpatient pharmacy costs .']","[10, 10, 11, 11, 11, 11, 11, 11, 12, 12, 12, 13, 13, 13, 13, 14, 14, 14, 14]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",22865017
111,"['young children with autism with a range of intellectual ability .', 'young children', 'autism with a range of intellectual ability', 'Participants were 55 children with autistic disorder , aged 4-7 years ( FSIQ 42-107 ) .', '55 children with autistic disorder', 'aged 4-7 years', 'young children with autism', 'young children with autism', 'young children with autism', 'young children with autism', 'young children with autism :', 'young children with autism :']","[2, 2, 2, 3, 3, 3, 10, 10, 12, 12, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['emotion training', 'emotion training', 'emotion training programme', 'emotion training programme', 'emotion recognition skills', '( the Transporters )', 'Thomas the Tank Engine .', 'emotion recognition skills', 'the Transporters', 'control', 'Thomas the Tank Engine .', 'The Transporters', 'The Transporters', 'the Transporters', 'Transporters', 'emotion recognition', 'emotion training programme .', 'emotion recognition', 'emotion training programme .']","[1, 1, 2, 2, 5, 5, 5, 5, 5, 5, 5, 10, 10, 12, 12, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'efficacy', 'ability to complete basic emotion recognition tasks , mindreading and theory of mind ( TOM ) tasks', 'basic emotion recognition tasks', 'mindreading and theory of mind ( TOM ) tasks', 'recognition of anger', 'recognition of anger', 'TOM or social skills .', 'TOM', 'social skills .', 'efficacy', 'emotion recognition skills', 'efficacy', 'recognition of expressions of anger', 'efficacy']","[2, 2, 6, 6, 6, 8, 8, 9, 9, 9, 10, 10, 10, 11, 12]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",22881991
112,"['in patients with mixed dyslipidaemia and MetS', 'patients with mixed dyslipidaemia and MetS', 'patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl', 'study , only patients with MetS were included', 'patients with MetS', 'in patients with mixed dyslipidaemia and metabolic syndrome', 'patients with mixed dyslipidaemia and metabolic syndrome']","[1, 1, 2, 3, 3, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['high-dose rosuvastatin', 'with fenofibrate or ω-3 fatty acids', 'rosuvastatin', 'fenofibrate', 'ω-3 fatty acids', '200 mg/dl to rosuvastatin', '30 ) or rosuvastatin', 'combined with fenofibrate', '30 ) or ω-3 fatty', 'rosuvastatin', 'rosuvastatin', 'fenofibrate', 'ω-3 fatty', 'in the', 'RF', 'prominent', 'compared with', 'resistance', 'noted', 'increased by', 'mean LDL', 'rosuvastatin', 'fenofibrate', 'ω-3 fatty acids', 'rosuvastatin', 'fenofibrate', 'ω-3 fatty acids']","[1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 6, 6, 7, 7, 9, 10, 0, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['the lipoprotein subfraction profile', 'lipoprotein subfraction profile', 'treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3 % gel electrophoresis', 'lipoprotein subfraction', 'RESULTS The mean', 'mean', 'its greater hypotriglyceridemic', 'decrease in insulin resistance', 'insulin resistance', 'significantly raised HDL-C', 'increasing the cholesterol of small HDL particles .', 'The cholesterol of larger HDL subclasses', 'cholesterol of larger HDL', 'regimens increased mean', 'noted on the HDL subfraction', 'on lipoprotein subfraction profile', 'lipoprotein subfraction profile']","[1, 1, 4, 4, 5, 5, 6, 7, 7, 8, 8, 9, 9, 10, 11, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",22897461
113,"['if patients receiving chemotherapy for breast cancer', 'breast cancer', 'for chemotherapy-naïve patients with breast cancer', 'chemotherapy-naïve patients with breast cancer', 'to 8 .', 'Median age of the 94 women was 51 years ( range 27-76 ) :', '94 women', '51 years ( range 27-76 )', 'for breast cancer', 'breast cancer']","[2, 2, 3, 3, 5, 6, 6, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['chemotherapy', 'receive dexamethasone', 'dexamethasone', 'with dexamethasone or placebo', 'chemotherapy', 'dexamethasone', 'placebo', 'oral dexamethasone', 'versus placebo', 'dexamethasone', 'placebo', 'intravenous granisetron and dexamethasone', 'oral granisetron', 'granisetron', 'dexamethasone pre-chemotherapy', 'granisetron', 'received fluorouracil/epirubicin/cyclophosphamide', 'received doxorubicin/cyclophosphamide', 'fluorouracil/epirubicin/cyclophosphamide', 'doxorubicin/cyclophosphamide', 'preferred placebo', '35-58 % ) preferred dexamethasone ;', 'placebo', 'dexamethasone', 'patients received dexamethasone', 'dexamethasone', 'regardless of whether dexamethasone', 'dexamethasone', 'dexamethasone', 'placebo-controlled', 'dexamethasone', 'chemotherapy']","[0, 1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 4, 6, 6, 6, 6, 8, 8, 8, 8, 10, 10, 12, 12, 0, 0, 0, 0]","['hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['cancer prefer', 'compare quality of life ( QOL )', 'quality of life ( QOL )', '( i ) patient preference ;', 'cycles in change of', 'patient preference', 'stating a preference , 31 preferred', 'CI : 35-58 % )', 'dexamethasone ; 12 had no', 'differences in intensity of vomiting , nausea , or time to onset of', 'decrease in', 'dexamethasone .', 'No other', 'symptom/QOL', 'was found in patient preference , QOL', 'patient preference', 'QOL', 'quality of life', 'quality of life']","[2, 2, 2, 5, 5, 5, 8, 8, 8, 9, 10, 10, 11, 11, 12, 12, 12, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",22956006
114,"['patients with mild to moderate depression .', 'patients with mild to moderate depression .', '15 depressive patients who had been under antidepressant treatment for at least one month .', '15 depressive patients who had been under antidepressant treatment for at least one month', 'Depressive patients', 'Depressive patients', 'patients with depression .', 'patients with depression .']","[0, 0, 2, 2, 7, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['physical activity', 'physical activity', 'sun exposure', 'physical activity', 'sun exposure', 'control', 'did not receive these explicit recommendations .', 'physical activity', 'sun exposure', 'control', 'not receive these explicit recommendations', 'sun exposure', 'physical activity', 'lifestyle recommendations', 'lifestyle recommendations', 'lifestyle']","[0, 3, 3, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 7, 0, 0]","['hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","[""patient 's adherence"", 'adherence', 'physical activity and sun exposure', 'physical activity', 'sun exposure', 'physical activity level', 'time of sun exposure', 'physical activity level', 'time of sun exposure', 'time of sun exposure and physical activity', 'time of sun exposure', 'physical activity', 'Adherence', 'Adherence']","[1, 1, 3, 3, 3, 5, 5, 5, 5, 6, 6, 6, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",23021296
115,"['patients with refractory monosymptomatic nocturnal enuresis .', '28 patients with refractory monosymptomatic nocturnal enuresis', '28', 'patients with refractory monosymptomatic nocturnal enuresis .', 'refractory monosymptomatic nocturnal enuresis :']","[0, 1, 1, 13, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p']","['posterior tibial nerve stimulation', 'posterior tibial nerve stimulation', 'posterior tibial nerve stimulation', 'placebo', 'posterior tibial nerve stimulation', 'placebo', 'posterior tibial nerve stimulation', 'posterior tibial nerve stimulation', 'Posterior tibial nerve stimulation', 'Posterior tibial nerve stimulation', 'posterior tibial nerve stimulation', 'posterior tibial nerve stimulation']","[0, 0, 2, 2, 2, 2, 3, 7, 13, 13, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['early clinical and urodynamic results', 'clinical and urodynamic findings .', 'baseline clinical and urodynamic data .', 'detrusor overactivity', 'bladder capacity .', 'detrusor overactivity', 'bladder capacity .', 'response to posterior tibial nerve stimulation', 'response', 'response', 'response', 'number of wet nights', 'number of wet nights', 'urodynamic parameters', 'urodynamic parameters', 'number of wet nights and urodynamic parameters', 'wet nights', 'urodynamic parameters', 'response', 'response']","[0, 3, 5, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 9, 9, 10, 10, 10, 11, 11]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",23103798
116,"['patients undergoing minimally invasive TKA', 'patients undergoing minimally invasive TKA', '80 patients', '80 patients']","[3, 3, 4, 4]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['total knee arthroplasty ( TKA )', 'total knee arthroplasty ( TKA )', 'custom-fit magnetic resonance imaging ( MRI ) -based pin guides .', 'minimally invasive TKA', 'custom-fit magnetic resonance imaging ( MRI ) -based pin guides .', 'intramedullary alignment jigs', 'intramedullary alignment jigs', 'custom-fit MRI-based pin guides', 'custom-fit MRI-based pin guides', 'cemented posterior-stabilized implant', 'cemented posterior-stabilized implant', 'custom-fit', 'custom-fit', 'custom-fit', 'custom-fit', 'custom-fit pin guides', 'custom-fit pin guides', 'total knee arthroplasty :', 'total knee arthroplasty :']","[0, 0, 3, 3, 3, 6, 6, 7, 7, 8, 8, 12, 12, 15, 15, 18, 18, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['blood loss', 'early outcomes .', 'blood loss', 'early outcomes .', 'blood loss and early clinical outcomes', 'blood loss', 'early clinical outcomes', 'volume in the drain bottles', 'Hb loss', 'Hb level .', 'Hb loss', 'Transfusion requirements and surgical time', 'Transfusion requirements', 'surgical time', 'Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .', 'Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .', 'drainage of blood', 'drainage of blood', 'loss of Hb', 'loss of Hb', 'Surgical time', 'Surgical time', 'KSS', 'KSS', 'Knee flexion', 'knee swelling', 'pain', 'Knee flexion', 'knee swelling', 'pain', 'blood drainage', 'Hb loss', 'transfusion rate .', 'blood drainage', 'Hb loss', 'transfusion rate .', 'Surgical time', 'Surgical time', 'early clinical outcomes .', 'early clinical outcomes .', 'blood loss and early clinical outcomes .', 'blood loss', 'early clinical outcomes']","[2, 2, 2, 2, 3, 3, 3, 9, 9, 9, 9, 10, 10, 10, 11, 11, 12, 12, 13, 13, 15, 15, 16, 16, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 19, 19, 20, 20, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",23114870
117,"['sickle cell anemia ( SCA )', 'children with SCA', 'children', 'SCA', '113 children with SCA studied in two hospitals', '113 children', 'SCA', 'in children with SCA', 'children', 'SCA', 'sickle cell anemia .', 'sickle cell anemia .']","[0, 3, 3, 3, 4, 4, 4, 9, 9, 9, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['lime juice', 'lime juice', 'lime juice', 'lime juice', 'lime juice', 'lime juice', 'lime', 'without lime', 'without lime', 'with lime', 'of lime juice', 'lime juice', 'lime juice', 'lime juice']","[1, 1, 2, 2, 3, 3, 4, 4, 4, 8, 9, 9, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['crisis', 'recurrent bone pain .', 'recurrent bone pain .', 'clinical and some laboratory characteristics', 'rates of significant painful episodes', 'significant painful episodes', 'had significant painful episodes', '92.7 % ) ; febrile illness', 'and admission rate', 'The mean hematocrit', 'However , transfusion rate , presence of hepatomegaly , splenomegaly , and jaundice', 'any significant side-effect']","[2, 2, 2, 3, 4, 4, 5, 5, 5, 6, 7, 8]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",23356250
118,"['children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .', 'children', 'high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety', '45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety', '45 children ( 7-11 years of age )', 'high-functioning ASD and clinically significant anxiety', 'youth with ASD .', 'children with autism spectrum disorders :', 'children', 'autism spectrum disorders']","[0, 0, 0, 1, 1, 1, 8, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['cognitive-behavioral therapy ( CBT )', 'treatment as usual ( TAU )', 'cognitive-behavioral therapy ( CBT )', 'treatment as usual ( TAU )', 'CBT', 'TAU', 'CBT', 'TAU', 'CBT', 'TAU', 'CBT', 'TAU', 'CBT', 'TAU', 'CBT', 'TAU', 'CBT', 'CBT', 'CBT', 'CBT', 'CBT', 'CBT', 'cognitive-behavioral therapy', 'treatment as usual', 'cognitive-behavioral therapy', 'treatment as usual']","[0, 0, 0, 0, 1, 1, 1, 1, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 7, 7, 8, 8, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'efficacy', 'primary anxiety outcomes .', 'primary anxiety outcomes .', 'treatment responders', 'anxiety symptoms .', 'anxiety symptoms .']","[0, 0, 4, 4, 5, 7, 7]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",23357440
119,"['diabetic nephropathy', 'Type 2 diabetic patients ( N.=57 ) were divided', 'Type 2 diabetic patients', 'N.=57', 'Diabetic nephropathy patients', 'Diabetic nephropathy patients', 'type 2 diabetes mellitus patients "" with nephropathy ""', 'type 2 diabetes mellitus patients', 'patients with nephropathy', 'patients', 'early-stage diabetic nephropathy patients', 'early-stage diabetic nephropathy patients']","[0, 1, 1, 1, 2, 2, 8, 8, 9, 9, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['thiamine ( vitamin B1 )', 'pyridoxine ( vitamin B6 )', 'thiamine ( vitamin B1 )', 'pyridoxine ( vitamin B6 )', 'B6', 'B1+B6', 'B6', 'B1+B6', 'B1+B6', 'B6 .', 'B1+B6', 'B6 .', 'B6', 'B6', 'B1+B6', 'B6', 'B1+B6', 'B6', 'B1+B6', 'B6', 'B1+B6', 'B6', 'thiamine', 'pyridoxine']","[0, 0, 0, 0, 2, 2, 2, 2, 5, 5, 5, 5, 6, 6, 7, 7, 7, 7, 9, 9, 9, 9, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i']","['circulatory AGE-peptide levels', 'circulatory AGE-peptide levels', 'glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides', 'glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides', 'AGE-peptides', 'AGE-peptides', 'AGE-peptides', 'AGE-peptides', 'HbA1c', 'HbA1c', 'C-peptide', 'C-peptide', 'plasma AGE-peptides', 'plasma AGE-peptides', 'AGE-peptides', 'AGE-peptides', 'C-peptide .', 'C-peptide .', 'Plasma AGE-peptides and C-peptide', 'Plasma AGE-peptides and C-peptide']","[0, 0, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",23392542
120,"['young people with HFA .', 'Eligible patients were children and adolescents with HFA .', 'children and adolescents', 'HFA', 'children with high-functioning autism :', 'children', 'high-functioning autism']","[2, 3, 3, 3, 0, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['Social Skills Training Group-based Program ( SST-GP )', 'Leisure Activities Group-based Program ( LA-GP )', 'Social Skills Training Group-based Program ( SST-GP )', 'Leisure Activities Group-based Program ( LA-GP )', 'SST', 'LA', 'SST', 'LA', 'SST', 'LA', 'SST', 'LA', 'SST', 'SST', 'SST', 'SST', 'SST-GP', 'LA-GP .', 'SST-GP', 'LA-GP .', 'Social skills']","[2, 2, 2, 2, 4, 4, 4, 4, 6, 6, 6, 6, 7, 7, 8, 8, 9, 9, 9, 9, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i']","['social skills', 'efficacy .', 'perception of facial emotions and quality of life ( QoL )', 'improvement of 2 points in error rates for facial emotion labeling ( DANVA2 ) from baseline .', 'error rates for facial emotion labeling ( DANVA2 )', 'labeling anger', 'ability to recognize anger', 'ability to recognize anger', 'QoL', 'QoL', 'efficacy', 'efficacy', 'Social skills']","[1, 1, 2, 5, 5, 6, 7, 7, 8, 8, 9, 9, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",23417625
121,"['231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 .', '231 patients who were 25 years or older', 'treated at community and academic settings between April 2008 and March 2011', 'grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .', 'grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .', 'patients with painful chemotherapy-induced peripheral neuropathy', 'patients with painful chemotherapy-induced peripheral neuropathy', 'patients with chemotherapy-induced painful peripheral neuropathy :', 'patients with chemotherapy-induced painful peripheral neuropathy :']","[2, 2, 2, 5, 5, 12, 12, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['duloxetine', 'duloxetine', 'duloxetine', 'placebo', 'placebo', 'duloxetine .', 'duloxetine', 'placebo', 'placebo', 'duloxetine .', 'paclitaxel', 'taxane', 'oxaliplatin', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'duloxetine', 'placebo', 'duloxetine', 'placebo', 'duloxetine', 'duloxetine']","[1, 1, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 9, 9, 10, 10, 10, 10, 11, 11, 11, 12, 12, 12, 12, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['average pain severity .', 'average pain severity .', 'effective', 'chemotherapy-induced peripheral neuropathic pain .', 'chemotherapy-induced peripheral neuropathic pain .', 'Pain severity was assessed using the Brief Pain Inventory-Short Form "" average pain "" item with 0 representing no pain and 10 representing as bad as can be imagined .', 'Pain severity', 'Brief Pain Inventory-Short Form "" average pain "" item', 'pain', 'average pain', 'average pain', 'average pain score', 'average pain score', 'pain', 'pain', 'chemotherapy-induced peripheral neuropathy', 'reduction in pain .', 'pain .', 'pain , function , and quality of life', 'pain', 'function', 'quality of life']","[1, 1, 7, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 11, 11, 12, 12, 12, 0, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o']",23549581
122,"['children with autism', 'children with autism', '47 teachers and children', '47 teachers and children', 'children with autism .', 'children with autism .']","[0, 0, 1, 1, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['COMPASS intervention', 'COMPASS intervention', 'The collaborative model for promoting competence and success']","[1, 1, 2]","['ss_i', 'hl_i', 'ss_i']","['Treatment predictor variables', 'Predictors', 'child , teacher , intervention practice , and implementation practice variables based on an implementation science framework', 'intervention quality ( IEP quality for targeted and not targeted elements )', 'implementation quality variables']","[1, 4, 4, 5, 5]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",23838728
123,"['status epilepticus', '720 unique patients in emergency departments and uses a Bayesian adaptive design .', '720', 'patients in emergency departments and uses a Bayesian adaptive design', 'status epilepticus .', 'status epilepticus .']","[0, 1, 1, 1, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['Bayesian adaptive comparative effectiveness trial', 'Bayesian adaptive', 'Bayesian adaptive design .', 'Bayesian adaptive design .', 'trial without adaptive randomization', 'Bayesian adaptive trials', 'Bayesian adaptive']","[0, 0, 1, 1, 2, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['effectiveness', 'proportion of patients', 'total patients', 'patient care', 'power', 'expected sample size .', 'patient care', 'power', 'expected sample size .', 'effectiveness']","[0, 2, 2, 3, 3, 3, 3, 3, 3, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o']",23849147
124,"['postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .', 'postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .', 'Four hundred patients with stage II and III rectal cancer received postoperative CRT', 'Four hundred patients with stage II and III rectal cancer received postoperative CRT', 'postoperative stage II and III rectal cancer patients', 'postoperative stage II and III rectal cancer patients', 'postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ]', 'postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ]']","[0, 0, 1, 1, 13, 13, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['capecitabine-based', 'chemoradiotherapy ( CRT )', 'capecitabine-based', 'chemoradiotherapy ( CRT )', 'capecitabine', 'oxaliplatin', 'capecitabine', 'oxaliplatin', 'capecitabine and radiotherapy ( Cap-CRT )', 'capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .', 'capecitabine', 'radiotherapy', 'Cap-CRT', 'capecitabine', 'oxaliplatin', 'radiotherapy', 'Cap-Oxa-CRT', 'Cap-Oxa-CRT', 'Cap-CRT', 'Cap-Oxa-CRT', 'Cap-CRT', 'chemoradiotherapy', 'capecitabine', 'oxaliplatin .', 'chemoradiotherapy', 'capecitabine', 'oxaliplatin .', 'chemoradiotherapy ]', 'chemoradiotherapy']","[0, 0, 0, 0, 1, 1, 1, 1, 3, 3, 3, 3, 3, 3, 3, 3, 3, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['association', 'single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs )', 'acute adverse events ( AEs )', 'Adverse events were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) .', 'Adverse events', 'Common Terminology Criteria for Adverse Events , v.', 'genotype of CCND1 A870G', 'polymerase chain reaction-based restriction fragment length polymorphism ( PCR-RFLP ) analysis .', 'associations between the SNP and acute AEs', 'odds ratios ( ORs )', 'confidence intervals ( CIs )', 'logistic regression model .', 'acute AEs', 'AEs .', 'AEs .', 'genotypes', 'AEs .', 'AEs .', 'Diarrhea', 'AE', 'severe diarrhea', 'Diarrhea', 'AE', 'severe diarrhea', 'genotypes', 'severe diarrhea .', 'severe diarrhea .', 'severe diarrhea', 'severe diarrhea', 'severe diarrhea', 'severe diarrhea .', 'severe diarrhea', 'severe diarrhea .', 'genetic polymorphism of CCND1 A870G', 'acute AEs', 'acute AEs', 'acute adverse events', 'acute adverse events']","[0, 0, 0, 4, 4, 4, 5, 5, 6, 6, 6, 6, 6, 7, 7, 8, 8, 8, 9, 9, 9, 9, 9, 9, 10, 10, 10, 11, 11, 12, 12, 12, 12, 13, 13, 13, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",23985254
125,"['children diagnosed with an autism spectrum disorder', 'children diagnosed with an autism spectrum disorder', 'children with autism', 'children with autism spectrum disorders :', 'children', 'autism spectrum disorders']","[0, 0, 8, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['gluten- and casein-free diet', 'gluten- and casein-free diet', 'dietary intervention .', 'dietary intervention .', 'dietary intervention .', 'dietary intervention .', 'dietary intervention', 'dietary intervention', 'dietary intervention .', 'dietary intervention .', 'gluten- and casein-free diet', 'gluten- and casein-free diet', 'gluten- and casein-free dietary intervention', 'gluten- and casein-free dietary intervention']","[0, 0, 3, 3, 4, 4, 5, 5, 6, 6, 8, 8, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['responses to dietary modification', 'behavioural and psychometric data', 'response to dietary intervention .', 'inattention and hyperactivity behaviours', 'responders to the dietary intervention .', 'inattention and hyperactivity behaviours', 'response to dietary intervention', 'symptom presentation .', 'response', 'Chronological age', 'dietary intervention .', 'urine compound , trans-indolyl-3-acryloylglycine', 'behavioural and psychometric measures of dietary response .', 'behavioural and psychometric measures']","[2, 3, 3, 4, 4, 4, 5, 5, 5, 6, 6, 7, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",24075141
126,"['patients with isolated hypertriglyceridemia .', 'patients with isolated hypertriglyceridemia .', '39 patients with elevated triglyceride levels and peripheral artery sclerosis', '39 patients with elevated triglyceride levels and peripheral artery sclerosis', 'fibrinolysis in patients with isolated hypertriglyceridemia', 'benefits to patients with elevated triglyceride levels', 'patients with isolated hypertriglyceridemia .', 'patients with isolated hypertriglyceridemia .']","[1, 1, 2, 2, 5, 5, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p']","['simvastatin', 'simvastatin', 'simvastatin', 'placebo .', 'simvastatin', 'placebo .', 'Simvastatin', 'placebo', 'Simvastatin', 'placebo', 'suggest that statin', 'simvastatin', 'simvastatin']","[1, 1, 2, 2, 2, 2, 4, 4, 4, 4, 5, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['coagulation and fibrinolysis', 'coagulation and fibrinolysis', 'Plasma lipids , glucose homeostasis markers and hemostasic variables', 'Plasma lipids , glucose homeostasis markers', 'hemostasic variables', 'plasma levels/activity of fibrinogen', '0.01 ) , factor VII', 'and plasminogen activator inhibitor-1', 'reduction in von Willebrand factor levels', 'prolong the prothrombin and partial thromboplastin', 'plasma levels/activity of fibrinogen', 'effect on coagulation and fibrinolysis', 'hemostasis']","[1, 1, 3, 3, 3, 4, 4, 4, 4, 4, 4, 5, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",24080592
127,"['root canal', 'Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots', 'Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots']","[0, 1, 1]","['ss_p', 'ss_p', 'hl_p']","['sonic , ultrasonic , and hydrodynamic devices', 'sonic , ultrasonic , and hydrodynamic devices', 'syringe irrigation', 'CanalBrush', 'passive ultrasonic irrigation', 'EndoActivator', 'RinsEndo', 'syringe irrigation', 'CanalBrush', 'passive ultrasonic irrigation', 'EndoActivator', 'RinsEndo', 'RESULTS Passive ultrasonic irrigation', 'other tested irrigation systems or syringe irrigation', 'Passive ultrasonic irrigation', 'irrigation systems', 'syringe irrigation', 'study protocol ultrasonic', 'ultrasonic', 'treatment failure .', 'Passive Ultrasonic', 'Passive Ultrasonic']","[0, 0, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 5, 5, 5, 5, 5, 7, 7, 9, 10, 10]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['efficiency', 'efficiency', 'randomization .', 'The amount of remaining sealer in the root canal irregularities was evaluated under a microscope using a 4-grade scoring', 'whereas the remaining sealer on the root canal surface was evaluated with a 7-grade scoring', 'amount of remaining sealer in the root canal irregularities', 'irrigation in removing sealer from root canal', 'significant effect on cleaning the lateral', 'superior effect on sealer removal from the root canal', 'RELEVANCE Incomplete removal of root canal', 'effective system to remove sealer from a']","[0, 0, 3, 4, 4, 4, 5, 6, 7, 9, 10]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",24317958
128,"['children and adolescents with autistic disorders .', 'children and adolescents', 'autistic disorders', 'patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase )', '5-17 years of age', 'RESULTS Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ;', 'children and adolescents with autistic disorder .', 'children and adolescents', 'autistic disorder']","[0, 0, 0, 1, 1, 4, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p']","['risperidone', 'risperidone', 'risperidone', 'risperidone', ""assessed risperidone 's"", 'risperidone', 'The risperidone', 'risperidone', 'with risperidone', 'for risperidone', 'risperidone', 'risperidone']","[0, 0, 1, 1, 3, 3, 9, 9, 11, 11, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['long-term safety and efficacy', ""risperidone 's safety ; efficacy"", 'safety', 'efficacy', 'or adverse events ( AE )', 'adverse events', 'group )', 'were increased appetite', '[ n=9 ] ) ; increased weight and vomiting', 'each ) ; sedation , pyrexia , and upper respiratory tract infection', 'each ) ; nasopharyngitis', 'and somnolence and fatigue', 'each ) .', 'increased appetite', 'increased weight', 'vomiting', 'sedation', 'pyrexia', 'upper respiratory tract infection', 'nasopharyngitis', 'somnolence', 'fatigue', 'Extrapyramidal', 'patients .', 'Extrapyramidal', 'Increase in mean weight', 'and body mass index', 'because of weight increase', 'weight', 'potentially prolactin-related AE ( irregular menstruation )', 'prolactin-related AE', 'irregular menstruation', 'greatest mean improvement in sleep visual analog scale', 'sleep visual analog scale', 'improvement in efficacy scale scores', 'efficacy', 'OLE , safety', 'current safety', 'improvement in irritability and related behaviors', 'safety', 'efficacy']","[0, 3, 3, 3, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 9, 9, 10, 10, 11, 11, 12, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",24350813
129,"['Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD )', 'Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD )', 'Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls ( 21 )', '15', '18', '21', 'ADHD and Autism .', 'ADHD and Autism .']","[0, 0, 3, 3, 3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['Fluoxetine', 'placebo', 'Fluoxetine', 'placebo', 'placebo', 'placebo', 'Fluoxetine', 'placebo', 'Fluoxetine', 'placebo', 'Fluoxetine', 'Fluoxetine', 'Fluoxetine', 'Fluoxetine']","[4, 4, 4, 4, 7, 7, 9, 9, 9, 9, 10, 10, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['shared and disorder-specific brain dysfunctions', 'functional magnetic resonance imaging ( fMRI )', 'fMRI', 'medial prefrontal cortex ( mPFC )', 'medial prefrontal cortex ( mPFC )', 'precuneus activation .', 'precuneus activation .', 'mPFC activation', 'task performance', 'mPFC activation', 'task performance', 'effects', 'mPFC activation', 'mPFC activation', 'Medial Prefrontal Cortex Activation']","[2, 3, 7, 7, 7, 8, 8, 9, 9, 9, 9, 10, 10, 10, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",24451919
130,"['autism spectrum disorder ( ASD )', 'autism spectrum disorder ( ASD )', 'children aged 3 to 17 years , with and without parent-reported ASD .', 'children aged 3 to 17 years', 'parent-reported ASD', 'Children with parent-reported ASD', 'Children with parent-reported ASD', 'childhood autism spectrum disorders .', 'childhood autism spectrum disorders']","[0, 0, 1, 1, 1, 3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['autism spectrum disorder ( ASD ) diagnoses', 'with and without parent-reported ASD .', 'ASD diagnosis', 'Children with parent-reported ASD', 'children without ASD', 'children in the ASD', 'control', 'parents who reported that their child had ASD', 'control', 'childhood autism spectrum disorders .']","[0, 1, 2, 3, 3, 4, 4, 6, 6, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i']","['service use , caregiver time , and cost outcomes .', 'service use', 'caregiver time', 'cost outcomes', 'annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time', 'annual utilization and costs', 'health care', 'school', 'ASD-related therapy', 'family-coordinated services', 'caregiver time', 'Regression analyses', 'association between ASD diagnosis and cost , controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .', 'cost', 'health care office visits and prescription drug use', 'health care office visits', 'prescription drug use', 'special educational services', 'special educational services', 'health care costs', 'non-health care costs', 'higher school costs .', 'health care costs', 'non-health care costs', 'higher school costs .', 'out-of-pocket costs', 'time on caregiving activities', 'out-of-pocket costs', 'time on caregiving activities', 'economic burden', 'economic burden', 'Economic burden']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 3, 3, 3, 4, 4, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 8, 0]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o']",24515505
131,"['COPD patients', 'COPD patients', 'days , 60 COPD patients', '60 COPD', 'stable COPD patients .', 'stable COPD patients .']","[0, 0, 3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['tone , bronchodilators', 'to bronchodilators', 'after placebo', '300μg indacaterol', 'placebo', 'indacaterol', 'functional effect of', 'closely related to', 'bronchodilator']","[1, 2, 3, 3, 3, 3, 7, 7, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i']","['forced expiratory volume at 1s ( ΔFEV1 ) and forced vital capacity ( ΔFVC )', 'decrease dynamic hyperinflation , gas trapping', 'possibly dyspnea at rest', 'that specific airway resistance changes ( ΔsRAW )', 'specific airway resistance changes ( ΔsRAW )', 'underwent dyspnea evaluation ( VAS score ) and pulmonary function testing', 'dyspnea evaluation ( VAS score )', 'pulmonary function', 'RESULTS Spirographic and ΔsRAW-based criteria', 'Spirographic', 'ΔsRAW-based', 'changes of intrathoracic gas volume ( ΔITGV )', 'p < 0.001 ) , residual volume', 'p < 0.001 )', 'p=0.001 )', 'p < 0.001 ) , while', 'correlated only', 'ΔsRAW', 'intrathoracic gas volume ( ΔITGV )', 'residual volume', 'in terms', 'ΔITGV ( p=0.002 )', '( p=0.023 )', 'stratified according', 'bronchodilator-induced improvements of lung mechanics and', 'ΔsRAW-based', 'FEV1-FVC-based', 'effects']","[0, 1, 1, 2, 2, 3, 3, 3, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",24726342
132,"['Individuals with autism spectrum disorder ( ASD )', 'Individuals with autism spectrum disorder ( ASD )', '13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls', '13 participants with ASD', 'age 7 ; 03-22 ; 03', '13 age-matched typically developing ( TD ) controls', 'Individuals with ASD', 'Individuals with ASD', 'Youth with autism spectrum disorder', 'Youth', 'autism spectrum disorder']","[0, 0, 3, 3, 3, 3, 4, 4, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['metaphors .', 'metaphors .', 'conceptual metaphors', 'conceptual metaphors', 'conceptual metaphors', 'lexicalized conceptual metaphors', 'metaphor', 'metaphor', 'lexicalized', 'primary conceptual metaphors .', 'lexicalized', 'primary conceptual metaphors .']","[0, 0, 1, 1, 3, 3, 4, 4, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['comprehending metaphors .', 'comprehending metaphors', 'conceptual metaphors', 'conceptual metaphors', 'lexicalized conceptual metaphors', 'novel ones', 'lexicalized conceptual metaphors', 'novel ones', 'metaphor', 'metaphor']","[0, 0, 1, 1, 3, 3, 3, 3, 4, 4]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",24803369
133,"['370 RH:1 Tunisian donors', '370 RH:1 Tunisian donors', '370 donors', '370 donors', 'Tunisians .', 'Tunisians :', 'Tunisians :']","[1, 1, 3, 3, 7, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['molecular test', 'molecular test', 'polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP )', 'polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP )', 'hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR )', 'polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP )', 'real time quantitative polymerase chain reaction ( RQ-PCR )', 'molecular tests', 'PCR', 'RQ-PCR .', 'PCR-SSP , PCR-RFLP and RQ-PCR', 'RQ-PCR', 'RQ-PCR', 'PCR-RFLP', 'PCR-RFLP', 'molecular tests .']","[0, 0, 1, 1, 1, 1, 1, 2, 2, 4, 5, 7, 7, 8, 8, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i']","['paternal RHD zygosity', 'RHD zygosity', 'polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP )', 'polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .', 'Positive predictive values', 'Positive predictive values', 'Negative predictive values', 'Negative predictive values', 'Rhesus box polymorphisms', 'RHD alleles :', 'Rhesus box polymorphisms', 'RHD alleles :', 'paternal RHD zygosity', 'PCR-RFLP', 'Paternal RHD zygosity']","[0, 1, 1, 1, 4, 4, 5, 5, 6, 6, 6, 6, 7, 8, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o']",24960665
134,"['children with autism spectrum disorders ( ASDs )', 'children with autism spectrum disorders ( ASDs )', 'children with ASD', 'children with ASD', '120 participants with ASD at the end of primary school ( 10-12 years of calendar age )', '120 participants with ASD at the end of primary school', '10-12 years of calendar age', 'Dutch children with ASD in a specific age range ( 10-12 years ) .', 'Dutch children with ASD in a specific age range ( 10-12 years ) .', 'preadolescent children with autism spectrum disorders :', 'preadolescent children', 'autism spectrum disorders']","[0, 0, 1, 1, 5, 5, 5, 12, 12, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['Social skills training ( SST )', 'Social skills training ( SST )', 'SSTs', 'SSTs', 'SST', 'SST', 'SST', 'SST', 'SST , SST-PTI ( SST with Parent & Teacher Involvement )', 'care-as-usual .', 'SST , SST-PTI ( SST with Parent & Teacher Involvement )', 'care-as-usual .', 'SST', 'SST', 'SST-PTI', 'SST-PTI', 'SST', 'SST', 'SST', 'SST', 'social skills training', 'social skills training']","[0, 0, 1, 1, 3, 3, 4, 4, 5, 5, 5, 5, 6, 6, 7, 7, 10, 10, 12, 12, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['social and communication skills .', 'effectiveness', 'long term outcome', 'generalization of learned skills', 'effectiveness', 'generalization of learned social skills to daily life .', 'treatment efficacy', 'generalization of learned skills to daily life .', 'socialization', 'adaptive functioning .', 'socialization', 'specific social skills', 'general social skills', 'specific social skills', 'general social skills', 'possible predictors of treatment outcome', 'generalization', 'efficacy']","[0, 1, 2, 2, 3, 3, 4, 4, 9, 9, 9, 10, 10, 10, 10, 11, 13, 13]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o']",24989854
135,"['in 4-5-year-old children', '4-5-year-old children', 'Cuban pneumococcal conjugate vaccine candidate in healthy children :', 'healthy children']","[3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['heptavalent conjugate vaccine ( PCV7-TT )', 'heptavalent conjugate vaccine ( PCV7-TT )', 'PCV7-TT', 'PCV7-TT', 'of PCV7-TT', 'children .', 'PCV7-TT', 'PCV7-TT', 'as Synflorix', 'PCV7-TT', 'Synflorix', 'in PCV7-TT', 'PCV7-TT', 'of PCV7-TT', 'PCV7-TT', 'Cuban pneumococcal conjugate vaccine', 'Cuban pneumococcal conjugate vaccine']","[0, 0, 1, 1, 3, 3, 3, 4, 4, 4, 4, 5, 5, 6, 6, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['the safety', 'the immunogenicity', 'safety', 'immunogenicity', 'well tolerated', 'as safe', 'of IgG GMC and OPA GMT', 'IgG GMC', 'OPA GMT', 'Safety', 'preliminary immunogenicity', 'Safety', 'preliminary immunogenicity']","[3, 3, 3, 3, 4, 4, 5, 5, 5, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",25068497
136,"['children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .', 'children and adolescents', 'ASD and attention-deficit/hyperactivity disorder ( ADHD )', '97 patients 6-17 years of age , with ASD and ADHD', '97', '6-17 years of age', 'ASD and ADHD', 'autism spectrum disorder :', 'autism spectrum disorder :']","[0, 0, 0, 1, 1, 1, 1, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['atomoxetine', 'atomoxetine', 'of atomoxetine', 'double-blind placebo-controlled', 'atomoxetine', 'placebo-controlled', 'treatment , atomoxetine', 'atomoxetine', 'of atomoxetine', 'However , atomoxetine', 'atomoxetine', 'Atomoxetine', 'Atomoxetine']","[0, 0, 1, 1, 1, 1, 3, 3, 4, 5, 5, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['effects', ""measures , the Aberrant Behavior Checklist ( ABC ) and the Children 's Social Behavior Questionnaire ( CSBQ )"", 'the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior', 'the CSBQ subscale Fear for Changes', 'ABC subscales Hyperactivity', 'Inappropriate Speech', 'Stereotypic Behavior', 'CSBQ subscale Fear for Changes', 'ameliorate restricted and stereotyped behaviors and communication', 'stereotyped behaviors', 'communication', 'social functioning ;', 'stereotyped behaviors , inappropriate speech , and fear of change .', 'social functioning ;', 'stereotyped behaviors', 'inappropriate speech', 'fear of change']","[0, 2, 3, 3, 3, 3, 3, 3, 5, 5, 5, 0, 0, 0, 0, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o']",25369243
137,"['303 patients taking blood pressure and/or lipid-lowering medications', '303 patients taking blood pressure and/or lipid-lowering medications', 'taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease', 'cardiovascular preventive treatment']","[2, 2, 10, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p']","['text messaging', 'text messaging', 'text messages ( Text', 'not being sent them ( No text', 'text messages ( Text', 'not being sent them', 'text', 'Text', 'Text', 'texts', 'text messaging', 'no text messaging .', 'text messaging', 'no text messaging .', 'text messaging']","[1, 1, 2, 2, 2, 2, 4, 8, 8, 9, 10, 10, 10, 10, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i']","['adherence to cardiovascular disease preventive treatment .', 'adherence', 'use of medication', 'prescribed regimen', 'adherence', 'adherence', 'stopped taking medication', 'medication adherence', 'medication adherence', 'adherence to cardiovascular preventive treatment', 'adherence']","[1, 1, 5, 7, 8, 8, 9, 10, 10, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",25479285
138,"['patients with corrected tetralogy of Fallot .', 'patients with corrected tetralogy of Fallot .', 'patients with tetralogy of Fallot aged 10 to 25 years .', 'patients with tetralogy of Fallot aged 10 to 25 years', 'training in children and young adults with repaired tetralogy of Fallot', 'children and young adults after repair of tetralogy of Fallot :', 'children and young adults after repair of tetralogy of Fallot']","[3, 3, 4, 4, 10, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['training', 'training', 'exercise training program', 'exercise training program', 'exercise training program', 'exercise training program', 'exercise', 'control', 'exercise', 'control', 'exercise', 'exercise', 'exercise', 'control', 'exercise', 'cm/s ; control', ""A ' exercise"", 'm/s ; control', 'exercise', 'control', 'dynamic exercise training', 'exercise training', 'exercise training', 'exercise training']","[2, 2, 3, 3, 5, 5, 7, 7, 7, 7, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['regional ventricular performance', 'adverse changes of regional ventricular performance', 'cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging', 'cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging', 'Change in tissue-Doppler imaging parameters', 'Change in tissue-Doppler imaging parameters', 'that regional ventricular performance']","[2, 3, 6, 6, 9, 9, 10]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",25784723
139,"['patients with rheumatoid arthritis ( RA )', ""RA patients '"", 'patients with rheumatoid arthritis ( RA )', 'Sixty-eight RA patients ( age=55±13 years , body mass index : 27.8±5.4 kg/m2 , median of disease duration=5 ( 2-8 ) yrs )', 'Sixty-eight RA', 'age=55±13 years', 'in people with RA', 'rheumatoid arthritis patients .', 'rheumatoid arthritis patients .']","[0, 0, 0, 4, 4, 4, 13, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['physical activity ( PA )', 'PA', 'PA', 'PA', 'PA', 'when PA', 'all PA', 'moderate PA', 'intensity PA', 'all PA', 'self-reported PA', 'physical activity']","[0, 0, 2, 3, 3, 5, 7, 8, 10, 11, 13, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i']","['agreement', 'subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels', 'associations', 'subjective and objective PA', 'scores on the maximal oxygen uptake test ( VO2max ) .', 'International Physical Activity Questionnaire ; IPAQ )', 'GT3X ) physical activity ( PA )', 'maximal oxygen uptake test ( VO2max )', 'IPAQ and VO2max test .', 'IPAQ', 'VO2max', 'Bland-Altman plot', 'agreement', 'Wilcoxon test', ""association between the PA measurement and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value ."", 'PA measurement', 'VO2max', 'the subjective and objective measures', 'level .', 'PA', 'Wilcoxon tests', 'in sedentary behaviours', 'and light PA', 'more moderate PA', 'sedentary behaviours', 'light PA', 'between VO2max', 'from accelerometry', 'to sedentary time ( ST )', 'P=.04 ) .', 'VO2max', 'PA levels', 'sedentary time', 'IPAQ-reported moderate PA and MVPA', 'with maxV02', 'IPAQ-reported', 'PA', 'MVPA', 'the IPAQ-VO2 max and GT3X-VO2 max', 'IPAQ-VO2 max', 'GT3X-VO2 max', 'the IPAQ', 'less sedentary', 'intensity PA', 'assessed .', 'Accelerometry', 'with VO2max', 'and MPVA', 'with VO2max', 'self-reported PA and ST', 'with accelerometry', 'physical activity']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 2, 2, 2, 3, 3, 3, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 9, 9, 9, 10, 10, 10, 10, 11, 11, 12, 12, 13, 13, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",25885649
140,"['trial invited 25,511 people aged 50-74 years', '25,511', 'aged 50-74']","[5, 5, 5]","['ss_p', 'hl_p', 'hl_p']","['tailored computerised decision support', 'non-tailored computer or paper information .', 'tailored computerised decision support', 'assigned to Tailored Personalised Decision Support ( TPDS ) , Non-Tailored PDS ( NTPDS ) , or Control', 'sample ) .', 'Tailored Personalised Decision Support ( TPDS )', 'Non-Tailored PDS ( NTPDS )', 'Control', 'TPDS and NTPDS', '.', 'TPDS', 'NTPDS', 'The', 'intervention', 'tailored intervention', 'CG , 74 % )', 'FOBT completion', 'baseline ( 1083/2227 )', 'those assigned to the', 'personalised decision support', 'personalised decision support']","[2, 2, 2, 6, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 12, 13, 16, 16, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['faecal occult blood testing ( FOBT )', 'FOBT return', 'FOBT return', 'on movement in decision to screen', 'on psychological variables', '.', 'RESULTS FOBT', 'In the PP sample', '80 % ; NTPDS', 'more likely to', 'FOBT than those', 'another ( OR = 1.16 , p = .42 )', 'predictors : Analysis of change indicated that salience and', 'faecal occult blood test :']","[0, 3, 3, 4, 4, 10, 11, 12, 12, 16, 16, 17, 18, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",25886492
141,"['study included 281 adults in 301 procedures .', '281 adults', 'retrograde cholangiopancreatography :', 'retrograde cholangiopancreatography :']","[2, 2, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['patient-controlled sedation', 'propofol', 'anesthetist-controlled sedation', 'standard of care , midazolam', 'patient-controlled sedation', 'propofol', 'anesthetist-controlled sedation', 'standard of care , midazolam', 'propofol', 'propofol', 'propofol', 'propofol', 'midazolam', 'midazolam', 'midazolam', 'midazolam', 'midazolam', 'midazolam', 'midazolam', 'midazolam', 'with propofol', 'to midazolam', 'propofol', 'midazolam', 'propofol', 'propofol']","[1, 1, 1, 1, 1, 1, 1, 1, 3, 3, 4, 4, 5, 5, 6, 6, 6, 6, 7, 7, 11, 11, 11, 11, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","[""safety , ease of treatment , recovery , and patients ' experiences"", 'safety', 'ease of treatment', 'recovery', ""patients ' experiences"", ""Observer 's Assessment of Alertness/Sedation ( OAA/S ) scale ."", 'ease of the procedure', 'number of sedation failures', 'ease of the procedure', 'number of sedation failures', 'Time to full recovery ( Aldrete score', 'Time to full recovery ( Aldrete score', 'least fatigue and pain', 'procedure .', ""Patients ' preference"", 'a rapid recovery , fewer respiratory events', 'as effective']","[1, 1, 1, 1, 1, 4, 6, 6, 6, 6, 8, 8, 9, 9, 10, 12, 12]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",25898782
142,"['children with autism spectrum disorder ( ASD ) .', 'children', 'autism spectrum disorder ( ASD )', 'Participants were 44 children ages 6-12 ( n = 22 typical , n = 22 ASD ) .', '44 children ages 6-12', 'n = 22 typical , n = 22 ASD', 'Children with Autism Spectrum Disorders :', 'Children', 'Autism Spectrum Disorders']","[0, 0, 0, 1, 1, 1, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['sensory adapted dental environment ( SADE )', 'sensory adapted dental environment ( SADE )', 'regular dental environment ( RDE )', 'SADE', 'regular dental environment ( RDE )', 'SADE', 'SADE', 'RDE', 'SADE .', 'SADE', 'RDE', 'SADE .', 'Sensory Adapted Dental Environments', 'Sensory Adapted Dental Environments']","[0, 0, 2, 2, 2, 2, 4, 4, 4, 4, 4, 4, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['distress , sensory discomfort , and perception of pain', 'distress', 'sensory discomfort', 'perception of pain', 'physiological anxiety , behavioral distress , pain intensity , and sensory discomfort .', 'physiological anxiety', 'behavioral distress', 'pain intensity', 'sensory discomfort', 'physiological anxiety', 'pain and sensory discomfort', 'physiological anxiety', 'pain', 'sensory discomfort']","[0, 0, 0, 0, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o']",25931290
143,"['patients undergoing laparotomy .', 'Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy', 'Eighty', '18 to 65 years of age', 'undergoing elective laparotomy', 'nausea in patients undergoing laparotomy', 'relief in patients undergoing laparatomy', 'patients undergoing laparatomy .', 'patients undergoing laparatomy .']","[0, 1, 1, 1, 1, 8, 9, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'ss_p', 'hl_p']","['pregabalin', 'lidocaine', 'pregabalin', 'lidocaine', 'placebo', 'normal saline infusion', 'placebo', 'lidocaine', 'mg oral pregabalin and normal saline infusion', '150 & nbsp ; mg oral pregabalin and lidocaine', 'placebo', 'normal saline infusion', 'placebo', 'lidocaine', 'pregabalin', 'normal saline infusion', 'pregabalin', 'lidocaine', 'Preoperative oral pregabalin', 'intravenous', 'pregabalin', 'lidocaine', 'Preoperative oral pregabalin', 'intravenous', 'pregabalin', 'lidocaine', 'preoperative pregabalin', 'or without', 'pregabalin', 'pregabalin', 'lidocaine', 'pregabalin', 'lidocaine']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","[""postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge"", 'postoperative morphine requirement', 'adverse effects', ""patients ' satisfaction"", 'mobilization', 'time to first defecation', 'time to discharge', 'skin closure .', ""Hemodynamic parameters , visual analogue scale ( VAS ) scores , analgesic consumption , side effects , time to mobilization , time to first defecation , time to discharge and patients ' satisfaction"", 'recorded .', 'RESULTS VAS', '( P < 0.05 ) .', 'Morphine consumption', '( P < 0.05 ) .', 'Morphine consumption', 'Incidence', 'group PL .', 'Time to first defecation and mobilization', 'Time to first defecation', 'mobilization', 'decreased postoperative VAS', 'decreased morphine requirement', 'decreased the incidence', 'morphine requirement', 'provides superior pain', 'postoperative morphine requirement', 'postoperative morphine requirement']","[0, 0, 0, 0, 0, 0, 0, 1, 2, 2, 3, 3, 4, 4, 4, 5, 5, 6, 6, 6, 7, 8, 8, 8, 9, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",25950425
144,"['autism spectrum disorders ( ASD ) in toddlers', 'autism spectrum disorders ( ASD )', 'toddlers', 'toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .', 'toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .', 'toddlers with no developmental concerns .', 'toddlers with no developmental concerns .', 'A total of 61 toddlers were enrolled .', 'A total of 61 toddlers', 'ASD in toddlers', 'ASD in toddlers', 'Autism Spectrum Disorders in Toddlers .', 'Autism Spectrum Disorders', 'Toddlers']","[0, 0, 0, 3, 3, 4, 4, 6, 6, 10, 10, 0, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['Rapid Interactive Screening Test', 'Rapid Interactive Screening Test', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'RITA-T', 'Interactive Screening Test', 'Interactive Screening Test']","[1, 1, 2, 2, 3, 3, 5, 5, 9, 9, 10, 10, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['Rapid Interactive Screening Test for Autism in Toddlers ( RITA-T )', 'RITA-T', 'RITA-T', ""test 's performance"", 'cutoff score', 'sensitivity , specificity , and positive predictive value of the RITA-T', 'cutoff score', 'sensitivity , specificity , and positive predictive value', 'RITA-T', 'RITA-T scores', 'RITA-T scores', 'scores', 'scores', 'RITA-T', 'sensitivity', 'specificity', 'positive predictive value', 'RITA-T']","[1, 2, 3, 4, 5, 5, 5, 5, 5, 7, 7, 8, 8, 9, 9, 9, 9, 10]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",26210844
145,"['poor-insight OCD .', 'patients with OCD with poor insight .', 'patients with OCD with poor insight .', '90 patients with OCD with poor insight', '90 patients with OCD with poor insight', 'Patients with OCD with poor insight', 'Patients with OCD with poor insight', 'patients with more extreme poor insight .', 'Obsessive-Compulsive Disorder with Poor Insight :', 'Obsessive-Compulsive Disorder with Poor Insight :']","[0, 2, 2, 3, 3, 9, 9, 11, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['inference-based approach ( IBA )', 'inference-based approach ( IBA )', 'cognitive behavior therapy ( CBT )', 'cognitive behavior therapy ( CBT )', 'CBT', 'IBA', 'CBT', 'IBA', 'IBA', 'CBT', 'IBA', 'CBT', 'CBT', 'IBA', 'CBT', 'IBA', 'IBA', 'CBT', 'IBA', 'CBT', 'Inference-Based Approach', 'Cognitive Behavioral Therapy', 'Inference-Based Approach', 'Cognitive Behavioral Therapy']","[1, 1, 2, 2, 3, 3, 3, 3, 8, 8, 8, 8, 10, 10, 10, 10, 11, 11, 11, 11, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['effectiveness', 'effectiveness', 'effectiveness', 'Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .', 'Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .', 'level of insight , anxiety and depressive symptoms , and quality of life .', 'level of insight , anxiety and depressive symptoms , and quality of life .', 'Mixed-effects models', 'OCD symptom reduction', 'condition effects', 'OCD symptom reduction', 'OCD symptom reduction', 'OCD symptom reduction', 'effective']","[0, 2, 2, 4, 4, 5, 5, 6, 7, 7, 7, 8, 8, 10]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",26278470
146,"['16 patients with ischaemic heart disease .', '16 patients with ischaemic heart disease']","[0, 0]","['ss_p', 'hl_p']","['Amidotrizoate', 'Iopromide', 'Amidotrizoate', 'Iopromide', 'dipyridamole', 'ionic', 'nonionic x-ray contrast', 'ionic', 'nonionic x-ray contrast']","[0, 0, 0, 0, 1, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['global myocardial perfusion and function ( pressures in the left ventricle , heart rate )', 'excitation formation and transmission', 'global myocardial perfusion and function', 'myocardial perfusion', 'myocardial perfusion', 'myocardial perfusion and myocardial function ]', 'myocardial']","[0, 0, 0, 1, 1, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",2678230
147,"['ear microsurgical operations .', 'ear microsurgical operations .', 'Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients', 'Simple mastoidectomies , radical mastoidectomies and tympano plastics', '49', 'ear surgery', 'ear surgery']","[0, 0, 1, 1, 1, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['halothane', 'lidocaine', 'ornipressin', 'fentanyl', 'lidocaine', 'ornipressin', 'fentanyl', 'lidocaine', 'epinephrine', 'prilocaine', 'epinephrine', 'halothane', 'lidocaine', 'ornipressin', 'fentanyl', 'lidocaine', 'ornipressin', 'fentanyl', 'lidocaine', 'epinephrine', 'prilocaine', 'epinephrine']","[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i']","['endocrine stress responses', 'plasma levels of epinephrine , norepinephrine , glucose , lactate and free glycerol', 'mean arterial pressure ( MAP ) and heart rate ( HR )', 'plasma levels of epinephrine , norepinephrine , glucose , lactate', 'Plasma catecholamine concentrations', 'Plasma catecholamine concentrations', 'Plasma catecholamines ( epinephrine and norepinephrine )', 'Plasma catecholamines ( epinephrine and norepinephrine )', 'MAP', 'HR .', 'MAP', 'HR .', 'plasma levels of epinephrine and norepinephrine', 'glucose , lactate and free glycerol .', 'plasma levels of epinephrine and norepinephrine', 'glucose , lactate and free glycerol .', '[ The sympatho-adrenergic stress reaction']","[0, 2, 2, 2, 4, 4, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",2803397
148,"['92 outpatients affected by generalized anxiety disorders', '92 outpatients affected by generalized anxiety disorders', 'Seventy-eight patients completed the first period and 75 the whole study .', 'Seventy-eight', '75', 'anxiety :', 'anxiety :']","[0, 0, 4, 4, 4, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['ketazolam', 'placebo', 'ketazolam', 'placebo', 'ketazolam', 'placebo', 'ketazolam', 'placebo', 'ketazolam', 'ketazolam', 'placebo', 'ketazolam', 'placebo', 'ketazolam', 'placebo', 'placebo', 'ketazolam', 'ketazolam']","[0, 0, 0, 0, 1, 1, 1, 1, 2, 2, 5, 5, 5, 5, 7, 7, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['total Hamilton Anxiety Rating Scale ( HAM-A )', 'total Hamilton Anxiety Rating Scale ( HAM-A )', 'Anxiety', ""Italian HAM-A scale and with a 4-point scale ( patient 's assessment ) ."", 'Italian HAM-A scale', ""4-point scale ( patient 's assessment ) ."", 'HAM-A score', 'HAM-A score', '4-point scale', '4-point scale', 'severe headache .', 'severe headache .']","[2, 2, 3, 3, 3, 3, 5, 5, 6, 6, 7, 7]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",2908133
149,"['Fifty-one patients with raised intraocular pressure ( IOP )', 'Fifty-one patients', 'raised intraocular pressure ( IOP )']","[0, 0, 0]","['ss_p', 'hl_p', 'hl_p']","['levobunolol', 'levobunolol', 'timolol .', 'levobunolol', 'levobunolol', 'timolol .', 'Levobunolol', 'timolol', 'Levobunolol', 'timolol', 'levobunolol', 'timolol', 'levobunolol', 'timolol', 'Levobunolol', 'timolol :', 'Levobunolol', 'timolol :']","[0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 3, 3, 3, 3, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['intraocular pressure ( IOP )', 'effective', 'overall mean IOP ;', 'overall mean IOP ;', 'effective']","[0, 2, 2, 2, 3]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",3067745
150,"['30 non-insulin dependent ( Type II ) diabetic subjects', '30 non-insulin dependent ( Type II ) diabetic subjects', 'Type II diabetes .', 'Type II diabetic patients .', 'Type II diabetic', 'non-insulin dependent diabetes mellitus .', 'non-insulin dependent diabetes mellitus .']","[0, 0, 4, 5, 5, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['captopril', 'placebo-controlled', 'placebo/wash-out )', 'captopril', 'placebo-controlled', 'Captopril', 'Captopril', 'captopril', 'captopril', 'ACE inhibitors', 'ACE inhibitors', 'angiotensin-converting enzyme inhibitors', 'angiotensin-converting enzyme inhibitors']","[0, 0, 0, 0, 0, 1, 1, 4, 4, 5, 5, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['blood pressure and metabolism', 'blood pressure', 'metabolism', 'systolic and diastolic blood pressure', 'systolic and diastolic blood pressure', 'postprandial blood glucose concentrations', 'blood kinin concentrations', 'postprandial blood glucose concentrations', 'blood kinin concentrations', 'Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as hepatic and renal function', 'Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile', 'hepatic and renal function', 'metabolic effect']","[0, 0, 0, 1, 1, 2, 2, 2, 2, 3, 3, 3, 4]","['ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o']",3074300
151,"['outpatients with primary depression', 'outpatients with primary depression', 'outpatients with a major depressive disorder .', 'outpatients with a major depressive disorder .']","[0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['bupropion', 'doxepin', 'bupropion', 'doxepin', 'placebo', 'placebo', 'Doxepin', 'bupropion', 'doxepin', 'bupropion .', 'Doxepin', 'bupropion', 'doxepin', 'bupropion .', 'Doxepin', 'bupropion .', 'Doxepin', 'bupropion .', 'doxepin', 'bupropion .', 'doxepin', 'bupropion .', 'doxepin', 'bupropion', 'doxepin', 'bupropion']","[0, 0, 0, 0, 1, 1, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6, 6, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy', 'safety differences', 'efficacy', 'safety', 'Antidepressant response', 'Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .', 'Antidepressant response', 'Hamilton Depression and Anxiety Scales', 'Clinical Global Severity and Improvement Ratings', 'Zung Self-Rating Depression Scale', 'efficacy', 'efficacy', 'sleep', 'Hamilton Depression Scale', 'sleep', 'sleep', 'Hamilton Depression Scale', 'sleep', 'anticholinergic side effects', 'dry mouth , constipation , sleepiness , and tiredness', 'anticholinergic side effects', 'dry mouth , constipation , sleepiness , and tiredness', 'increased appetite and weight gain', 'side effects', 'appetite and weight gain']","[0, 0, 0, 0, 2, 2, 2, 2, 2, 2, 3, 3, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",3081600
152,"['United States', 'United States', 'General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .', 'General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .', 'Eight hundred and eighty eight patients were entered into this trial and 744 ( 85 % ) completed the study .', 'Eight hundred and eighty eight', '744']","[5, 5, 6, 6, 8, 8, 8]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['dihydroergotamine ( DHE )', 'heparin', 'dihydroergotamine ( DHE )', 'heparin', 'DHE', 'heparin', 'DHE', 'heparin', 'heparin', 'DHE', 'placebo .', 'DHE', 'heparin', 'DHE', 'heparin', 'heparin', 'DHE', 'placebo .', 'DHE/Hep', 'placebo', 'DHE/Hep', 'placebo']","[3, 3, 3, 3, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 9, 9, 9, 9]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['stasis , a hypercoagulable state and venous endothelial damage .', 'stasis and the hypercoagulable state', 'prophylactic efficacy', 'prophylaxis']","[0, 3, 5, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o']",3534803
153,"['600 cases', '600 cases', 'advanced breast cancers', 'in eight French anticancer centres .', 'advanced breast cancers', 'in eight French anticancer centres', '603 patients', '603 patients', 'advanced breast cancer .', 'advanced breast cancer .']","[0, 0, 1, 1, 1, 1, 3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['chemotherapy', 'vincristine', 'cyclophosphamide', '5-fluoro-uracil', 'doxorubicine', 'methotrexate .', 'chemotherapy', 'vincristine', 'cyclophosphamide', '5-fluoro-uracil', 'doxorubicine', 'methotrexate .', 'doxorubicine', 'doxorubicine', 'chemotherapy', 'chemotherapy', 'chemotherapy', 'chemotherapy']","[4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 6, 6, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['results', 'quality', 'quality']","[5, 5, 5]","['ss_o', 'ss_o', 'hl_o']",361799
154,"['Three hundred forty-one Tanzanian preschool children', 'Three hundred forty-one Tanzanian preschool children', 'children']","[0, 0, 3]","['ss_p', 'hl_p', 'hl_p']","['levamisole', 'placebo', 'levamisole', 'placebo', 'levamisole', 'placebo-treated', 'levamisole', 'placebo-treated', 'levamisole', 'placebo', 'levamisole', 'placebo', 'placebo', 'placebo']","[0, 0, 0, 0, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['Weights and heights', 'Weights and heights', 'rate of weight gain', 'rate of weight gain', 'rate of weight gain', 'rate of weight gain', 'rate of height gain', 'rate of height gain', 'growth rates :']","[1, 1, 2, 2, 3, 3, 4, 4, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",384815
155,"['45 type I ( insulin dependent ) diabetics without proliferative retinopathy', '45 type I ( insulin dependent ) diabetics without proliferative retinopathy', 'insulin dependent diabetes mellitus :', 'insulin dependent diabetes mellitus :']","[0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['insulin infusion', 'insulin injections', 'insulin treatment', 'insulin infusion', 'insulin injections', 'insulin treatment']","[0, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['blood glucose', 'fluorescein angiograms', 'progression of retinopathy', 'fluorescein angiograms', 'progression of retinopathy', 'cotton wool spots .', 'cotton wool spots .', 'glycosylated haemoglobin and blood glucose values', 'frequent episodes of hypoglycaemia', 'duration of diabetes', 'retinopathy at onset .', 'glycosylated haemoglobin', 'blood glucose values', 'episodes of hypoglycaemia', 'duration of diabetes', 'retinopathy', 'blood glucose concentration', 'retinopathy .', 'blood glucose concentration', 'blood glucose', 'transient deterioration of retinopathy', 'retinopathy']","[0, 2, 2, 2, 2, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 0, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",3919804
156,"['391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969 .', '391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969']","[0, 0]","['ss_p', 'hl_p']","['amantadine', 'amantadine', 'amantadine', 'placebo', 'amantadine', 'placebo', 'amantadine :', 'amantadine']","[0, 0, 1, 1, 1, 1, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['Serologically verified influenza', 'complement fixation and/or haemagglutination inhibition', 'Serologically verified influenza', 'complement fixation and/or haemagglutination inhibition']","[1, 1, 1, 1]","['ss_o', 'ss_o', 'hl_o', 'hl_o']",4919024
157,"['31 adult asthmatic patients', '31 adult asthmatic', 'asthma in adults', 'asthma', 'adults']","[0, 0, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['Sodium cromoglycate', 'placebo', 'Sodium cromoglycate', 'placebo', 'Sodium cromoglycate', 'placebo', 'Sodium cromoglycate', 'placebo', 'sodium cromoglycate .', 'sodium cromoglycate .', 'sodium cromoglycate', 'placebo .', 'sodium cromoglycate', 'placebo .', 'sodium cromoglycate', 'placebo', 'sodium cromoglycate', 'placebo', 'sodium cromoglycate', 'sodium cromoglycate']","[0, 0, 0, 0, 1, 1, 1, 1, 2, 2, 3, 3, 3, 3, 5, 5, 5, 5, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['breathlessness at rest', 'breathlessness on exertion', 'quality of sleep', 'morning peak expiratory flow rate value', 'breathlessness at rest', 'breathlessness on exertion', 'quality of sleep', 'morning peak expiratory flow rate value', 'treatment opinions', 'treatment preferences', 'treatment preferences', 'side-effects', 'side-effects', 'superior', 'asthmatic symptoms', 'bronchodilator therapy required .', 'asthmatic symptoms']","[1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 4, 4, 5, 5, 5, 5]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o']",6418441
158,"['31 healthy middle aged men', '31 healthy middle aged men', 'healthy middle aged men', 'healthy middle aged men', 'middle aged men .', 'middle aged men .']","[0, 0, 4, 4, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['physical exercise', 'regular physical exercise', 'physical exercise', 'regular physical exercise', 'regular exercise', 'regular exercise', 'exercise', 'regular exercise .', 'exercise .', 'mild regular physical exercise', 'mild regular physical exercise', 'mild physical exercise', 'mild physical exercise']","[0, 0, 0, 0, 1, 2, 2, 3, 3, 4, 4, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['biochemical risk factors for ischaemic heart disease', 'biochemical risk factors for ischaemic heart disease', 'serum cholesterol concentrations', 'high density lipoprotein subfraction two ( HDL2 )', 'subfraction three ( HDL3 )', 'low density lipoprotein fraction', 'serum cholesterol concentrations', 'high density lipoprotein subfraction two ( HDL2 )', 'subfraction three ( HDL3 )', 'low density lipoprotein fraction', 'plasma 6-keto-prostaglandin F1 alpha concentration', 'serum thromboxane B2 concentration', 'prostaglandin E2 concentrations', 'plasma 6-keto-prostaglandin F1 alpha concentration', 'serum thromboxane B2 concentration', 'prostaglandin E2 concentrations', 'plasma 6-keto-prostaglandin F1 alpha concentration', 'serum HDL2 cholesterol concentration', 'plasma 6-keto-prostaglandin F1 alpha concentration', 'serum HDL2 cholesterol concentration', 'serum lipoproteins', 'circulating metabolites of arachidonic acid .', 'serum lipoproteins', 'circulating metabolites of arachidonic acid .', 'serum lipoproteins and metabolites of arachidonic acid :', 'serum lipoproteins', 'metabolites of arachidonic acid :']","[0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 0, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",6421395
159,"['premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .', 'premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .', 'Twelve dams', 'Twelve dams', 'Twelve control animals', 'Twelve control animals', 'in this animal model ;', 'the premature monkey :', 'the premature monkey :']","[0, 0, 1, 1, 2, 2, 8, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['glucocorticoid', 'glucocorticoid', 'dexamethasone', 'dexamethasone', 'saline .', 'saline .', 'dexamethasone-treated', 'dexamethasone-treated', 'dexamethasone-treated', 'dexamethasone-treated', 'dexamethasone-treated', 'dexamethasone-treated', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone', 'dexamethasone .', 'dexamethasone .']","[0, 0, 1, 1, 2, 2, 3, 3, 5, 5, 6, 6, 7, 7, 8, 8, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['incidence and severity of HMD', 'incidence and severity of HMD', 'volume-pressure behavior', 'distensibility', 'deflation stability', 'volume-pressure behavior', 'distensibility', 'deflation stability', 'production of surface active material ( SAM ) phospholipids', 'total lung phospholipid', 'alveolar lavage fluid phospholipid', 'alveolar lavage fluid disaturated phosphatidylcholine', 'production of surface active material ( SAM ) phospholipids', 'total lung phospholipid', 'alveolar lavage fluid phospholipid', 'alveolar lavage fluid disaturated phosphatidylcholine', '14C-palmitate', 'lung lipid', 'DPC fraction', '14C-palmitate', 'lung lipid', 'incidence and severity of experimental HMD', 'effects', 'fetal pulmonary functions', 'incidence and severity of experimental HMD', 'fetal pulmonary functions']","[3, 3, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",6920252
160,"['previously untreated patients with prostatic cancer', 'previously untreated patients with prostatic cancer', 'patients with advanced disease no longer responsive to hormonal treatment', 'patients with advanced disease no longer responsive to hormonal treatment', 'prostatic cancer .', 'prostatic cancer .']","[1, 1, 3, 3, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['Stilboestrol', 'Cyproterone acetate', 'Medroxyprogesterone acetate', 'Stilboestrol', 'Estracyt', 'Stilboestrol', 'Cyproterone acetate', 'Medroxyprogesterone acetate', 'Stilboestrol', 'Estracyt', 'Stilboestrol', 'Stilboestrol', 'Adriamycin', 'Procarbazine .', 'Adriamycin', 'Procarbazine .', 'Procarbazine', 'Procarbazine']","[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 3, 3, 3, 3, 4, 4]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i']","['side effects', 'gynaecomastia .', 'side effects', 'gynaecomastia .', 'Toxicity and early death', 'Toxicity and early death']","[2, 2, 2, 2, 4, 4]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",6938020
161,"['One hundred and twenty patients presenting at Macquarie Hospital for admission', 'One hundred and twenty patients presenting at Macquarie Hospital for admission', 'psychiatric patients', 'psychiatric patients']","[0, 0, 6, 6]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['standard hospital care and follow-up .', 'standard hospital care and follow-up .', 'taken back to the community', 'follow-up treatment', 'back to the community', 'follow-up treatment', 'psychiatric hospital', 'community treatment', 'psychiatric hospital', 'community treatment']","[1, 1, 2, 2, 2, 2, 0, 0, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['admission', 'burden on the relatives', 'burden on the control group relatives .', 'burden on the relatives', 'satisfied', 'satisfied', 'burden on their relatives .', 'burden on their relatives .', 'effect on relatives .', 'effect on relatives .']","[3, 4, 4, 4, 5, 5, 6, 6, 0, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",6951573
162,"['95 patients with atherosclerotic disease .', '95 patients with atherosclerotic disease']","[1, 1]","['ss_p', 'hl_p']","['clofibrate', 'niceritrol .', 'clofibrate', 'niceritrol', 'clofibrate', 'niceritrol', 'diet , clofibrate', 'niceritrol', 'diet', 'clofibrate', 'niceritrol', 'dietary treatment', 'diet', 'clofibrate', 'niceritrol', 'diet', 'clofibrate', 'niceritrol', 'Clofibrate', 'Clofibrate', 'clofibrate', 'clofibrate', 'diet', 'clofibrate', 'diet .', 'clofibrate', 'diet .', 'diet , clofibrate', 'niceritrol .', 'diet', 'clofibrate', 'niceritrol .']","[0, 0, 3, 3, 3, 3, 5, 5, 5, 5, 5, 7, 9, 9, 9, 9, 9, 9, 10, 10, 12, 13, 13, 14, 14, 14, 14, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['proportion of linoleate', 'linoleate', 'fatty acid composition of the plasma lipid esters', 'fatty acid composition of the plasma lipid esters', 'serum lipid reductions .', 'serum lipid', 'fatty acid composition in the plasma lipid esters', 'degree of dietary adherence .', 'fatty acid composition in the plasma lipid esters', 'content of saturated and monounsaturated fatty acids', 'polyunsaturated fatty acids', 'ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .', 'content of saturated and monounsaturated fatty acids', 'polyunsaturated fatty acids', 'ratio between pulyunsaturated and saturated fatty acids ( P/S ratio )', 'phospholipids .', 'phospholipids .', 'changes of the fatty acid composition .', 'fatty acid composition .', 'amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids', 'content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .', 'monounsaturated fatty acids', 'oleate', 'triglycerides and phospholipids', 'content of linoleic ( 18 : 2 ) acid', 'P/S ratio', 'relative content of saturated fatty acids', 'P/S ratio', 'saturated fatty acids', 'change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters', 'ratio between polyunsaturated and saturated fatty acids .', 'polyunsaturated to monounsaturated fatty acids in the plasma lipid esters', 'ratio between polyunsaturated and saturated fatty acids .', 'The fatty acid changes', 'acid changes', 'Changes in the fatty acid composition of the plasma lipid esters', 'fatty acid composition of the plasma lipid esters']","[0, 0, 1, 1, 5, 5, 6, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 9, 9, 10, 10, 10, 10, 10, 10, 12, 12, 12, 12, 13, 13, 13, 13, 14, 14, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",6989377
163,"['360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .', '360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH )', 'major gynecologic surgery .']","[1, 1, 0]","['ss_p', 'hl_p', 'ss_p']","['ondansetron , droperidol , perphenazine', 'metoclopramide', 'ondansetron', 'droperidol', 'perphenazine', 'metoclopramide', 'ondansetron', 'droperidol', 'perphenazine', 'metoclopramide', 'placebo', 'ondansetron', 'droperidol', 'perphenazine', 'metoclopramide', 'placebo', 'metoclopramide', 'ondansetron', 'metoclopramide', 'droperidol', 'ondansetron', 'droperidol', 'perphenazine', 'placebo', 'Metoclopramide', 'ondansetron , droperidol', 'perphenazine', 'perphenazine', 'perphenazine', 'ondansetron , droperidol , perphenazine', 'metoclopramide', 'ondansetron', 'droperidol', 'perphenazine', 'metoclopramide']","[1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 4, 7, 7, 7, 7, 8, 9, 9, 10, 11, 0, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i']","['efficacy', 'Hypotension', 'systolic hypotension', 'Hypotension', 'severe nausea , retching , or vomiting , defined as severe emetic sequelae ( SES )', 'severe nausea , retching , or vomiting', 'severe emetic sequelae ( SES )', 'SES', 'SES', 'effective', 'effective', 'side effects .', 'side effects .', 'efficacy']","[0, 3, 3, 3, 5, 5, 5, 7, 7, 9, 9, 10, 10, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",7598243
164,"['first-degree relatives of index breast cancer patients', 'first-degree relatives of index breast cancer patients', '200 women aged 35 years and older who had a family history of breast cancer in a first-degree relative .', '200 women aged 35 years and older', 'family history of breast cancer in a first-degree relative', 'Women with a personal history of cancer were excluded .', 'Women', 'personal history of cancer']","[2, 2, 4, 4, 4, 5, 5, 5]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['individualized breast cancer risk counseling', 'counseling .', 'individualized breast cancer risk counseling', 'individualized breast cancer risk counseling', 'general health counseling ( control ) .', 'individualized breast cancer risk counseling', 'general health counseling ( control ) .', 'risk counseling', 'risk counseling', 'counseling .', 'risk counseling', 'risk counseling', 'risk-counseling programs', 'risk-counseling programs', 'individualized breast cancer risk counseling :', 'individualized breast cancer risk counseling :']","[2, 2, 2, 3, 3, 3, 3, 7, 7, 8, 9, 9, 12, 12, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['risk', 'risk', 'risk', 'benefit', 'comprehension of personal risk', 'risk', 'Risk comprehension', 'concordance between perceived "" subjective "" lifetime breast cancer risk and estimated "" objective "" lifetime risk .', 'Risk comprehension', 'risk', 'risk comprehension', 'risk comprehension', 'lifetime risks', 'lifetime risks', 'risk', 'comprehension', 'comprehension', 'risks', 'effective', 'risk', 'risk-counseling', 'risk counseling :']","[0, 1, 2, 2, 2, 3, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9, 9, 11, 11, 12, 12, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",7707420
165,"['patients suffering from post-operative pain after cholecystectomy .', 'patients suffering from post-operative pain after cholecystectomy .', '99 patients with severe pain following surgery .', '99 patients with severe pain following surgery']","[0, 0, 3, 3]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['ketorolac tromethamine', 'placebo', 'ketorolac tromethamine', 'placebo', 'ketorolac tromethamine', 'ketorolac tromethamine', 'placebo', 'placebo', 'placebo', 'ketorolac', 'ketorolac', 'ketorolac', 'placebo-controlled', 'ketorolac tromethamine', 'ketorolac tromethamine']","[0, 0, 0, 0, 5, 5, 9, 9, 10, 10, 12, 12, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['efficacy', 'tolerability', 'efficacy', 'tolerability', 'analgesia activity', 'assessing pain intensity and pain relief', '4 point scale ( VRS )', 'pain intensity and pain relief', '4 point scale ( VRS )', 'safety', 'efficacy', 'safety', 'efficacy', 'pain intensity', 'pain intensity', 'rescue analgesic drug', 'rescue analgesic drug', 'adverse events', 'adverse events', 'systemic and local tolerability', 'systemic and local tolerability', 'effective', 'effectiveness', 'tolerability', 'effectiveness', 'tolerability']","[0, 0, 0, 0, 5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 9, 9, 10, 10, 11, 11, 12, 0, 0, 0, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",7808649
166,"['Staphylococcus aureus mastitis , 37 Holstein cows', '37 Holstein cows', 'Staphylococcus aureus mastitis .']","[0, 0, 0]","['ss_p', 'hl_p', 'ss_p']","['oxytetracycline', 'cephapirin benzathine', 'cephapirin benzathine', 'oxytetracycline', 'oxytetracycline', 'cephapirin benzathine', 'cephapirin benzathine', 'oxytetracycline', 'oxytetracycline', 'cephapirin', 'cephapirin', 'oxytetracycline', 'cephapirin', 'cephapirin', 'cephapirin', 'cephapirin', 'oxytetracycline', 'oxytetracycline', 'oxytetracycline', 'oxytetracycline']","[0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 3, 3, 3, 3, 4, 4, 5, 5, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['efficacy', 'Milk samples', 'infected', 'rate of cure', 'rate of cure', 'culture', 'rate of cure', 'rate of cure', 'Efficacy']","[0, 1, 1, 3, 3, 4, 5, 5, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",7814711
167,"['elderly patients', 'elderly patients', 'in older patients .', 'older patients', 'Old Patients with Hypertension', 'older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .', 'Old Patients with Hypertension', 'older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .', 'older patients .', 'older individuals with hypertension .', 'older individuals with hypertension .']","[0, 0, 2, 2, 3, 3, 3, 3, 4, 5, 5]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['preventive pharmacological strategies in elderly patients', 'preventive pharmacological strategies', 'treating older patients', 'treating older patients .', 'treatment of older individuals']","[0, 0, 3, 4, 5]","['ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i']","['preventive pharmacological strategies', 'incidence of stroke', 'Cost-effectiveness data', 'Cost-effectiveness data']","[0, 2, 5, 5]","['ss_o', 'ss_o', 'ss_o', 'hl_o']",7827398
168,"['dyspnoeic patients .', '100 consecutive patients .', 'patients with severe pulmonary disease ;']","[2, 3, 6]","['ss_p', 'ss_p', 'ss_p']","['Transfer factor of the lung for carbon monoxide', 'TLCO ( TLCO', 'standard ( Jones and Meade )', 'TLCO ( TLCO', 'TLCO ( TLCO', 'standard ( Jones and Meade )', 'TLCO ( TLCO', 'TLCO', 'TLCO .']","[0, 3, 3, 3, 3, 3, 3, 7, 8]","['ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i']","['Transfer factor of the lung for carbon monoxide ( TLCO )', 'ratio of the concentrations of carbon monoxide', 'Transfer factor of the lung for carbon monoxide ( TLCO )', 'Exhalation TLCO ( TLCO , ex )', 'standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )', 'Exhalation TLCO ( TLCO , ex )', 'standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )', 'relation', 'FEV1', 'relation', 'clinical measurement of TLCO .']","[0, 0, 0, 3, 3, 3, 3, 6, 6, 6, 8]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",7831628
169,"['School districts', 'School districts']","[2, 2]","['ss_p', 'hl_p']","['teacher training', 'live workshop training', 'video training condition .', 'live workshop training', 'video training condition .', 'video-trained teachers', 'video-trained', 'Video-trained teachers', 'Video-trained', 'teacher training', 'teacher training', 'teacher training']","[1, 2, 2, 2, 2, 4, 4, 5, 5, 6, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['effectiveness', 'diffusion of Smart Choices', 'effectiveness', 'diffusion of Smart Choices', 'impact', ""teachers ' implementation of Smart Choices ."", ""teachers ' implementation of Smart Choices ."", 'completeness and fidelity of implementation', 'completeness and fidelity of implementation', 'implementation of Smart Choices :']","[0, 0, 0, 0, 1, 3, 3, 4, 4, 0]","['ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",7844976
170,"['patients with previously undetected anxiety', 'patients with previously undetected anxiety', '573 patients who had unrecognized and untreated anxiety identified from the approximately 8,000 patients who completed the waiting room screening questionnaire .', '573 patients who had unrecognized and untreated anxiety', 'primary care patients with untreated anxiety .', 'primary care patients with untreated anxiety .']","[0, 0, 4, 4, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['screener', 'physician intervention', 'demonstration', 'demonstration', 'physician intervention', 'physician intervention', 'screening', 'feedback']","[0, 0, 1, 1, 5, 5, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['elevated anxiety levels', 'anxiety symptom levels', 'functioning status', 'Patient outcomes', 'global anxiety scores , functioning and well-being', ""patients ' reports of global improvements ."", 'global anxiety scores', 'functioning and well-being', ""patients ' reports of global improvements ."", 'outcomes']","[0, 5, 5, 6, 6, 6, 6, 6, 6, 0]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o']",7853069
171,"['20 patients undergoing lateral thoracotomy for lung resection', 'patients undergoing lateral thoracotomy', 'post-thoracotomy']","[4, 11, 0]","['ss_p', 'ss_p', 'ss_p']","['Intercostal nerve blocks ( INB )', 'subarachnoid morphine ( SM )', 'Intercostal nerve blocks ( INB )', 'subarachnoid morphine ( SM )', 'SM', 'INB', 'bupivacaine', 'SM', 'INB', 'saline ( INB- )', 'SM', 'INB with bupivacaine ( INB+ )', 'SM', 'INB using saline ( INB- )', 'INB+', 'INB+', 'INB+', 'INB-', 'INB+', 'INB-', '( INB-', 'INB+', 'INB-', 'INB+', 'INB', 'SM', 'INB', 'SM', 'INB', 'SM .', 'INB', 'SM', 'intercostal nerve blocks', 'morphine', 'intercostal nerve blocks', 'morphine']","[1, 1, 1, 1, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 11, 11, 11, 11, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['pain', 'pulmonary function .', 'pain', 'pain', 'post-thoracotomy pain', 'postoperative pulmonary function', 'post-thoracotomy pain', 'postoperative pulmonary function', 'Visual analog scale pain scores at rest , with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 ) , and forced vital capacity ( FVC )', 'Visual analog scale pain scores', 'with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 )', 'forced vital capacity ( FVC )', 'Opioid use', 'Opioid use', 'FEV1', 'FVC', 'resting and cough pain', 'FEV1', 'FVC', 'FEV1', 'pain scores', 'FEV1', 'pain scores', 'Opioid usage', 'Opioid usage', 'pain and pulmonary function']","[0, 0, 2, 2, 3, 3, 3, 3, 5, 5, 5, 5, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 10]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",8519720
172,"['47 healthy women undergoing elective ambulatory surgery .', '47 healthy women undergoing elective ambulatory surgery', 'women', 'women', 'outpatient surgery .', 'outpatient surgery .']","[0, 0, 1, 1, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['sevoflurane', 'isoflurane', 'sevoflurane', 'isoflurane', 'sevoflurane', 'isoflurane', 'sevoflurane', 'isoflurane', 'thiopental', 'vecuronium', 'fentanyl', 'thiopental', 'vecuronium', 'fentanyl', 'sevoflurane', 'isoflurane', 'sevoflurane', 'isoflurane', 'isoflurane', 'sevoflurane', 'isoflurane ;', 'sevoflurane', 'isoflurane', 'sevoflurane', 'isoflurane']","[0, 0, 0, 0, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 4, 4, 4, 4, 5, 6, 6, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['Duration of anesthesia , time to emergence , orientation , length of stay in the surgical unit , and hospital discharge', 'Duration of anesthesia', 'time to emergence', 'orientation', 'length of stay in the surgical unit', 'The emergence , length of stay , and discharge times after discontinuation', 'emergence , length of stay , and discharge times', 'postoperative cough .', 'postoperative cough .', 'level of anesthesia', 'anesthesia']","[3, 3, 3, 3, 3, 4, 4, 5, 5, 6, 6]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o']",8726604
173,"['90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses .', '90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses']","[3, 3]","['ss_p', 'hl_p']","['prosthesis', 'bileaflet prostheses .', 'bileaflet prostheses .', 'Sorin Bicarbon or CarboMedics bileaflet prostheses .', 'Sorin Bicarbon or CarboMedics bileaflet prostheses .', 'prostheses', 'prostheses', ""prosthesis '"", 'Prosthesis', 'Prosthesis', 'bileaflet prostheses :', 'bileaflet prostheses :']","[1, 2, 2, 3, 3, 4, 4, 5, 10, 10, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['feasibility', 'accuracy', 'postoperative fluoroscopic evaluation', 'feasibility', 'accuracy', 'Fluoroscopic evaluation', ""valve 's hemodynamic performance was investigated through Doppler study ."", 'hemodynamic performance', 'fluoroscopic evaluation', 'fluoroscopic evaluation', 'hemodynamic performance', 'hemodynamic performance', 'rate of success of the fluoroscopic evaluation .', 'rate of success of the fluoroscopic evaluation .', 'feasibility and accuracy of fluoroscopy', ""valve 's hemodynamic performance ."", 'feasibility', 'accuracy of fluoroscopy', ""valve 's hemodynamic performance ."", 'fluoroscopic', 'fluoroscopic', 'Fluoroscopic functional evaluation']","[2, 2, 2, 2, 2, 5, 6, 6, 7, 7, 9, 9, 10, 10, 11, 11, 11, 11, 11, 12, 12, 0]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",8771302
174,"['82 patients having postoperative epidural analgesia', '82 patients having postoperative epidural analgesia']","[0, 0]","['ss_p', 'hl_p']","['tunnelling', 'tunnelling', 'Tunnelling', 'Tunnelling', 'tunnelled catheters', 'non-tunnelled catheters', 'tunnelled catheters', 'non-tunnelled catheters', 'tunnelling .', 'tunnelling .', 'tunnelling', 'tunnelling']","[0, 0, 1, 1, 3, 3, 3, 3, 4, 4, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['migration .', 'migration .', 'incidence of inward migration', 'incidence of inward migration', 'position', 'catheter migration', 'catheter migration', 'effect']","[0, 0, 1, 1, 3, 4, 4, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o']",8779382
175,"['drug-free adult patients with autistic disorder .', 'drug-free adult patients with autistic disorder .', 'Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years )', 'Twenty drug-free adults with autistic disorder', '16 men and 4 women', 'mean [ +/- SD ] age , 30.5 +/- 8.5 years', 'patients with autism .', 'patients with autism .', 'drug-free adults with autistic disorder .', 'drug-free adults', 'autistic disorder']","[0, 0, 1, 1, 1, 1, 12, 12, 0, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['tryptophan depletion', 'tryptophan depletion', 'tryptophan depletion', 'low-tryptophan diet', 'amino acid drink .', 'low-tryptophan diet', 'amino acid drink .', 'amino acid drink', 'amino acid drink', 'tryptophan depletion', 'sham depletion', 'Tryptophan depletion', 'tryptophan-deficient amino acid drink .', 'tryptophan depletion .', 'tryptophan depletion']","[0, 1, 1, 2, 2, 2, 2, 3, 3, 6, 6, 7, 10, 11, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i']","['behavioral and biochemical responses', 'Behavioral ratings', 'Plasma free and total tryptophan levels', 'Plasma free and total tryptophan levels', 'behavioral symptoms', 'behaviors such as whirling , flapping , pacing , banging and hitting self , rocking , and toe walking', 'whirling , flapping , pacing , banging and hitting self , rocking , and toe walking', 'calm and happy', 'anxious .', 'calm and happy', 'anxious .', 'social relatedness or repetitive thoughts and behavior .', 'social relatedness or repetitive thoughts and behavior .', 'Plasma total and free tryptophan levels', 'Plasma total and free tryptophan levels', 'symptoms', 'plasma total tryptophan levels', 'Autism Behavior Checklist scores', 'symptoms', 'plasma total tryptophan levels', 'Autism Behavior Checklist scores', 'symptoms', 'symptoms']","[0, 3, 4, 4, 6, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 11, 11, 11, 11, 11, 11, 13, 13]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",8911222
176,"['Thirty adults with autistic disorder', 'Thirty adults', 'autistic disorder', 'autistic disorder in adults .', 'adults with autistic disorder .', 'adults with autistic disorder .']","[3, 3, 3, 10, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['placebo-controlled', 'fluvoxamine maleate .', 'placebo-controlled', 'fluvoxamine maleate .', 'fluvoxamine-treated', 'placebo', 'fluvoxamine-treated', 'placebo', 'Fluvoxamine', 'placebo', 'Fluvoxamine', 'placebo', 'fluvoxamine', 'fluvoxamine', 'Fluvoxamine', 'placebo', 'Fluvoxamine', 'placebo', 'fluvoxamine', 'fluvoxamine', 'fluvoxamine', 'placebo-controlled', 'fluvoxamine']","[3, 3, 3, 3, 5, 5, 5, 5, 6, 6, 6, 6, 8, 8, 10, 10, 10, 10, 11, 11, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i']","['social interaction , impairments in communication', 'restricted repertoire of activities and interests .', 'symptoms', 'Behavioral ratings', 'Behavioral ratings', 'repetitive thoughts and behavior', 'maladaptive behavior', 'aggression', 'social relatedness', 'language usage', 'repetitive thoughts and behavior', 'maladaptive behavior', 'aggression', 'social relatedness', 'language usage', 'Treatment response', 'age level of autistic behavior', 'full-scale IQ .', 'mild sedation and nausea', 'mild sedation and nausea', 'dyskinesias , adverse cardiovascular events , or seizures', 'dyskinesias , adverse cardiovascular events , or seizures', 'effective', 'symptoms']","[0, 0, 2, 4, 4, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9, 10, 10]","['ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o']",8911223
177,"['patients with multivessel coronary artery disease', 'patients with multivessel coronary artery disease', '4,244 BARI randomized and registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995', '4,244', 'registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995']","[1, 1, 6, 6, 6]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p']","['coronary artery bypass grafting', 'percutaneous transluminal coronary angioplasty .', 'coronary artery bypass grafting', 'percutaneous transluminal coronary angioplasty .']","[1, 1, 1, 1]","['ss_i', 'ss_i', 'hl_i', 'hl_i']","['serial changes in Q , ST , and T wave items according to Minnesota code ( MC ) criteria', 'serial changes in Q , ST , and T wave items', 'changes', 'MC Q wave progression', 'MC Q wave progressions', 'Q wave progression codes']","[2, 2, 4, 6, 7, 8]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o']",8913901
178,"['youth substance abuse prevention program', 'prevention program']","[4, 0]","['hl_p', 'hl_p']","['prevention programs', 'generalized estimating equations ( GEE )', 'GEE-independent', 'generalized estimating equations ( GEE )', 'GEE-independent', 'GEE-independent', 'GEE-independent', 'prevention program']","[0, 2, 2, 2, 2, 3, 3, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i']",['effectiveness'],[0],['ss_o'],8916620
179,"['in elderly patients .', 'elderly patients', 'Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement', 'Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement', 'elderly patients undergoing elective procedures', 'elderly patients undergoing elective procedures', 'in the elderly :', 'the elderly']","[1, 1, 2, 2, 6, 6, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['crystalloid', 'colloid solution', 'crystalloid', 'colloid solution', 'no prehydration', 'crystalloid', 'colloid prehydration', 'no prehydration', 'crystalloid', 'colloid prehydration', 'crystalloid solution ( Hartmanns', 'colloid ( Haemaccel', 'no prehydration', 'crystalloid solution', 'colloid ( Haemaccel', 'no prehydration', 'colloid', 'colloid', 'ephedrine', 'ephedrine', 'prehydration', 'crystalloid', 'colloid prehydration .', 'crystalloid', 'colloid prehydration .', 'crystalloids , colloids', 'no prehydration .', 'crystalloids', 'colloids', 'no prehydration .']","[0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 4, 4, 5, 5, 6, 6, 6, 6, 6, 0, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i']","['efficacy', 'incidence and frequency of hypotension and vasopressor therapy', 'incidence and frequency of hypotension and vasopressor therapy', 'Hypotension', '30 % decrease from baseline systolic blood pressure ( BP )', 'systolic < 90 mm Hg', 'Hypotension', 'systolic blood pressure', 'absolute systolic BP readings', 'incidence of hypotension', 'absolute systolic BP readings', 'incidence of hypotension', 'incidence of ephedrine use , incidence of nausea/vomiting , and median total dose of ephedrine', 'incidence of ephedrine use', 'incidence of nausea/vomiting', 'median total dose of ephedrine', 'degree of hypotension or need for vasopressor therapy', 'hypotension', 'need for vasopressor therapy']","[0, 1, 1, 3, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",8989009
180,"['69 patients', '69 patients', 'acute allergic conjunctivitis ]', 'acute allergic conjunctivitis ]']","[2, 2, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p']","['Antazolin/Tetryzolin', 'Levocabastine', 'Antazolin/Tetryzolin', 'Levocabastine', 'Antazolin/Tetryzolin', 'Antazolin/Tetryzolin', 'Antazolin/Tetryzolin', 'Antazolin/Tetryzolin', '[ Antazoline/tetryzoline', 'levocabastine', 'Antazoline/tetryzoline', 'levocabastine']","[1, 1, 1, 1, 5, 5, 7, 7, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['efficacy , local tolerance and safety', 'subjective and objective ocular symptoms', 'subjective and objective ocular symptoms', 'subjective and objective ocular symptoms', 'subjective and objective ocular symptoms', 'onset of action', 'onset of action', 'effective onset of action']","[1, 3, 3, 4, 4, 5, 5, 6]","['ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",9229602
181,"['patients with alcoholic liver disease .', 'patients with alcoholic liver disease .', 'Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )', 'Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )', '15 healthy controls .', '15 healthy controls', 'patients with alcoholic liver disease .', 'patients with alcoholic liver disease .', 'patients with alcoholic liver disease -- a', 'patients with alcoholic liver disease']","[1, 1, 2, 2, 4, 4, 8, 8, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['antibiotic', 'paromomycin sulfate', 'placebo', 'paromomycin sulfate', 'placebo', 'paromomycin', 'placebo', 'paromomycin', 'placebo', 'paromomycin', 'placebo', 'paromomycin', 'placebo', '( paromomycin', 'placebo', 'paromomycin', 'paromomycin', 'placebo', 'paromomycin', 'paromomycin', 'paromomycin', 'paromomycin', 'placebo-controlled', 'paromomycin', 'placebo-controlled']","[1, 2, 2, 2, 2, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 0, 0, 0, 0]","['ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['endotoxemia', 'endotoxemia', 'Endotoxin concentration , liver function tests , and other laboratory parameters', 'Endotoxin concentration', 'liver function tests', 'Endotoxin concentration', 'Endotoxin concentration', 'endotoxin concentrations', 'endotoxin concentrations', 'endotoxin concentration', 'endotoxin concentration or liver function tests', 'endotoxin concentration', 'endotoxin concentration', 'liver function tests', 'endotoxemia', 'endotoxemia']","[1, 1, 3, 3, 3, 4, 4, 6, 6, 7, 7, 7, 7, 7, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o']",9394106
182,"['temporomandibular ( TMJ ) joint pain', 'Twenty subjects , who have TMJ pain , were included for this study', 'Twenty subjects , who have TMJ pain', 'temporomandibular joint pain .', 'temporomandibular joint pain .']","[0, 1, 1, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['indomethacin phonophoresis', 'placebo-controlled', 'indomethacin phonophoresis', 'placebo-controlled', 'indomethacin', 'placebo', 'indomethacin', 'placebo', 'indomethacin phonophoresis', 'indomethacin phonophoresis', 'indomethacin phonophoresis', 'indomethacin phonophoresis']","[0, 0, 0, 0, 3, 3, 3, 3, 6, 6, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['pain-relieving', 'pain-relieving', 'Pre- and post-treatment pain levels and pain sensitivity', 'visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .', 'pain levels', 'pain sensitivity', 'visual analogue scales ( VAS )', 'pressure pain threshold ( PPT )', 'post-treatment VAS', 'post-treatment PPT', 'post-treatment VAS', 'post-treatment PPT', 'pain', 'pain', 'pain .']","[0, 0, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 0]","['ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o']",9481998
183,"['16 decompensated heart failure patients', '16 decompensated heart failure patients', 'decompensated heart failure .', 'patients with hemodynamically decompensated heart failure .', 'patients with hemodynamically decompensated heart failure .']","[2, 2, 14, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['Human brain natriuretic peptide ( hBNP )', 'Human brain natriuretic peptide ( hBNP )', 'hBNP', 'hBNP', 'hBNP', 'placebo-controlled', 'hBNP', 'placebo-controlled', '( placebo', 'hBNP', 'placebo', 'hBNP', 'hBNP .', 'hBNP .', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'placebo , hBNP', 'placebo', 'hBNP', 'hBNP ;', 'hBNP ;', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'hBNP', 'human brain natriuretic peptide', 'human brain natriuretic peptide']","[0, 0, 1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 14, 14, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i']","['systemic hemodynamic , neurohormonal , and renal effects', 'systemic hemodynamic', 'neurohormonal', 'renal effects', 'Urinary volume losses', 'adverse events .', 'adverse events .', 'right atrial pressure and pulmonary capillary wedge pressure', 'right atrial pressure and pulmonary capillary wedge pressure', 'systemic vascular resistance', 'systemic vascular resistance', 'cardiac index', 'heart rate .', 'cardiac index', 'heart rate .', 'plasma norepinephrine and aldosterone .', 'plasma norepinephrine and aldosterone .', 'Renal hemodynamics', 'natriuretic effect .', 'Renal hemodynamics', 'natriuretic effect .', 'hemodynamic effects', 'cardiac preload and systemic vascular resistance .', 'hemodynamic effects', 'cardiac preload and systemic vascular resistance .', 'cardiac output', 'heart rate .', 'cardiac output', 'heart rate .', 'Plasma norepinephrine and aldosterone levels', 'Plasma norepinephrine and aldosterone levels', 'Systemic hemodynamic , neurohormonal , and renal effects', 'Systemic hemodynamic , neurohormonal', 'renal effects']","[1, 1, 1, 1, 4, 5, 5, 6, 6, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 10, 10, 11, 11, 11, 11, 12, 12, 12, 12, 13, 13, 0, 0, 0]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o']",9573502
184,"['One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis', 'One hundred and fifty-six infants aged between 7 weeks and 24 months', 'had an episode of wheezing and other signs and symptoms of bronchiolitis', 'acute bronchiolitis .', 'acute bronchiolitis .', 'acute bronchiolitis .']","[2, 2, 2, 10, 0, 0]","['ss_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p']","['placebo', 'salbutamol .', 'salbutamol', 'salbutamol', 'saline ;', 'saline', 'mist', 'salbutamol', 'saline', 'saline', 'mist', 'oxygen', 'oxygen', 'Salbutamol', 'Salbutamol', 'Salbutamol', 'mist', 'Salbutamol', 'mist']","[1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 10, 10, 0, 0, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i']","['clinical response', 'respiratory score', 'Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions', 'Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions', 'respiratory score', 'respiratory score', 'Heart rate', 'Heart rate', 'Oxygen saturation', 'Oxygen saturation', 'effective', 'safe', 'effective', 'safe']","[1, 4, 5, 5, 6, 6, 8, 8, 9, 9, 10, 10, 10, 10]","['ss_o', 'ss_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o']",9695300
185,"['bronchiectasis .', 'Twenty-four patients ( 12 female ; mean age 51 yr )', 'Twenty-four', '12', 'mean age 51 yr', 'bronchiectasis .', 'bronchiectasis .', 'bronchiectasis .', 'severe bronchiectasis .', 'severe bronchiectasis .']","[1, 2, 2, 2, 2, 7, 8, 8, 0, 0]","['ss_p', 'ss_p', 'hl_p', 'hl_p', 'hl_p', 'ss_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p']","['placebo-controlled', 'fluticasone', 'placebo-controlled', 'fluticasone', 'fluticasone', 'placebo .', 'fluticasone', 'placebo .', 'fluticasone', 'fluticasone', 'fluticasone', 'placebo', 'fluticasone', 'placebo', 'fluticasone', 'steroid', 'fluticasone', 'fluticasone']","[1, 1, 1, 1, 2, 2, 2, 2, 4, 4, 5, 5, 5, 5, 7, 8, 0, 0]","['ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i']","['inflammatory and infective markers', 'inflammatory and infective markers', 'spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 )', 'spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities', 'concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha )', 'leukotriene B4 ( LTB4 )', 'sputum leukocyte density and IL-1beta , IL-8 , and LTB4', 'sputum leukocyte density', 'IL-1beta , IL-8', 'LTB4', 'spirometry', 'reported adverse reactions', 'spirometry', 'adverse reactions', 'sputum inflammatory indices', 'sputum inflammatory indices', 'inflammatory components', 'sputum inflammatory indices', 'sputum inflammatory indices']","[0, 0, 3, 3, 3, 3, 4, 4, 4, 4, 6, 6, 6, 6, 7, 7, 8, 0, 0]","['ss_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",9730996
186,"['previously untreated metastatic breast cancer patients', 'previously untreated metastatic breast cancer patients', 'Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .', 'Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .', 'Patients could not have had prior chemotherapy for metastatic disease .', 'Patients could not have had prior chemotherapy for metastatic disease .', 'Prior adjuvant chemotherapy was permitted .', 'Prior adjuvant chemotherapy was permitted .', 'Patients could not have visceral crisis .', 'Patients could not have visceral crisis .', 'previously untreated breast cancer patients', 'previously untreated advanced breast cancer -- a', 'previously untreated advanced breast cancer -- a']","[5, 5, 9, 9, 10, 10, 11, 11, 12, 12, 20, 0, 0]","['ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'ss_p', 'hl_p', 'hl_p', 'ss_p', 'hl_p']","['Amonafide', 'Amonafide', 'Amonafide', 'Amonafide', 'cyclophosphamide-doxorubicin-5-fluorouracil', 'cyclophosphamide-doxorubicin-5-fluorouracil .', 'amonafide', 'amonafide', 'cyclophosphamide-doxorubicin-5-fluorouracil', 'Amonafide', 'Amonafide', 'amonafide', 'amonafide', 'amonafide', 'Amonafide :', 'Amonafide :']","[0, 0, 4, 4, 5, 5, 7, 7, 8, 13, 13, 20, 20, 22, 0, 0]","['ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i', 'ss_i', 'hl_i', 'ss_i', 'ss_i', 'hl_i']","['assess the difference in survival , toxicity , and overall response', 'survival', 'toxicity', 'overall response', 'Toxicity', 'hematological', 'leukopenia', 'thrombocytopenia ;', 'leukopenia', 'thrombocytopenia .', 'Toxicity', 'leukopenia', 'thrombocytopenia', 'leukopenia', 'thrombocytopenia', 'response rate', 'response rate', 'hematological toxicity', 'leukopenia', 'hematological toxicity', 'leukopenia', 'thrombocytopenia', 'thrombocytopenia', 'Rates of responses', 'hematotoxicity )', 'Rates of responses']","[6, 6, 6, 6, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 18, 18, 18, 18, 19, 19, 22, 22, 22]","['ss_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o', 'hl_o', 'ss_o', 'hl_o', 'ss_o', 'ss_o', 'hl_o']",9816035
